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ABSTRACT
 
Thiopurine methyltransferase (TPMT) metabolises the widely prescribed 
thiopurine drugs. The activity of this enzyme varies between individuals and this 
can influence treatment success. Rapid and accurate assays of TPMT and 
6TGN, the active thiopurine metabolites, are increasingly recognised as valuable 
clinical tools, to guide dosing and treatment.  
This work examines and develops methods for determining a patient's TPMT 
status and measuring 6TGN levels, adapting them for analysis using whole blood 
rather than washed red blood cell preparations. The advantages and limitations 
of these new assays in practice are investigated, which clearly shows that the 
more rapid new methods have increased clinical significance and utility. 
Experimental work and research provides an increased understanding of factors 
influencing determination and significance of a patient's TPMT status and 
thiopurine metabolite levels. This includes possible misclassification of TPMT 
status when expressing results in relation to patient haemoglobin and a 
longitudinal study of TPMT activity of patients commencing thiopurine therapy 
which demonstrates no enzyme induction. 
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1. INTRODUCTION 
 
1.1. Pharmacogenetics 
A patient’s response to a drug can be influenced by the genetic make-up of the 
individual. Genetic variation affecting drug metabolism can result in an 
unpredictable outcome to treatment.  Pharmacogenetics is the linking of 
differences in gene expression (genotype) to drug response (phenotype) and 
advances in this field are helping to better predict drug efficacy and toxicity. 
These developments have obvious major medical benefits as they enable 
optimization of drug dosage.  
The field of pharmacogenetics dates back to the 1950s, when it was first 
proposed that inherited traits may account for individual variability in drug 
response (Motulsky 1957). Today, one of the main applications of 
pharmacogenetics is research into disease mechanisms and new drug 
discovery. Meanwhile, development and clinical application, help to improve 
drug efficacy and safety. 
The possibility of therapy being more effective and better tolerated has enormous 
financial implications. Each year in the United Kingdom, adverse drug reactions 
(ADR) account for an estimated 6.5% of hospital admissions, at a cost to the 
National Health Service of approximately £466 million (Pirmohamed et al 2004). 
In the future, these medical costs may be compounded by claims for 
compensation, as patients may have a strong legal case, if their suffering could 
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have been averted. Many of the drugs responsible for ADR are metabolized by 
an enzyme with variant alleles (Zhou et al 2008). Pre-treatment screening of the 
enzyme phenotype or genotype could predict therapy outcome. Currently, the 
best clinically applied example of pharmacogenetics is the determination of 
thiopurine methyltransferase (TPMT) status prior to commencement of thiopurine 
drugs (Wang & Weinshilboum 2006), and it is this which forms the basis of this 
thesis. 
 
1.2. Clinical significance of TPMT 
TPMT (EC 2.1.1.6.7) is a cytosolic enzyme present in most cells of the body. It 
catalyses the S-methylation of aromatic and heterocyclic sulphydryl compounds 
(Weinshilboum 1989). TPMT is of clinical interest as it is involved in the 
metabolism of thiopurine drugs, for example azathioprine, 6-mercaptopurine 
(6MP) and 6-thioguanine (6TG). These drugs are largely used in the 
management of auto-immune diseases, in the disciplines of gastroenterology, 
dermatology and rheumatology. They are also used effectively in the 
management of acute lymphoblastic leukaemia and to prevent transplant organ 
rejection (Weinshilboum & Sladek 1980; Lennard & Lilleyman 1996; Anstey et al 
2004; Ernest & Seidman 2003; Whisnat & Pelkay 1982).  
 
It is estimated that approximately 60,000 patients per year commence thiopurine 
drug treatment in the UK. The most widely prescribed thiopurine drug is 
azathioprine, with the brand name IMURAN. This is now a generic drug, of 
  3 
relatively low cost, having been at the centre of a cost reduction agreement 
between the Government and the pharmaceutical industry. It is used extensively 
as it provides an attractive alternative to steroid treatment. Although thiopurine 
drugs are widely used, gastrointestinal intolerance, pancreatitis, hypersensitivity 
and myelosuppression are observed in up to 30% of patients. These ADR often 
result in the withdrawal of treatment (Weinshilboum & Sladek 1980; Lennard & 
Lilleyman 1996; Clunie & Lennard 2004; Anstey et al 1992). In some instances 
the unexpected reaction to therapy can be fatal, for example in cases of severe 
myelosuppression (Slaner et al 2008).  If this occurs, all cells produced in the 
bone marrow become suppressed. The reduction in leucocytes leaves the body 
susceptible to infection, while reduced platelets cause clotting abnormalities and 
red cell anaemia results. 
 
Comprehensive evaluation of the clinical benefit and cost effectiveness of 
screening strategies for pharmacogenetic testing in the UK is incomplete, despite 
the Government published a strategy in 2003 for maximizing the potential of 
genetics in the NHS (Department of Health). So far evidence has indicated 
sufficient benefit to warrant informing prescribers, pharmacists and patients of the 
available tests and their possible role in the selection and dosing of these drugs. 
This has prompted the Food and Drug Administration (FDA), in the United States 
of America, to approve label changes for 6MP and Azathioprine. 
 
 
41.3. Thiopurine drug metabolism
Figure 1.1 Azathioprine structure
Azathioprine is the 1-methyl-4-nitro-imadazolyl of thioguanine. It is classed as a 
pro-drug which is converted by the sulphydryl compounds, glutathione and 
cysteine, in red blood cells (RBC) to 6-mercaptopurine (6MP). This metabolite 
undergoes activation, via a multi-step enzymatic pathway, into thioguanine 
nucleotides (6TGN) (Lennard & Maddocks 1983) as seen in Figure 1.2. 6TGN 
achieve therapeutic efficacy primarily by virtue of their cytotoxic action. They are 
incorporated as false bases into newly synthesized DNA, preventing proliferation 
of the target bone marrow and white blood cells, and also interfere with other 
biochemical pathways. 
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Figure 1.2 Simplified azathioprine and 6MP biotransformation 
HPRT= hypoxanthine phosphoribosyltransferase, XO = xanthine 
oxidase, TPMT= thiopurine methyltransferase, IMPDH = inosine 
monophosphate dehydrogenase, GMPS = guanosine 
monophosphate synthase , SAM = S-adenosyl methionine  
 
 
 
Three enzymes, hypoxanthine phosphoribosyltransferase (HPRT), xanthine 
oxidase (XO) and thiopurine methyltransferase (TPMT) compete to break down 
6MP.  
 
The primary anabolic (HPRT) route, leads to pharmacologically active 6TGN. 
Normally, methylation by TPMT diverts a proportion of available substrate away 
from this pathway to form 6-methylmercaptopurine (6MMP). Therefore, a 
deficiency in TPMT activity will result in more substrate following the HPRT route 
and much higher concentration of 6TGN. Conversely, a high TPMT activity will 
result in more 6MMP but less 6TGN being produced, posing potential treatment 
AZATHIOPRINE 
6-THIOURIC ACID 6-MERCAPTOPURINE 6-METHYL MERCAPTOPURINE  
TGN 
 
GMPS 
IMPDH 
HPRT 
TPMT XO 
SAM 
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failure. The increased levels of 6MMP produced in this scenario can inhibit purine 
biosynthesis (Dever 2001) and lead to liver damage.  
 
Xanthine oxidase (XO) metabolises 6MP, by oxidation of the purine ring, to 
inactive thiouric acid which is excreted from the body. This catabolic process 
takes place in the liver and intestinal mucosa after oral administration of the drug. 
It has been shown that there is a 4 to 10 fold inter-individual variation in XO 
activity, with a significant sex related difference, XO activity tending to be higher 
in men (Guerciolini et al 1991). XO activity is very difficult to measure. 
Consequently, the effect of this on thiopurine treatment is not, as yet, clearly 
defined.  
 
1.4. Pharmacogenetics of TPMT 
Activity and stability of TPMT are primarily governed by a common autosomal co-
dominant polymorphism. This genetic variation gives rise to a trimodal distribution 
of TPMT activity, as shown in Figure 1.3, with approximately 89% of the 
population having normal TPMT activity, 0.3% with undetectable enzyme activity 
and a further 11% having low activity. (Weinshilboum & Sladek 1980).  
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Figure 1.3  Distribution of TPMT activity in a 1000 individuals 
Ford LT, Cooper SC, Lewis MJV & Berg JD.  Ann Clin Biochem 
2004; 41: 303-8 
 
Differences in mean TPMT activity between many ethnic groups have been 
observed. A local study by Cooper et al (2008) showed that Afro-Caribbeans 
have lower activity than Caucasians and south Asians. Gender differences have 
also been shown to exist, with slightly lower activity being observed among 
females (Klemetsdal et al 1993), especially South Asians (Cooper et al 2008). 
The first description of a TPMT assay was at the Mayo Clinic in the USA 
(Szumlanski et al 1992). In the UK, one centre has offered an assay since 1990, 
initially setting up the assay to prove that adverse reactions were often due to 
treatment of unknown TPMT deficient patients (Holme et al 2002). 
In recent years, it has gradually become established clinical practice to determine 
TPMT activity prior to treatment with azathioprine (Ernest & Seidman 2003). This 
0 
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screening does not reduce the necessity for careful clinical monitoring. Other 
factors can influence individual degrees of tolerance and clinical guidelines 
appropriate for one disease are not necessarily applicable to other pathological 
states. Mutations in the inosine triphosphatate pyrophosphohydrolase (ITPA) 
gene may also cause intolerance to azathioprine (Marinaki et al 2004 a & b; Von 
Ahsen et al 2005; Marsh & van Boovan 2009). Deficiency in this enzyme could 
lead to potentially increased concentrations of thioinosine triphosphate 
metabolites. Resulting symptoms would be non-myelosuppressive, for example 
nausea and pancreatitis (Ansari 2008). 
 
Thiopurine drugs have a relatively narrow therapeutic index, with little difference 
between therapeutic and toxic doses. Consequently, inappropriate dosing may 
result in ADR, at one end of the spectrum and treatment failure at the other. 
 
Individuals with undetectable TPMT activity are those most at risk of severe ADR 
including haemopoietic toxicity, myelosuppression or even death, as grossly high 
levels of 6TGN can occur if they are given standard thiopurine medication (Clunie 
& Lennard 2004).  Treatment with thiopurine drugs is contra-indicated for these 
patients, although there are reports of individuals with undetectable TPMT being 
treated successfully with <20% of normal thiopurine drug dosage (Kaskas et al 
2003). Individuals with normal TPMT activity can be given the full dose of the 
thiopurine drug from the start. Those with low activity can be treated, with fewer 
adverse effects, using a reduced dose (Lennard & Lilleyman 1996; Sanderson et 
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al 2004; Gardiner et al 2006; Richard et al 2007). Studies, including our own, 
have provided evidence of a cohort, of approximately 1.8%, with high TPMT 
activity (Szumlanski et al 1996; Sanderson et al 2004; Coulthard et al 2002; Ford 
et al 2006b), which may be predicted by an unknown genetic polymorphism. 
These patients may not respond to standard doses of thiopurine drugs, and are 
at risk of hepatotoxicity from increased production of methylated thiopurine 
metabolites such as 6MMP (Dubinsky 2004).  
 
1.5. Strategies for determining patient TPMT status 
1.5.1. Phenotyping 
Human TPMT phenotype is typically determined by measuring the enzyme 
activity in RBC. TPMT in these cells is easily accessible and demonstrates a 
level of enzyme activity and immunoreactive protein which is representative of 
that found in tissues, such as the liver, where the majority of thiopurine 
metabolism takes place. (Szumlanski et al 1992; Van Loon & Weinshilboum 
1982; Woodson et al 1982).   
 
The following methods are routinely used for TPMT phenotyping: 
 Radio-enzymatic methods - these rely on the transfer of methyl groups 
from radio-labelled 14C-methyl-S-adenosyl-methionine to 6-
mercaptopurine. The 14C-methyl thio-ether reaction product is then 
extracted into 20% iso-amyl alcohol in toluene. The radioactivity, which is 
directly proportional to TPMT activity, is measured using a scintillation 
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counter. (Weinshilboum et al 1978). These methods are unpopular as the 
use of radioactive isotopes has health and safety implications.  
 
 High Performance Liquid Chromatography (HPLC) - this is the most 
widely used strategy in routine clinical use. In a typical assay, the products 
of a reaction in which rate is directly related to TPMT activity, are 
measured by HPLC with ultra-violet, fluorescence or mass spectrometry 
detection. The metabolites are injected into a stream of high pressure 
liquid. This mobile phase carries the sample into a column where 
separation takes place, as different components have a different affinity for 
the column packing. Those with least affinity elute first and are carried to 
the detector where they are quantified. 
 
 Immunoassays - qualitative (Rapid Immunomigration) and quantitative 
(Enzyme Linked Immunosorbant) assays have been developed by 
BIOLOGIX Research Corporation. These utilize an antibody specific to the 
riboside of 6-methyl mercaptopurine. There is a kit on the market, but so 
far these methods have not found their way into routine use. 
 
The advantages of phenotyping are the relatively low costs and ease of 
analysis. The result assesses the activity of TPMT, giving an idea of the extent 
of gene expression which can be of major benefit. The three to four fold 
variations in activity, seen amongst wild type individuals, can influence dosing 
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even among this group (Yip et al 2008). Phenotypic assays can also assess 
other factors that may affect enzyme activity, for instance presence of inhibitors 
such as aminosalicylates (Dewit et al 2002). Disadvantages of phenotyping 
include possible misclassification for recently transfused patients. This can 
have serious consequences as the deficient status of a patient can be masked 
by TPMT activity present in the patient’s sample due to donor cells. (Ford et al 
2004b). Misclassification using phenotypic analysis could theoretically occur in 
patients whose therapy interferes with the in vitro reaction or which induces 
enzyme activity (Ames et al 1986; Lysaa RA 1996; Szumlanski & Weinshilboum 
1995; Woodson et al 1983; Xin et al 2005). 
 
1.5.2 Genotyping 
The TPMT cDNA and gene were cloned and characterized by Honchel et al in 
1993. The TPMT gene is located on chromosome 6 and is approximately 34 kb in 
length. It consists of 10 exons, 8 of which encode for a 245 amino acid long 
protein. The allele for normal TPMT activity (wild-type) has been designated 
TPMT *1 (Szumlanski et al 1996). At least twenty five genetic polymorphisms 
have so far been identified (Tamm et al 2008), the majority of which are 
associated with decreased levels of TPMT activity. Differences in specific mutant 
allele frequency have been observed between population groups (Otterness et al 
1997). The predominant variant alleles are TPMT*3A, TPMT*3C and to a lesser 
extent TPMT*2. In Caucasians the most common variant is TPMT*3A (~5%) 
which has two nucleotide polymorphisms (SNPs), on exon 7 and 10 (Yates et al 
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1997).  In African-Americans the most common mutant allele is TPMT *3C, which 
has the same, exon 10 SNP as for TPMT *3A (Szumlanski et al 1996), this is 
also the most common mutation in East Asians (Collie-Duguid et al 1998). It has 
also been observed that the frequency of mutations in the TPMT gene is lower in 
Chinese populations (Engen et al 2006). 
 
Techniques used for TPMT genotyping include:  
 Restriction Fragment Length Polymorphism (RFLP) - differentiation by 
analysis of patterns derived from cleavage of DNA, using restriction 
endonucleases, which cleave DNA molecules at specific nucleotide 
sequences. 
 
 Amplification Refractory Mutation System (ARMS) - takes advantage 
of the fact that the 3’-OH end of a primer bound to template DNA is 
required for the polymerase enzyme to synthesize a new copy of DNA. 
Any mismatch leads to PCR failure. Consequently, any point mutation can 
be detected by synthesizing two primers specific to the wild type or mutant 
DNA. Several mutations can be screened for at once, using multiplex 
reactions containing more than one set of primers. 
 
 Single Strand Conformational Polymorphism (SSCP) - this is a method 
to screen the exons of the TPMT gene for mutations using 
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electrophoresis. This method, although relatively simple and low cost, is 
time consuming and is not suited for routine use in a clinical setting. 
 
 Denaturing High-Performance Liquid Chromatography (DHPLC) - 
identifies mutations by detecting sequence variation in re-annealed DNA 
strands (hetero-duplexes). This method efficiently detects single 
nucleotide and insertion/deletion variation in crude PCR products directly 
without DNA sequencing. 
 
 DNA microchip technology - fluorescently labelled amplified DNA is 
hybridized with oligo-nucleotide DNA probes immobilized in gel pads on a 
biochip. This specially designed, costly biochip can recognize six point 
mutations in the TPMT gene and seven corresponding alleles associated 
with TPMT deficiency (Nasedkina et al 2006). 
 
 Mass spectrometry - highly multiplexed genotyping of TPMT variants has 
been performed using matrix-assisted laser desorption/ionization - time of 
flight analysis (MALDI-TOF) (Schaeffeler et al 2008). A matrix is used to 
protect the molecules during ionisation, transforming the energy from the 
laser into excitation energy. The time-of-flight analyser separates the ions 
according to their mass (m) to charge (z) (m/z) ratio by measuring the time 
it takes for them to travel through a field free region. 
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Most of these techniques require polymerase chain reaction (PCR), which 
amplifies a specific region of DNA, defined by a set of two ‘primers’. DNA 
synthesis is initiated by a thermo-stable DNA polymerase. It was developed in 
1987 by Kary Mullis and associates. Usually, at least a million-fold increase of a 
specific section of a DNA molecule can be realised, the amplified products 
(amplicons) are usually between 150-3,000 base pairs in length and can be 
separated and detected using gel electrophoresis. 
One of the main limitations of PCR based genotyping techniques is that they do 
not identify on which allele a mutation lies. Consequently, where two different 
heterozygous mutations are identified, it is not possible to distinguish whether 
they lie on the same allele or on different alleles. If they lie on the same allele, 
one allele is wild type. This is a heterozygote genotype which will result in low 
activity, requiring treatment with a reduced dose of thiopurines. If the mutations 
lie on different alleles the patient would be classed as a compound heterozygote. 
They would have deficient TPMT status and thiopurine drug therapy would be 
contraindicated. It is rarely practical to screen for all known TPMT mutations, so 
rare mutations are likely to be missed as well as any new deficient TPMT activity 
causing mutations. Another important disadvantage of TPMT genotyping is that it 
does not identify the small percentage of high methylators which are at risk of 
hepatoxicity (Dubinsky & Lamothe 2000). Genotypic analysis has the advantage 
of not being affected by drug interactions, RBC transfusions or sample age but 
methods are slower, much more costly than phenotyping, can only detect 
common mutations and do not give a quantitative result. Consequently, 
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genotyping is not often the first-line approach to routine TPMT screening. 
However, it has a clear complementary role, alongside phenotyping in a routine 
TPMT service, in the following scenarios: 
 
 To confirm the deficient TPMT status of patients identified by phenotyping. 
 Phenotypic / genotypic correlation. This will establish a clearer reference 
interval between patients heterozygous for the deficient TPMT activity 
allele and those who are homozygous for normal TPMT activity alleles. 
 To determine the TPMT status of patients who have recently been 
transfused, for whom phenotyping is not reliable. 
 
The concordance between phenotyping and genotyping has been reported to be 
approximately 60-70% for patients with low TPMT activity and >90% overall 
(Ford et al 2009; Schaeffeler et al 2004). 
 
1.6. City Hospital Birmingham International TPMT Screening Service 
At City Hospital a nationwide referral service was established in 2003. This is 
now used by over 200 external laboratories. This service has made TPMT testing 
in the UK quicker, cheaper and more accessible. In this time the laboratory has 
received over 60000 requests for TPMT phenotypic analysis.  Approximately 
12% of these were reported as a low TPMT activity, while over 200 patients with 
undetectable TPMT activity have been identified. At present, (Sept 2009) over 
350 samples are analysed per week, with the capability for over 160 per day. 
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The service provided for TPMT phenotyping used the determination of thiopurine 
S-methyltransferase activity in erythrocytes using 6-thioguanine as substrate and 
a non-extraction liquid chromatographic technique (Ford & Berg 2003). This was 
an improvement on older assays, making it more suitable for routine use. This 
was the first NHS hospital in-house assay to be CE marked. This has required 
the use of a rigorous vigilance system, described in Chapter 5, which has helped 
control this inherently complex assay.  
A strategy for routine genotyping TPMT alleles is also in place which underpins 
the phenotyping service. Based on the multiplex amplification refractory mutation 
system (ARMS) of Roberts et al, modifications make it more suitable for routine 
use. This offers a screening method for the TPMT gene, without having to resort 
to expensive molecular biology equipment. In comparison to restriction digest 
techniques, where incomplete cutting of the target DNA can lead to inaccurate 
results, it seems to be more reliable and is less time consuming. This can detect 
the common mutations of the TPMT gene, TPMT*2, TPMT *3A and TPMT *3C. 
 
1.7. Thioguanine Nucleotides 
The next step to aid management of patients on thiopurine drugs is the 
measurement of 6TGN. Monitoring of 6TGN levels can increase drug efficacy 
and reduce the likelihood of side effects as it guides dosage (Gearry et al 2006). 
A correlation has been demonstrated between 6TGN concentration and clinical 
remission rates (Cuffari et al 2001 & 2004; Dubinsky 2005). An inverse 
correlation has also been observed between the level of RBC 6TGN and 
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leucocyte counts, which is consistent with the immunosuppressive effects 6TGN 
(Lennard et al 2004). 
6TGN are formed as shown in Figure 1.3. This figure also shows the TPMT 
catalysed methylation of 6-thioinosine 5’-monophosphate which leads to the 
production of 6-methylthioinosine 5’-monophosphate. This metabolite is found in 
relatively high concentrations. It is an inhibitor of de novo purine synthesis and 
high levels are associated with hepatotoxicity (Gardiner et al 2008). 
 
 
Figure 1.4 Thioguanine nucleotide formation 
HPRT=hypoxanthine phosphoribosyltransferase, XO=xanthine 
oxidase, TPMT=thiopurine methyltransferase, IMPDH=inosine 
monophosphate dehydrogenase GMPS=guanosine 
monophosphate synthetase. The diphosphates and triphosphates 
are formed by their respective monophosphate (MPK) and 
diphosphate (DPK) kinases 
 
OXIDIZED 
METABOLITES 
6-MP 6-METHYL MERCAPTOPURINE  
6-THIOINOSINE 5’-MONOPHOSPHATE 
 
IMPDH 
HRPT 
TPMT XO 
6-THIOXANTHOSINE 5’-MONOPHOSPHATE 
GMPS 
6-THIOGUANOSINE 5’-MONOPHOSPHATE 
MPK 
6-THIOGUANOSINE 5’-DIPHOSPHATE 
DPK 
6-THIOGUANOSINE 5’-TRIPHOSPHATE 
6-THIOGUANINE 
NUCLEOTIDES 
TPMT 
HRPT 
6-METHYLTHIOINOSINE  
5’-MONOPHOSPHATE 
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Therapeutic drug monitoring of thiopurine drugs is complex. Plasma 6MP levels 
and the measurement of plasma and urine thiouric acid, the xanthine oxidase 
pathway metabolite, have been utilised (Weller et al 1995; Bruunshuus & 
Schmiegelow 1989). Thiouric acid is only useful in assessing compliance, as it 
does not give any indication of therapeutic response. Both these assays are 
limited in their reliability to predict efficacy or toxicity. A greater understanding of 
thiopurine metabolic pathways has led to the development of methods to estimate 
6TGN concentration. These assays use erythrocytes as an indicator of 
intracellular levels of metabolites in the target cells i.e. peripheral blood 
leucocytes or bone marrow pre-cursors. The RBC is not an ideal surrogate for 
these target cells as it is not nucleated. It therefore lacks full purine functionality, 
as IMPDH, one of the enzymes required for the conversion of 6MP to 6TGN, is 
not expressed in erythrocytes. The 6TGN produced, as a result of 6MP 
metabolism, are made indirectly, largely in hepatic tissue. Therefore erythrocyte 
6TGN levels are more likely to reflect liver cell, rather than target white blood cell 
metabolism. (Dulay & Florin 2005).  This is different for patients being treated with 
6-thioguanine (6TG), a guanine analogue that can be converted to 6TGN via 
HRPT. This direct incorporation of 6TG into 6TGN, compared with the indirect 
route followed by 6MP, results in relatively higher RBC 6TGN in patients 
receiving 6TG than those on 6MP. Patients who prove intolerant to 6MP may 
benefit from 6TG therapy. (Dulay & Florin 2005). Ideally 6TGN should be 
measured in non-stimulated target cells. This would be difficult in practice as it 
would involve the laborious purification of leucocytes. In the measurement of 
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RBC 6TGN it is difficult to avoid contamination with white blood cells, which could 
affect results. Further problems arise when considering sample stability between 
collection and analysis. The degree of degradation of the labile cell nucleotides 
depends on factors such as storage conditions, time and anti-coagulant used. 
 
Increased RBC 6TGN and improved efficacy of 6MP and azathioprine have been 
noted when these thiopurines are co-administered with allopurinol (Teml et al 2007). 
This is a treatment which prevents hyperuraemia, gout and formation of calcium 
oxalate renal stones. Allopurinol inhibits xanthine oxidase, theoretically increasing the 
conversion from 6MP to 6TGN. A patient receiving this drug would require a reduction 
in their thiopurine dose, to a third or less, suggesting that two thirds of a normal dose 
is catabolized by xanthine oxidase. This contradicts the experience of patients that are 
deficient for TPMT who are successfully treated with 5% of a normal dose. This would 
suggest that 95% of 6MP is catabolized by TPMT. It has been found that allopurinol 
co-therapy with low-dose Azathioprine can alleviate thiopurine hepatotoxicity (Ansari et 
al 2008). 
Studies have demonstrated elevated 6TGN levels and subsequent thiopurine 
sensitivity in patients treated with methotrexate, an antifolate drug. It has been 
suggested that a polymorphism of a key folate gene (MTHFR) may be 
responsible. This gene regulates the supply of the s-adenosyl - methionine (SAM) 
co-factor. 
Complex variations e.g. differing tissue distribution, possible inhibition or 
induction of enzymes, require research to explain these drug interactions further. 
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1.8. Research Objectives 
1.8.1 Development and implementation of whole blood TPMT assay 
Since its introduction, improvement of the TPMT service at City Hospital has 
been ongoing. Pre-analytical steps of TPMT phenotype analysis, using the 
method of Ford & Berg 2003, were quite laborious, using a series of 
centrifugation and washing steps to prepare erythrocytes, from which a lysate 
was finally produced. This required a relatively large primary sample volume. 
Also, it had become apparent that the pellet of washed red blood cells, produced 
as part of this process, was not homogeneous, as repeat aliquots did not give the 
same result. Further washing and mixing was required to obtain a sample that 
could be aliquoted repeatedly to give acceptable precision.  
 
Further issues involved higher than expected numbers of patients having results 
reported in the low activity range. It was suspected that the cut-off between low 
and normal activity was set too high. Possible explanations for this include: 
 
 Reference ranges were established using results from samples that had 
been taken in the last 24hrs, which is not typical for the samples routinely 
received for analysis, although our studies have shown TPMT activity to 
be stable at 4°C for up to 8 days. 
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 The patient group from which samples are received is not a 'normal' 
population; many could be undergoing therapy that could affect observed 
TPMT activity. 
 
 As the method has become optimised, under the efforts of continuous 
quality improvement, variables that could impact on results have come 
under more vigilant control. 
 
A major research objective in this work has been to develop a new method for 
analysis of TPMT in whole blood. Research would then be carried out to 
determine if whole blood is better than RBC for monitoring TPMT activity and 
detection of any induction effects as the new assay entered routine use. A major 
comparative study between activity in RBC preparations and activity in whole 
blood samples alongside relevant screening for common genetic mutations is 
also presented. 
 
1.8.2 Monitoring the new assay 
This work assesses the whole blood TPMT phenotyping methodology. This has 
involved looking at all aspects of the method, identifying actual and potential 
causes of variation and implementing limiting measures wherever possible. 
Reagents, enzyme kinetics, operator variability and instrumentation are all 
evaluated. The effect of sample age and haemoglobin concentration will also be 
considered. Finally the use of the service will be assessed. 
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1.8.3 Development and implementation of whole blood 6TGN assay 
A method for 6TGN analysis in RBC lysates has already been developed in the 
City Hospital Laboratory. This technique is rapid and well suited for routine use in 
a clinical laboratory and provides a service for 6TGN monitoring in the UK. A 
further aim of this work has been to improve this method and assess the 
feasibility of measuring 6TGN in whole blood rather than washed erythrocytes. 
 
1.8.4 Induction study 
It has been suggested that TPMT activity may be induced by thiopurine drugs 
(Weyer et al 2001; Thervet et al 2001). If induction occurs this may necessitate 
dose adjustment during therapy to maintain adequate active metabolite levels 
and associated therapeutic effects. Induction effects may be more apparent in 
whole blood samples, due to the presence of nucleated cells which unlike 
erythrocytes can continually synthesize protein. To test this hypothesis it is 
intended to monitor TPMT activity and 6TGN levels in patients commencing on 
azathioprine treatment. 
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2. MATERIALS AND METHODS 
 
2.1 TPMT Phenotyping 
 
2.1.1 Assay principle 
TPMT catalyses the methylation of 6-thioguanine (6TG), in the presence of a 
methyl donor, to produce highly fluorescent 6-methylthioguanine (6MTG). The 
amount of 6MTG produced is directly proportional to the amount of enzyme in the 
sample. Results are expressed in nmol 6MTG/g Hb/hour. 
 
6 - Thioguanine    6 - Methylthioguanine 
 
 
 
S- Adenosyl Methionine 
       (methyl donor) 
 
 
2.1.2 Red blood cell (RBC) method 
A lysate of RBC was prepared from a whole blood sample containing the 
anticoagulant ethylenediaminetetraacetic acid (EDTA). The sample was 
centrifuged at 2000g for 5 minutes then the plasma and buffy coat removed. An 
equal volume of sterile physiological saline was added to the cells; the sample 
was then mixed and re-centrifuged. The supernatant and white blood cells 
(WBC) were removed and the RBC rewashed in saline, retaining the WBC for 
genotyping if required. After a third centrifugation the supernatant and any white 
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cells were discarded, 200ul of the washed, packed RBC were then mixed with 
1ml of phosphate buffer (0.02M KH2PO4 (Sigma-Aldrich) titrated with 0.02M 
K2HPO4 (Sigma-Aldrich) to pH 7.4). The hypotonic shock lysed the RBC.  
The haemoglobin concentration of the lysate was measured using a colorimetric 
method. The reagent (Bayer ADVIA Haemoglobin) is 20mM potassium cyanide in 
a 2% dimethyllaurylamine oxide solution. In this method the haem iron in the 
haemoglobin is oxidised from the ferrous to the ferric state. It is then combined 
with cyanide to form the reaction product, which is measured at 546nm. 
(Instrumentation Laboratories ILab 600 analyser). 
 
Haemoglobin + Reagent          Methaemoglobin       Cyanide haemoglobin 
  Fe++     Fe+++            Fe+++.CN 
 
2.1.3 TPMT incubations 
200ul of lysate was added to 500ul of Test Reagent (59mg S-adenosyl 
methionine (Sigma-Aldrich) and 140mg 6TG (Alpha Aesar) in 1 litre of 0.1M 
phosphate buffer 0.01M KH2PO4 (Sigma-Aldrich) titrated with 0.01M K2HPO4 
(Sigma-Aldrich) to pH 7.4). This mixture was incubated at 37°C, for one hour. 
Protein was precipitated by heating to 90°C and removed by centrifugation.  
 
2.1.4 HPLC analysis 
The 6MTG produced was measured by reverse phase HPLC, using a Kingsorb 
3µ C18 90A, 75 x 4.6mm column (Phenonomex). The mobile phase used was 
0.05M phosphate buffer (0.05M KH2PO4 (Sigma-Aldrich) titrated with 0.05M 
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K2HPO4 (Sigma-Aldrich) to pH 6.2), acetonitrile (VWR) and tetrahydrofuran 
(VWR) in the ratio 89:7:4. Fluorescence detection was performed at an emission 
wavelength of 390nm, excitation 315nm (Shimadzu HPLC, LC Solutions 
software). A 0.11nmol/L 6MTG (Sigma-Aldrich) one-point calibrator (20ng/L) was 
used. Normal and low TPMT control samples were prepared from volunteers with 
a known genotype. The Sandwell and West Birmingham Ethical Committee have 
given approval for collection of these samples. Calibrators and controls were 
treated in the same way as patient samples.  
This method used is based on that of Ford & Berg, published in 2003. Reference 
ranges were published based on 1000 results from out-patients in the local 
population (Ford et al 2004a). 
   nmol/6MTG/gHb/h 
TPMT Deficient  <5   
Low Activity    6-24   
Normal Activity  25-55  
High activity  >55 
 
2.2 TPMT genotyping extraction 
2.2.1 Cell lysis 
0.5ml of the white blood cell rich buffy coat was treated, on ice for 20 minutes, 
with 1ml buffer (0.32M sucrose, 1% Triton-X 100, 0.01M Tris pH 7.5, 0.005M 
MgCl2 (Sigma-Aldrich)), to lyse the cells The samples were then centrifuged, the 
cell lysis step repeated and centrifuged once more, before removal of the 
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supernatant. The resulting nuclear material pellet was re-suspended in 100µl 
buffer (10mM Tris-HCl, 0.4M NaCl, 2mM EDTA titrated to pH 8.2 with NaOH 
(Sigma-Aldrich)) and 5µl 10% sodium dodecysulphate (Sigma-Aldrich). Protein 
digestion was achieved by incubation with 10µl 10mg/ml DNAse free Proteinase 
K (Sigma-Aldrich) in a water bath, for 2.5 hours at 65°C or 37°C overnight. 
 
2.2.2 Phenol/chloroform extraction 
The protein digests were mixed gently with an equal volume of buffered phenol 
pH 8.0 (QBiogene), then centrifuged and the upper aqueous layer removed and 
retained. Treatment with phenol and centrifugation was repeated until the 
resultant aqueous layer was clear. 300ul of Chloroform/Butanol 80:20 (Sigma-
Aldrich) was added to the aqueous phase and mixed gently by inversion, 
followed by centrifugation. The supernatant was transferred to a sterile micro-
centrifuge tube. 
 
2.2.3 DNA precipitation 
Sodium acetate (3M) was added to the supernatant in the ratio 1:10. The sodium 
ions shield the negative charges on the DNA phosphates. This decreases inter-
strand repulsion and allows the nucleic acids to aggregate. Four volumes of ice-
cold 100% ethanol (Sigma-Aldrich) were then added, the precipitated DNA 
appeared as white strands. After gentle mixing, followed by centrifugation for 10 
minutes, the ethanol was removed. 300µl of ice-cold 70% ethanol was added to 
the pellet of DNA. After gentle mixing, the ethanol was removed and the pellet 
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left to dry at room temperature for approximately 20 minutes. The dried pellet 
was re-suspended in 50-200µl (depending on the size of the pellet) buffer (10 
mM Tris pH 8.0 and 
1 mM EDTA (Sigma-Aldrich)). The pellet was left to dissolve at room temperature 
for a minimum of 30 min then stored at -80C. 
 
2.2.4 Purity and concentration of DNA 
Care must be taken to ensure protein and phenol are absent from the isolated 
DNA as both can interfere with PCR reactions.  The purity of the isolated DNA 
can be assessed by measuring the absorbance at 260 and 280nm.  Pure 
preparations of DNA have ratios of optical density at 260nm / optical density at 
280nm of 1.7-2.0 (a ratio < 1.7 suggests phenol or protein contamination, >2.0 
suggests RNA contamination). 
The DNA concentration in g/ml can be estimated using the Beer-Lambert Law, 
A = cl, which relates the amount of light absorbed at a given wavelength to the 
molar extinction coefficient and concentration of an absorbing molecule. Where A 
is absorbance,  is the molar extinction coefficient, c is the concentration of the 
solute, and l is the length of the light path of the solution measured (cm). Maximal 
spectral absorption by double stranded DNA occurs at 260 nm and is 
characterized by a specific absorption coefficient of 0.02(µg/ml) –1 cm –1. This 
absorption is a function of the molar extinction coefficients of the substituent 
nucleotide bases.  
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If the DNA concentration is very low (<50 g/ml) the DNA can be concentrated by 
re-precipitation in ethanol, drying then re-suspension in a smaller volume of 
buffer. If the DNA concentration is very high (>500 g/ml), it can be diluted with 
buffer, until a final concentration of 500 g/ml is achieved. 
2.3. TPMT genotyping polymerase chain reaction 
This simplified version of the ARMS of Roberts et al uses a PCR master-mix 
which contains pre-optimised concentrations DNA polymerase, MgCl2, 
deoxynucleotide triphosphate and buffer. Using a master-mix reduces the 
number of pipetting steps which decreases the time taken to set up a reaction, 
reducing the likelihood of pipetting errors and increasing reproducibility. 
Primers used for ARMS analysis were for the common mutations of the TPMT 
gene TPMT*2, and TPMT*3C and were custom-synthesised to order. The 
synthesis scale used was Standard >15 O.D. units.  
The specificity of the primers was checked using NCBI BLAST programme 
(www.ncbi.nih.gov/BLAST/) 
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2.3.1   Primer sequences 
 
 
 
Primer Type 
(wildtype/mutation) 
Direction  Sequence (5’ – 3’) 
TPMT2C Common wild type Sense ATCTgCTTTCCTgCATgTTCT TTgAAACCC 
TPMT2W Wild type Antisense CACACCAACTACACTgTgTCCCCggTCTCC 
TPMT2M TPMT*2 mutation Antisense CACACCAACTACACTgTgTCCCCggTCTCg 
TPMT3CC Common wild type Sense ATTTTTAgTAgAgACAgAgTTTCACCATCT 
NTPMT3CW Wild type Antisense TgTCTCATTTACTTTTCTgTAAgTAgTT 
NTPMT3CM TPMT*3C mutation Antisense TgTCTCATTTACTTTTCTgTAAgTAgTC 
 
Table 2.1 Primer sequences 
 
Primer positions indicated are relative to the sequence of human TPMT gene, 
Genbank Accession number AB045146.  
 
2.3.2 Primer composition 
Two different multiplex reactions are required for TPMT genotyping: 
TPMT32Wild 
TPMT32Mutant 
 
EXON 1 2 3 4 5 6 7 8 9 10
TPMT3CC
TPMT3CW
TPMT3CM
TPMT*3C A719G
5’ 3’
TPMT2W
TPMT2MTPMT2C
TPMT*2 G238C
TPMT3BW
TPMT3BM TPMT3BCPRIMERS
TPMT*3B G460AMUTATION
  30 
The primer composition of each multiplex reaction is shown in the table below: 
Multiplex 
Reaction 
Reaction Forward 
Primer 
Reverse 
Primer 
Predicted Product 
Size 
TPMT32Wild B2M (Control) BMIF BMIR 574 
 WildType TPMT*2 TPMT2C TPMT2W 194 
 WildType TPMT*3 TPMT3CC NTPMT3CW 325 
TPMT32Mut B2M (Control) BMIF BMIR 574 
 Mutant TPMT*2 TPMT2C TPMT2M 194 
 Mutant TPMT*3 TPMT3CC NTPMT3CM 325 
 
Table 2.2 Multiplex reaction primer composition 
 
Method 
For each multiplex reaction, 20 l of the appropriate 100mol/L primer stocks 
(Alta Bioscience) were added and made up to a final volume of 1 ml using sterile 
water.  After mixing by inversion 10 x 100 L fractions were aliquoted into 1.5 ml 
labelled sterile micro-centrifuge tubes and store at -20C. Before use, the 
multiplex PCR master mix kit, multiplex primer mixes and patient DNA samples 
were completely thawed at room temperature. 
To guard against cross-contamination a blank containing no DNA template was 
performed for both the TPMT32Wild and TPMT32Mut multiplex reactions 
Analysis of TPMT*1/*1, TPMT*1/*2, TPMT*1/*3C and TPMT*3C/*3C control DNA 
was included each time the PCR analysis was performed 
Both TPMT32Wild and TPMT32Mut multiplex reactions were performed for every 
patient sample. 2.5µl of the appropriate primer master mix and 1ul of DNA was 
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added to a 0.2ml thermal tube containing 9µl of RNase-free water and 12.5µl 
multiplex master mix (Queen).  
The tubes were processed in the thermal cycle using the following parameters: 
Stage Temp Time Cycles Prig N
o
 Link 
HotStarTaq DNA 
polymerase activation 
95C 15 min 1 4 5 
PCR Amplification: 
Denaturing 
Annealing 
Extension 
 
94C 
62.5C 
72C 
 
30s 
90s 
30s 
30 5 7 
Final Primer Extension 72C 2 min 1 7 8 
Hold at 4C 4C Hold 1 8 E 
 
Table 2.3 PCR Parameters 
2.4. TPMT genotyping electrophoresis and visualisation 
Agarose (2g) (Sigma-Aldrich) was heated until dissolved in 100ml of a 1:5 
dilution of Tris borate EDTA (TBE) buffer (54g Tris base (Sigma-Aldrich), 27.5g 
boric acid (Sigma-Aldrich), 7.4g EDTA (Sigma-Aldrich) made up to 1 litre in 
distilled water). After cooling to approximately 65°C, 5µl ethidium bromide 
(Sigma-Aldrich) was mixed in and the molten gel poured into a welled casting 
tray. When set the gel was placed in the electrophoresis gel chamber and 
submerged in 1:5 TBE buffer.  
A loading dye was prepared from (25mg Orange-G (Sigma-Aldrich), 1.5g Ficoll 
(Sigma-Aldrich), 100µl 1M Tris pH 8.0 (Sigma-Aldrich), 20µl 0.5M EDTA (Sigma-
Aldrich)). 5µl of dye was mixed with each 25ul of ARMS PCR reaction mix, 20µl 
of this mixture was loaded into the wells. Electrophoresis of the PCR products 
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was carried out at 100V for approximately 45 minutes, until adequate separation 
was achieved as indicated by the dye front. 
The resulting DNA fragments were visualised under UV light using a Gene 
Genius Bio-imaging system (Syngene). 
2.5. Thioguanine nucleotides 
2.5.1 Assay principle 
6TGN extraction is performed using a single reagent containing perchloric acid, 
an internal standard (IS) and an anti-oxidant. 6TGN are hydrolysed back to 6TG 
which is measured using isocratic HPLC with UV detection. 
2.5.2 Method 
RBC were first isolated from other blood components in a whole blood EDTA 
sample. This was achieved by centrifugation, removal of plasma and buffy coat 
and washing RBC in an equal volume of physiological saline. These steps were 
repeated and the resulting RBC re-suspended in saline, aiming for an 
approximate red cell count of 8x1012 cells/L. 
A red cell count was performed (Bayer Advia 120). Two 100µl aliquots were 
pipetted into labelled micro-centrifuge tubes, using a displacement pipette, these 
were frozen for a minimum of 15 minutes at -80°C before analysis. 
A concentrated calibrator stock solution (20mg/100ml) was prepared from 20mg 
6TG (Alpha Aesar) dissolved in 4ml of 0.1M NaOH (Sigma-Aldrich) made up to 
100ml with distilled water. This was diluted 1:20 in distilled water to give 
1mg/100ml. This was further 1:20 diluted with Paratek (Alpha Laboratories) a 
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haematology blood control (checked to contain no measurable 6TGN/6TG), to 
give a working concentration of 50ng/ml. 
An internal quality control sample was also prepared from pooled patient 
samples. Samples where clinical details indicated that the patient was on 
thiopurine therapy were collected and the RBC washed as previously described. 
These were pooled, mixed and aliquoted into 100µl fractions and stored at -80°C. 
This was initially analysed 5 times to give a target internal quality control 
concentration. 
Two 100µl aliquots of calibrator, internal quality control and each patient sample 
were allowed to defrost at room temperature. 500µl of hydrolysing reagent (10ml 
70% perchloric acid (Sigma-Aldrich), 400µl 10mM 5-bromouricil (Sigma-Aldrich), 
500mg DL-Dithiothreitol (DTT) (Sigma-Aldrich) made up to 100ml with distilled 
water) was added to each aliquot. Each aliquot was capped and vortex mixed 
immediately after addition of the hydrolysing reagent. The samples were then 
centrifuged, to separate the precipitated proteins. The supernatant from each 
micro-centrifuge tube was then transferred, using a micro-pastette, into 
appropriately labelled HPLC vials. The vials were then capped and heated at 
95°C for 1 hour to hydrolyse liberated 6TGN back to their parent 6TG. The 
addition of DTT prevents oxidative degradation of 6TG, which is promoted by 
contaminant ions and UV light and prevents the binding of 6TG to acid denatured 
RBC proteins. The 6TG concentration is measured using HPLC with UV 
detection at a wavelength of 304nm.  Any losses are accounted for by inclusion 
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of the internal standard, 5-bromouracil, which is detected at a wavelength of 
342nm. 
The hydrolysing reagent was found to stable for at least 1 week at room 
temperature. Aliquots of a sample stored at -80°C were analysed over an eight 
day period with both freshly prepared reagent and reagent prepared on Day 1.  
Results are as follows: 
 
Day 
 
6TGN pmol/8x108 cells 
Fresh Reagent 
 
6TGN pmol/8x108 cells 
Pre-prepared Reagent 
1 215 215 
4 248 232 
6 249 261 
7 201 201 
8 257 253 
 
Table 2.4   Stability of 6TGN hydrolysing reagent 
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Figure 2.1  Stability of 6TGN hydrolysing reagent 
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3. WHOLE BLOOD TPMT ACTIVITY 
 
3.1 Development of a new phenotyping assay underpinned by genotyping 
 
 
This section of work develops a new TPMT phenotyping method, which analyses 
whole blood rather than washed RBC. This new method uses freezing at -80C as 
the method of cell rupture, instead of using a lysis buffer.  
Whole blood samples (n=402) that had been collected into EDTA tubes and 
received for routine analyses of TPMT activity, were selected randomly over a 
four-week period.  Samples were stored for a maximum of 2 days at 4C prior to 
analysis. Samples greater than 8 days old at time of analysis were excluded from 
the study as earlier work in the department has shown TPMT activity to decline 
after a week at room temperature. 
 
3.1.1 Phenotype 
The whole blood samples were mixed well by inversion and two 200 l aliquots 
were accurately pipetted into test tubes and capped.  The tubes were frozen for 
15 minutes at -80C to disrupt the cells, percentage cells lysed is detailed in 
Chapter 5.3.  The cells were shock thawed by the addition of 600 l of whole 
blood suspension buffer (0.1 M KH2PO4 titrated with 0.1 M K2HPO4 (Sigma-
Aldrich) to pH 7.4), then vortex mixed.  RBC lysates were also prepared in 
duplicate, from the same EDTA blood samples. The buffy coats were retained in 
separate labelled test tubes for DNA extraction and TPMT genotyping.   
  36 
 
Figure 3.1  Whole blood TPMT analysis 
 
Freeze 200µl whole blood at -80°C for 15 
minutes. Add 600µl buffer and mix to produce 
a whole blood lysate 
Determine lysate haemoglobin concentration 
Incubate 200µl of lysate with 500ul of test 
reagent for exactly 1 hour at 37°C 
Stop the reaction by heat inactivation at 95°C  
for 10 minutes 
Centrifuge vials to produce a clear supernatant 
Measure 6MTG by HPLC fluorimetry 
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The TPMT enzyme reaction, determination of haemoglobin concentration and 
HPLC analysis were performed on all whole blood and RBC lysates, as 
described in the methods chapter. 
 
For both the standard RBC and whole blood methods, TPMT activities were 
calculated from 6-methyl-thioguanine (6MTG) peak height, and expressed in 
relation to haemoglobin concentration (nmol 6MTG/gHb/h).  
 
3.1.2 Genotyping   
DNA was extracted from buffy coats using phenol-chloroform extraction and our 
multiplex amplification refractory mutation system (ARMS) strategy was used to 
screen for the common TPMT mutations, TPMT*2 and TPMT*3 (TPMT*3A, 
TPMT*3C and TPMT*3D). The gel provides the support medium for the 
separation of the DNA fragments which were visualised using ethidium bromide, 
under UV light as shown in Figure 3.1. 
For each PCR run it was checked that there were no products in the blank 
reactions. If there were, due to cross-contamination, the run was rejected and 
repeated.  
For each DNA sample it was checked that the control B2M product was present 
in both the wild and mutant reactions, if it was not the ARMS reaction was 
rejected and repeated. 
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TPMT*3/*3TPMT*1/*3TPMT Genotype: TPMT*1/*1 TPMT*1/*2
TPMT*3 325bp
TPMT*2 194bp
Control  574bp
ARMS Reaction: 
PCR Product
Wild Mut Wild Mut Wild Mut Wild Mut
As part of the DNA method, quality control checks were made to ensure that the 
TPMT*1/*1, TPMT*1/*3C, TPMT*1/*2 and TPMT*3C/*3C control DNA reactions 
had all worked. If these QC checks failed the run was rejected and repeated. 
 
 
 
 
 
Figure 3.2  Examples of DNA fragments visualized for wild type, 
heterozygous and homozygous deficient genotypes 
 
To evaluate this new technique the whole blood results were compared to both 
the established RBC lysate method results and the TPMT genotype.  Agreement 
between duplicates for each assay was compared and the percentage difference 
between methods was calculated. Reference intervals were determined for the 
new whole blood assay, in-line with the RBC method, by using the already 
established percentages for deficient, low and normal TPMT status individuals, 
previously obtained from the RBC method phenotyping-genotyping data (Ford et 
al 2004a). 
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3.1.3 Results 
The data for this study can be found in Appendix 2 
Method Mean TPMT Median Std Dev SE Mean Min Max 
RBC 37.0 36.0 11.3 0.56 0.0 82.0 
Whole Blood 51.0 50.0 13.6 0.68 0.0 102.0 
 
 
Table 3.1 Summary of TPMT activities in nmol 6MTG/gHb/h for 
RBC / whole blood comparison study. 402 samples analysed in 
 duplicate by both methods 
 
The intra and inter batch variation for the new method was determined using 
EDTA whole blood collected from a healthy volunteer. 
Method Imprecision Mean TPMT activity 
(nmol 6MTG/gHb/h) 
CV (%) n 
 
Conventional 
RBC 
Within batch 39 3.6 10 
Between batch 53 8.0 20 
 
New 
Whole Blood 
Within batch 45 2.7 10 
Between batch 53 7.6 20 
 
Table 3.2 Within batch and between batch imprecision data for RBC and 
whole blood phenotyping methods 
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3.2 Correlation of enzyme activities 
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Figure 3.3 Relationship between mean whole blood and mean RBC TPMT 
activity r = 0.834  
 
3.3  Comparison with genotyping 
 
TPMT activities were higher, per g of Hb, in whole blood than in RBC, in 98.5% 
of samples. The mean percentage increase observed in whole blood was 
calculated to be 42%, with a range of -8.5% to 172.5%. The mean TPMT activity 
for whole blood was 51 nmol 6MTG/gHb/h compared to the RBC lysate mean of 
37. 
The normal, low and deficient TPMT groups give rise to tri-modal distributions of 
activity. These three groups can be seen for both methods in Figure 3.4.  
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TPMT Activity (nmol 6-MTG/gHb/h) 
(b) 
10 13 16 19 22 25 28 31 34 37 40 43 46 49 52 55 58 61 64 67 70 73 76 79 82 85 88 91 94 97 10
0 
20 
0 
5 
10 
15 
1 4 7 
  
(a) 
Figure 3.4  Distribution of TPMT activity and genotype in 402 individuals  
(a) TPMT activity measured using red blood cell lysate. (b) TPMT activity measured using 
Whole blood lysate.  Individuals with a TPMT*3/*3 genotype are shaded red, a heterozygous  
genotype, either TPMT*1/*2 or TPMT*1/*3 are shaded black and TPMT*1/*1 genotype white. 
TPMT, thiopurine S-methyltransferase; 6-MTG, methylthioguanine 
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Genotype Number of Patients % of Patient Total 
TPMT *3/*3 2 0.5 
TPMT *1/*3 31 7.7 
TPMT *1/*2 3 0.8 
TPMT *1/*1 366 91 
 
Table 3.2 Summary of TPMT genotypes for RBC / whole blood 
comparison study 
 
 
Concordance between low TPMT activity and heterozygotes was 79% for both 
the new whole blood and standard RBC lysate methods, while overall 
concordance with genotypic analysis was 97% for both phenotypic methods. This 
is as expected as the RBC assay has been used to determine the whole blood 
assay reference intervals.  
 
3.4 Advantages of new assay 
 
Offering whole blood TPMT phenotyping has a number of benefits: 
 Easier and quicker - Washed RBC do not need to be prepared. 
Elimination of washing the cells twice in physiological saline saves around 
two hours of biomedical scientist time on an average working day. This 
has obvious cost and turnaround time implications. 
 Safer - Sampling is directly from the primary tubes which are used to take 
blood from the patient and are fully labelled. This minimises any sample 
handling errors. 
 More reproducible - The original whole blood sample is more 
homogeneous than a pellet of washed cells. The mean percentage 
difference between duplicates was 9.4% for RBC lysates and 5.1% for 
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whole blood. This shows that the new whole blood method can inherently 
give more reproducible results 
 Increased accuracy - Whole blood may give a better indication of what is 
happening in vivo rather than RBC only, being representative of the 
reactions taking place in drug metabolizing tissues. 
 
Multiplex ARMS testing for TPMT*2 and 3*C mutations has been used to define 
the reference ranges for low and normal TPMT activity. This has been used to 
demonstrate that the new whole blood TPMT phenotyping method performs as 
well as the conventional RBC lysate assay.  This new method overcomes the 
need to prepare washed RBC, a process that is time-consuming, and increases 
analytical variation.  The resulting assay is better suited to a regional or national 
TPMT phenotyping service. 
When whole blood samples were analysed, using the RBC method, higher 
activity was virtually always observed. It was postulated that this increase was 
due to the contribution to TPMT activity by leucocytes. In some samples, the 
whole blood activity was markedly higher than in RBC. This led to the hypothesis 
that TPMT activity maybe induced in some patients, which would be seen 
primarily in the nucleated white blood cells. 
The development of this assay has been published by us; Ford L, Graham V, 
Berg J. (2006) Whole-blood thiopurine S-methyltransferase activity with genotype 
concordance: a new, simplified phenotyping assay. Ann Clin Biochem. Sep;43(Pt 
5):354-60
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4. EVALUATION OF PHENOTYPING 
 
4.1 Enzyme Assay 
4.1.1 Introduction 
Our TPMT phenotyping method depends on the measurement of the product 
formed in the reaction: 
     
 
 
 
 
  6TG        6MTG 
 
Figure 4.1  TPMT phenotyping reaction 
 
A constant rate of reaction, where velocity throughout the incubation time is 
directly proportional to enzyme concentration, is required in order to calculate 
enzyme activity. 
In reactions of this type reaction rate can decline due to: 
 Substrate depletion - velocity decreases as the enzyme becomes less 
saturated 
 Product inhibition 
 Instability of components 
TPMT 
S- Adenosyl 
Methionine 
  45 
 Assay method artefact - if the specific detection procedure ceases to 
respond linearly to increasing product concentration, this can lead to a 
decline in the measured rate of reaction with time 
 Change in assay conditions - for example if a reaction causes a pH 
change, this will affect the rate if adequate buffering systems are not in 
place.  
These factors are controlled in the assay and the reaction is stopped after a fixed 
incubation time, within the linear period. 
 
4.1.2 Establishing substrate concentrations 
Enzyme kinetics are examined periodically, usually when a new lot of substrate is 
received, or when problems are encountered, to ensure measurement is being 
performed in the linear range. 
In our assay, where the amount of enzyme present is being determined, the 
amount of product needs to be influenced by the level of enzyme activity only. 
Therefore zero order kinetics are established, with regard to our two substrates. 
The concentration of 6TG and SAM is determined using a Michaelis Menten 
approach to ensure there is sufficient of each substrate in the reaction mixture to 
achieve such zero order kinetics. This is carried out by analysing a high activity 
sample using the routine phenotyping method, but varying the substrate 
concentrations independently as shown in Figures 4.2 and 4.3. 
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Figure 4.2 Michaelis Menten plot for 6TG showing the final choice of 
 substrate concentration used in the assay 
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Figure 4.3 Michaelis Menten plot for S-adenosyl methionine showing the 
  final choice of substrate concentration used in the assay 
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Working concentrations of the substrates have been selected so that the reaction 
is at, or close to, its maximum rate (Vmax). Concentrations above this are 
avoided, as this excess substrate is seen to contribute to increased blank 
readings. 
4.1.3 Linearity of the reaction 
It is also required that the kinetics of the reaction are first order in relation to the 
enzyme. This is demonstrated in Figure 4.4, where the enzyme concentration is 
directly proportional to the product formed.  
 
Lysate volume (ul)
6
M
T
G
 (
p
e
a
k
 h
e
ig
h
t)
200150100500
20000
15000
10000
5000
0
Linearity of TPMT method
 
Figure 4.4 Linearity of the TPMT assay 
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Another experiment was carried out to check the linearity of the TPMT 
phenotyping method. Four samples covering a range of TPMT activity were 
carried through the method using a series of dilutions of the whole blood lysate. 
Activity per gram of Hb was calculated for each reaction. Results are presented 
in Figure 4.5. 
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Figure 4.5 Study of linearity using a range of lysate dilutions 
 
 
It can be seen in Figure 4.5, that as the amount of sample in the reaction mixture 
is increased, activity tends to reduce slightly, this may reflect substrate depletion. 
For this reason, only lysates with a Hb concentration within the range indicated 
are acceptable. 
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4.1.3 Controlling reaction conditions 
Accurate reaction start times may be difficult to determine and bursts or lag 
phase in product formation can occur, which could distort the reflection of the 
linear reaction. Effects of these are minimised in our assay by using sand in the 
hot block wells to dissipate heat, thus avoiding spikes in temperature and by pre-
warming all components of the reaction mixture prior to their combination. 
Additional important practical considerations include purity and stability of all 
reagents and samples. This necessitates appropriate supply, storage and 
handling. The chemicals for our assay are purchased in bulk from consistent 
sources. Reagents are prepared in lots then stored appropriately. Preparation, 
freezing and thawing is carried out as quickly as possible, to avoid any reagent 
deterioration. Samples are stored at 4°C and analysed on the next working day, 
to minimise further loss of enzyme activity. 
 
4.1.4 Importance of blank 
Background rates of reaction can be observed in the absence of TPMT. Causes 
for these readings include contamination of one of the components or non-
enzymatic reactions. It is important to compensate for these ’blank’ readings, or 
falsely high readings could be recorded. This is achieved for our assay by 
preparing a vial containing all components except the sample lyste which is 
replaced with saline. This vial is carried through the method and the resulting 
chromatography is automatically subtracted from that of the unknown samples. 
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4.1.5 Checking for artefactual product peaks 
It is routine practice to check for any underlying peaks for samples with very high 
TPMT activity. Any substance present in the sample, which elutes at the same 
retention time as 6MTG and exhibits similar fluorescent properties, could lead to 
falsely elevated results. This could cause major consequences if such a peak 
‘masked’ a deficient result. The original method for checking for any such 
interfering substances was to immediately move the reaction vial to the 90°C 
precipitation block as soon as the test reagent had been added to the sample. In 
theory this was a zero incubation time. On several occasions a 6MTG peak was 
observed on these samples. This seemed to be the result of some reaction 
actually taking place, as these were very high activity samples and a finite period 
of time was being taken to reach a sufficient temperature to stop the reaction. An 
attempt has been made to overcome this problem by a change of practice. 
Reaction vials containing the test reagent are preheated to 90°C, before addition 
of the sample lyste. At this temperature no reaction can occur, as all protein is 
denatured immediately. Even though this is a true zero time incubation some 
6MTG is still observed. This seems to be due some methylation of the 6TG in the 
preheating stage. For this reason a blank zero minute incubation reagent vial is 
prepared and the blank reading subtracted from the tests. To date well over 1000 
such checks on high TPMT activity samples have not identified any directly 
interfering substances. 
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4.1.6 HPLC 
After the reaction, the incubate is treated so that it is suitable for analysis by 
HPLC with fluorescence detection. The metabolites of the TPMT reaction are 
injected into a stream of high pressure liquid (mobile phase) which carries the 
sample into a column and then to the detector. Separation takes place in the 
column as different components have a different affinity for the column packing. 
Those with least affinity will exit first. Each component elutes from the column as 
a narrow band or peak. The retention time on the column is specific to the 
compound and the peak height is proportional to its concentration. 
The retention time is influenced by: 
 Characteristics of the stationary phase (pore diameter, particle shape, 
surface area and pH) 
 Composition of the mobile phase - the elution power increases as the 
polarity of the solvent decreases 
 pH and salts 
 Temperature 
 
Fluorescence is the detection method of choice for our assay as it has greater 
specificity and sensitivity than UV detection. Fluorescence-based photometric 
detection methods are capable of much greater sensitivity than absorbance 
assays as comparisons are being made between a reading and zero, in contrast 
to the comparison between two relatively high readings. 
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Figure 4.6 Chromatography typical of high, normal, low and deficient  
  TPMT  
0.00 0.50 1.00 1.50 2.00 min 
Deficient TPMT Activity NO PEAK 
0.00  0.50  1.00  1.50  2.00 min 
6-Methylthioguanine 
Low TPMT Activity 
0.00 0.50 1.00 1.50 2.00 min 
6-Methylthioguanine 
Normal TPMT Activity 
0.00 0.50 1.00 1.50 2.00 min 
6-Methylthioguanine 
High TPMT Activity 
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Originally, a calibration curve was constructed to cover the range expected from 
the assay. This exhibited a linear relationship; therefore calculations are now 
based upon the measured fluorescence of a single point calibrator, whereby a 
6MTG standard of known concentration is on each run. 
 
4.2 Effect of sample age 
The samples received for TPMT phenotyping come from all over the world and 
can take several days to reach the laboratory. The storage and transport 
conditions prior to receipt are unknown, therefore it is important to have some 
understanding of the stability of TPMT at various temperatures. 
An experiment was carried out looking at the change in TPMT activity for 5 donor 
samples. These samples were aliquoted immediately after taking and stored at 
three different storage temperatures. 
 
The results of this study are presented graphically in Figures 4.6 - 4.8. 
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Figure 4.7  TPMT activity in samples stored at 80°C 
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Figure 4.8  TPMT activity in samples stored at 4°C 
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Figure 4.9  TPMT activity in samples stored at room temperature 
 
 
These results show that TPMT is stable for over 10 days at -80°C and 4°C, but 
activity is seen to fall after about 6 days at room temperature. 
A second experiment was carried out where blood from a suitable donor was 
collected into 3 specimen tubes. These were stored as follows: 
1. Aliquoted into 200µl fractions and stored at -80°C 
2. 4°C 
3. Room Temperature (ranged from 18.5 - 24°C)  
On each working day a frozen aliquot and 200µl of whole blood from each of the 
other storage conditions were analysed using the whole blood TPMT method. 
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4.2.1 Results 
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Figure 4.10 TPMT activity of samples stored at 4°C and room temperature 
compared to activity when stored at -80°C 
 
 
Activity of 4°C and room temperature samples were calculated as a percentage 
of the 80°sample activity, on each day. 
The results from both these experiments suggest that TPMT activity is stable for 
over 10 days at 4°C but begins to fall after 6 days at room temperature.  
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4.3 Haematology effects 
4.3.1 Low patient haemoglobin 
TPMT activity is expressed per gram of haemoglobin. The RBC act as a 
surrogate marker for cells, such as the liver, where TPMT activity takes place. 
(Szumlanski et al 1996). The inter-relationship between Hb and calculated TPMT 
activity has been studied in several ways: 
 
 From 14/08/07 to 28/08/07 527 samples were phenotyped for TPMT. In 
this period there were 13 high TPMT activity results, 54% of these had a 
low lysate haemoglobin concentration (defined as <2.6g/dL). If the applied 
haemoglobin correction for these samples is removed, all but one of these 
samples would be classified as normal. 
 Nineteen EDTA samples from patients with low Hb (<7.6g/dL) were 
collected from the haematology department. The whole blood and RBC 
TPMT activity of these patients was determined. This was found to be high 
(>80 nmol 6MTG/gHb/hr) in 42% of the specimens, as shown in Table 4.1. 
This is a significant proportion as routinely only 2 to 3% of our results fall 
into this high category. 
 In 2005 a questionnaire was sent out with all high TPMT activity reports. 
Of the 42 responses received 45% of patients were classed as anaemic at 
the time of testing. 
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RBC TPMT 
(nmol 6MTG/gHb/h) 
Normal (25-56) 
Whole blood TPMT 
(nmol 6MTG/gHb/h) 
Normal (35-79) 
Sample Hb (g/dL) 
Normal 
Female 11.5-16.0 
Male 13.2-17.5 
78 103 6.9 
113 117 11.8 
48 61 6.5 
127 134 6.6 
45 65 6.9 
71 88 6.9 
22 27 4.1 
24 32 6.0 
119 160 6.4 
39 45 7.3 
74 96 6.3 
32 52 7.3 
28 50 7.1 
31 45 7.3 
75 94 7.3 
33 71 7.5 
119 129 7.5 
26 28 7.5 
36 68 7.5 
 
Table 4.1 RBC and whole blood TPMT for patients with low Hb 
 
This combined evidence shows that a relatively high proportion of samples that 
have a low haemoglobin concentration have abnormally high calculated TPMT. 
This suggests that when the Hb content of RBC is low, it may actually be a poor 
marker of cellular contents. This raises the question, as to whether elevated 
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results on patients with low Hb are misleading, sometimes resulting in 
misclassification of the TPMT status. 
Previous experimental work (4.1.3) has shown that differing concentrations of 
lysates prepared from the same sample give similar results, once corrected for 
Hb. This demonstrates that the increased substrate/enzyme ratio that exists, in 
lower concentration lysates, should not significantly affect the reaction rate. 
 
4.3.2 TPMT activity uncorrected for Hb 
For the reasons highlighted in 4.3.1 and 4.3.2, it was studied whether it would it 
be more straightforward to express TPMT activity in units per litre of whole blood 
(U/L) instead of using haemoglobin correction. This could have advantages over 
the existing method, as it would be simpler, faster and cheaper and may avoid 
misclassification of patients with low Hb. 
The whole blood phenotype/genotype concordance study data was re-analysed. 
Comparisons were made between genotype and TPMT activity corrected and not 
corrected for Hb concentration. 
Looking at the whole blood results of samples from the whole blood study 
(Chapter 3), phenotyping and genotyping for 400 wild type or heterozygous 
samples were available. 
This data was examined more closely to look for differences in 
phenotype/genotype concordance between activity expressed per gram of Hb 
and TPMT activity not corrected for Hb. 
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Results corrected for Hb    Total Concordance = 96.5% 
 
Low Phenotype 
(<35 nmol 6MTG/g/Hb/h) 
 
 
Normal/High Phenotype 
(>34 nmol 6MTG/g/Hb/h) 
 
33 (8.3%) 
 
 
367 (91.7%) 
 
Wild 
Genotype 
 
 
Heterozygous 
Genotype 
 
Wild 
Genotype 
 
Heterozygous 
Genotype 
 
6 
 
 
27 
 
359 
 
8 
 
Table 4.2  Phenotype / Genotype concordance when Hb correction  
  applied 
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Figure 4.11 TPMT activity distribution for 400 study samples, corrected for 
  Hb 
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Results not corrected for Hb    Total Concordance = 95.6% 
 
Low Phenotype 
(Peak Height 6MTG <7.5) 
 
 
Normal/High Phenotype 
(Peak Height 6MTG >7.4) 
 
36 (9.0%) 
 
 
364 (91%) 
 
Wild 
Genotype 
 
 
Heterozygous 
Genotype 
 
Wild 
Genotype 
 
Heterozygous 
Genotype 
 
9 
 
 
27 
 
356 
 
8 
 
Table 4.3 Phenotype / Genotype concordance without Hb correction 
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Figure 4.12 TPMT activity distribution for 400 study samples, uncorrected  
  for Hb 
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A cut-off of 6MTG peak height of 7.5 as the bottom of the 'normal' range for 
results uncorrected for Hb was set. This gave very similar genotype concordance 
data to that obtained for results corrected for Hb. 
Discordance where the phenotype is low but a wild type genotype is observed is 
likely to be due to sample deterioration or the presence of a mutation that is not 
being screened for. Discordance due to the samples that have a normal activity 
but exhibit a TPMT mutation can be due to one allele coding for relatively high 
enzyme production or misclassification. 
Looking at the results corrected for Hb, there were 8 samples where a 1/*3 
genotype was determined but the calculated TPMT activity was in the normal 
range. 
Calculated TPMT 
activity 
(nmol/6MTG/gHb/h) 
6MTG 
(Peak 
Height) 
Genotype 
36 6.8 1/*3 
36 8.7 1/*3 
37 7.3 1/*3 
38 8.8 1/*3 
40 7.3 1/*3 
42 7.4 1/*3 
45 7.8 1/*3 
60 12.4 1/*3 
 
Table 4.4 Data for samples with phenotype / genotype discordance 
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Looking at 6MTG peak heights, half of these patients would not have been 
misclassified if interpretation had been based on activity uncorrected for Hb 
concentration. These results raise the question whether there is any advantage 
and indeed possibly a disadvantage in correcting for Hb. 
 
4.3.3 Haemoglobin concentration and white blood cell counts 
Full blood counts were carried out on 55 samples that had a high calculated 
TPMT activity. These results suggest a strong correlation between low Hb and 
high calculated TPMT activity, with approximately 80% of these samples having a 
Hb concentration below the quoted reference intervals. No obvious correlation 
was observed between level of TPMT and WBC count. 
RBC TPMT 
(nmol 6MTG/gHb/h) 
 
Normal (25-56) 
Hb (g/dL) 
Normal 
Female 11.5-16.0 
Male 13.2-17.5 
WBC count 
(x10
9
/L) 
 
Normal (4.0-11.0) 
79 7.1 4.03 
80 8.5 6.61 
80 9.6 2.93 
80 9.5 7.67 
80 12.4 12.38 
81 13.7 14.71 
81 13.8 12.41 
82 11.3 14.20 
82 9.9 5.37 
82 9.8 13.04 
83 13.7 5.74 
84 8.8 1.29 
84 9.6 5.35 
84 11.7 5.36 
84 11.2 4.55 
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RBC TPMT 
(nmol 6MTG/gHb/h) 
 
Normal (25-56) 
Hb (g/dL) 
Normal 
Female 11.5-16.0 
Male 13.2-17.5 
WBC count 
(x10
9
/L) 
 
Normal (4.0-11.0) 
85 8.1 5.97 
85 10.3 3.33 
85 16.2 6.73 
86 11.7 3.79 
86 9.0 7.47 
86 9.4 4.75 
86 13.2 6.00 
87 9.5 10.31 
87 13.9 8.35 
87 10.5 4.68 
88 7.3 5.39 
88 12.0 8.62 
88 11.8 9.52 
88 10.7 12.74 
89 9.7 6.57 
89 9.6 12.99 
89 12.9 4.39 
87 10.9 7.06 
90 10.3 8.42 
91 10.7 12.13 
92 10.3 7.19 
92 11.3 12.48 
92 9.5 11.73 
92 9.5 5.08 
92 9.5 6.23 
94 10.3 7.06 
95 10.4 5.03 
96 9.5 11.93 
96 11.0 4.90 
97 8.5 7.17 
97 12.6 8.20 
97 10.2 6.63 
100 13.4 3.58 
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RBC TPMT 
(nmol 6MTG/gHb/h) 
 
Normal (25-56) 
Hb (g/dL) 
Normal 
Female 11.5-16.0 
Male 13.2-17.5 
WBC count 
(x10
9
/L) 
 
Normal (4.0-11.0) 
102 6.6 11.32 
102 6.2 5.92 
112 7.9 12.59 
113 7.6 5.91 
115 9.8 6.09 
135 7.7 13.34 
163 9.8 9.10 
 
Table  4.5 Haematology of high TPMT activity samples 
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Figure 4.13 Correlation of WBC count and TPMT activity r=0.156 
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4.4 Phenotype / genotype comparison 
 
4.4.1 Audit data 
 
 
Requests 
 
Deficient 
<6 
Low 
6-34 
Normal 
35-79 
High 
>79 
No. % No. 
 
% No. 
 
% No. 
 
% 
Jun-07 682 1 0.1 98 14.3 577 84.8 6 0.8 
Jul-07 1078 1 0.1 160 14.8 910 84.4 7 0.7 
Aug-07 1100 5 0.5 137 12.5 942 85.5 16 1.5 
Sep-07 1136 1 0.1 109 9.6 990 87.1 36 3.2 
Oct-07 1336 1 0.1 134 10.0 1148 85.9 53 4.0 
Nov-07 1305 6 0.5 118 9.0 1146 87.8 35 2.7 
Dec-07 1103 1 0.1 106 9.6 964 87.4 32 2.9 
Jan-08 1315 4 0.3 129 9.8 1146 87.1 36 2.7 
Feb-08 1248 5 0.4 103 8.3 1112 89.1 28 2.2 
Mar-08 1113 5 0.5 116 10.4 974 87.5 18 1.6 
Apr-08 1372 3 0.2 121 9.0 1216 88.5 32 2.3 
May-08 1353 8 0.6 121 8.9 1203 88.9 21 1.6 
Jun-08 1360 7 0.5 144 10.6 1180 86.8 29 2.1 
Jul-08 1496 10 0.7 125 8.4 1322 88.3 39 2.6 
Aug-08 1326 3 0.2 104 7.8 1180 89.1 39 2.9 
Sep-08 1464 10 0.7 148 10.1 1278 87.3 28 1.9 
Mean 
 
1237 
 
 
4.4 
 
 
0.3 
 
 
123 
 
 
10.2 
 
 
1081 
 
 
87.2 
 
 
28 
 
 
2.2 
 
 
Table 4.6 Breakdown of phenotyping results 
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Deficient 
<6 
Low 
6-23 
Low 
24-29 
Low 
30-34 
Normal 
>34 
Heterozygote 
Concordance 
Jun-07 100.0 100.0 69.3 8.0 92.4 63.2 
Jul-07 100.0 100.0 84.0 79.6 100.0 67.3 
Aug-07 100.0 84.6 91.8 53.6 80.9 78.1 
Sep-07 100.0 89.5 94.4 82.9 68.8 89.8 
Oct-07 100.0 76.5 90.6 78.0 75.0 83.7 
Nov-07 83.3 89.5 64.1 82.1 42.8 82.9 
Dec-07 100.0 95.8 75.0 79.3 33.3 73.9 
Jan-08 75.0 86.7 95.6 90.0 100.0 86.0 
Feb-08 80.0 100.0 94.1 83.9 50.0 85.1 
Mar-08 100.0 91.3 93.9 86.2 33.0 88.1 
Apr-08 100.0 95.2 90.9 76.5 91.0 87.5 
May-08 100.0 100.0 87.0 58.0 94.0 81.7 
Jun-08 100.0 87.1 94.8 73.3 94.3 85.1 
Jul-08 100.0 100.0 94.5 90.0 76.6 94.8 
Aug-08 100.0 100.0 97.5 78.6 60.5 92.0 
Sep-08 100.0 97.0 91.5 81.2 82.4 89.9 
Mean 96.1 93.3 88.1 73.8 73.4 83.1 
 
Table 4.7 Phenotype/Genotype Concordance 
 
 
The overall concordance between TPMT phenotype and genotype reported in 
this audit was 83.1%.  This is lower than our previous concordance rate of 96.8% 
in the whole blood study. However, this audit concentrated on TPMT activity 
results either side of the cut-off between low and normal TPMT activity rather 
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than all results, which is the likely explanation for the lower phenotype-genotype 
concordance found. 
The mean concordance between deficient TPMT activity and the 3*/3* genotype 
is 90%, with the concordance being 100% in thirteen out of the sixteen months 
the audit was performed. It is likely, where the concordance for deficient TPMT 
samples is less than 100%, that these samples have TPMT mutations not 
screened for using our current genotyping strategy.  Where no or only one 
mutant allele was identified these individuals are either compound heterozygous 
or homozygous for rare mutations, which are not screened for. These findings 
are highly significant as it demonstrates the importance of our testing strategy, 
using phenotyping to screen all samples and genotyping for selective testing. 
Using genotyping alone these patients would have been misclassified and could 
have been treated with thiopurine drugs with serious consequences. In the period 
April 2007 to April 2009, 10 patients were identified possessing both*2 and *3 
mutations, two of these had deficient activity and 8 had low activity. 
Sample instability may have impacted on concordance in some instances where 
delays in transit meant many samples were older than 8 days when analysed. 
This could result in a normal genotype being classified as 'low' using phenotyping 
only. All such 'old' samples are flagged as such on patient reports. 
This vigilance system requires constant communication and interaction between 
the DNA and TPMT laboratories in our department. This produces clinically valid 
and reproducible results that aid the appropriate treatment of patients screened 
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by our test. This type of audit is invaluable in monitoring the performance of the 
phenotyping assay and will remain a part of the stringent quality system. 
4.4.2 Mutation type 
There have been over 25 mutations in the TPMT gene identified. The location of 
the mutation and its effect on the protein, for the most common mutations are 
detailed in Table 4.6. 
Designation Mutation Exon Effect on TPMT protein 
TPMT*2 G238C 5 80  (Ala) A  (Prol) P 
TPMT*3A G460A 7 I54 (Ala) A  (Thr) T 
Double mutant allele A719G 10 240 (Tyr) Y  (Cys) C 
TPMT*3B G460A 7 I54 (Ala) A  (Thr) T 
TPMT*3C A719G 10 240 (Tyr) Y  (Cis) C 
TPMT*3D T146C 5 98 (Glu) E  (Stop)X 
Triple mutant allele G460A 7 I54 (Ala) A  (Thr) T 
 A719G 10 240 (Tyr) Y  (Cys) C 
 
Table 4.8  Common TPMT mutations 
 
The presence of TPMT*2 or TPMT*3C results in a significant decrease in TPMT 
activity and protein expression, while TPMT*3A results in a more dramatic 
reduction (Tai et al 1996). As each type of mutation has a different effect on the 
protein coding for the enzyme, type of mutation may influence the degree of 
activity reduction. To test this hypothesis, audit data for one year was examined 
to look at the correlation between mutation type and TPMT activity. This did not 
show any significant difference in activity between samples that were genotyped 
as 1/*2 and those identified as 1/*3.  
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An explanation for this could lie in the screening strategy. One of the mutations 
screened for is A719G, which is present in both *3A and *3C genotypes, as can 
be seen from Table 4.8. If this mutation is detected, it is not possible to tell 
whether patient is a *3A or a *3C genotype. 
Several allelic variants are silent, producing no detectable effect, the most 
common being TPMT *1s (Alves et al 2000). 
 
4.5 Use of the service 
 
4.5.2 Requestors 
 
The demand for the service has increased steadily over the last three years. This 
is demonstrated graphically in Figure 4.14. 
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Figure 4.14 Increase in TPMT requests from July 2003 to January 2009 
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The clinical disciplines requesting TPMT phenotyping are represented 
diagrammatically in Figure 4.15.  These data were obtained by looking at the 
location and clinical details of requests over a one month period. 
Sources of TPMT requests    August 2007
IBD 5%
Crohn's 24%
Colitis 22%
Misc 4%
Eczema 6%
Pemphigoid 3%
Misc 7%
Rheumatoid Arthritis 
6%
Polymyalgia 
Rheumatica 3%
Misc 4%
Respiratory 5%
Immunology 5%
Liver 2%
Misc 4%
 
 
Figure 4.15 Breakdown of TPMT requests by clinical discipline and clinical 
condition. Data for August 2007 
 
 
 
4.6 Individual variability in TPMT activity 
4.6.1 Repeat testing 
 
To look at individual TPMT variability, results for samples received for repeat 
testing were analysed. Change in activity for patients where two samples had 
been assayed at a time interval greater than one month but no more than six 
Gastroenterology 
Dermatology 
Rheumatology 
Miscellaneous 
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months apart were recorded. The correlation between the two results for each 
patient is shown in Figure 4.16. 
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Figure 4.16  Correlation between activities for patients repeat tested for  
  TPMT 
 
 
The r value is 0.791, this indicates a fairly strong positive correlation between the 
first TPMT result and the second TPMT result. 
Variables beyond our control in this study included: 
 Age and storage of samples - after approximately 6 days at room 
temperature TPMT activity begins to fall, as shown in Chapter 4.2. It is not 
known what conditions the samples were subject to before receipt, which 
could account for differences in activity. 
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 Change in patient haemoglobin - as results are expressed per gramme of 
Hb, fluctuations in a patient's Hb status could influence the calculated 
TPMT activity. High TPMT activity per gramme of Hb is often observed in 
patients with very low Hb concentration, as shown in Chapter 4.3. 
 Drug treatment, which may affect activity - for example possible inhibition 
of activity by non-steroidal anti-inflammatory drugs (Oselin & Anier 2007). 
 
A paired T-test was also performed. The results are shown in Table 4.7. 
 n Mean 
Standard 
Deviation 
SE Mean 
1st TPMT result 111 53.4 16.1 1.5 
2nd TPMT result 111 52.4 15.6 1.5 
Difference 111 1.0 10.3 1.0 
 
Table 4.9 Paired T for C1 - C2 
 
With a null hypothesis that the mean difference is equal to zero and an 
alternative hypothesis that it does not equal zero gives 95% confidence intervals 
for mean difference (-0.90484, 2.95890) 
T-Test of mean difference = 0 (vs not = 0): T-Value = 1.05 P-Value = 0.294 
With a level of significance of 0.05 the T value does not exceed 2.96, implying 
there is no evidence to reject the null hypothesis. The data strongly suggest that 
the mean for the first TPMT test is the same as the mean for the second TPMT 
test. 
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4.6.2 Gender / age differences in TPMT activity 
 
All 15580 TPMT results from May 2008 through to May 2009 were analysed with 
respect to gender and age. (Results <10 or >100 were excluded from the 
calculated mean). 
 
Female 
(Years) 
 
Number of 
samples 
Mean SD 
High Activity 
(>100) 
 
<20 
 
694 52.3 15.6 11 
21-40 
 
2374 50.4 12.9 6 
41-60 
 
2453 50.8 12.9 8 
61+ 
 
2688 51.4 13.1 8 
All females 8209 51.0 13.2  
 
Male (Years) 
 
Number of 
samples 
Mean SD 
High Activity 
(>100) 
Age <20 
 
760 52.8 14.0 4 
21-40 
 
1900 51.8 14.0 10 
41-60 
 
2079 51.6 13.6 8 
61+ 
 
2632 52.4 13.8 10 
All males 7371 52.1 13.8  
 
 
Total Overall Mean  
Proportion of 
total results 
 
 
 
15580 51.7 13.5 0.42% 
 
Table 4.10 Gender / age differences in TPMT activity 
 
This data shows no variation in TPMT activity with respect to gender or age. This 
is based on a t-test at 99.9% level of significance which suggests values outside 
the range 38.8 to 64.6 for differences to be significant. 
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5. INTEGRITY OF RESULTS 
 
5.1 Quality system 
An incorrect TPMT result has the potential to cause serious harm; therefore a 
Quality Control System is in place to minimise errors. This vigilance system has 
CE marking of this assay as an integral component and it covers the following 
elements: 
 
5.1.1 Failure modes and effect analysis (FMEA) 
This is a bottom up approach, where every element of the system is examined 
with regard to the potential for failure. Following FMEA, mechanisms are put in 
place to eliminate or minimise the risks identified. 
An example of how analysis of the method in this way can prevent erroneous 
results has been demonstrated by identifying the effects of column age on peak 
resolution. It has been found that salicylate elutes and is detected slightly after 
6MTG. As column use increases the resolution between these two peaks 
diminishes, to the extent that a deficient activity could be missed as the saliyclate 
peak could be mistaken for a 6MTG peak. For this reason columns are changed 
after approximately 1000 injections. The degree of separation between 6MTG 
and salicylate is monitored by including salicylate in our quality control material. 
The column is changed when resolution of the 6MTG and salicylate peak back to 
baseline is lost. Reduction of peak height and resolution is shown in Figure 5.1 
and 5.2.  
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Figure  5.1 Separation between 6MTG and salicylate using a new column 
 
 
Figure 5.2 Separation between 6MTG and salicylate using a column after 
approximately 1000 injections 
 
 
 
 
 
 
0.00 0.50 1.00 1.50 2.00 min 
6MTG 
Salicylate 
0.00 0.50 1.00 1.50 2.00 min 
6MTG 
Salicylate 
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5.1.2 Acceptance criteria 
Once a run is complete the quality of the chromatography is examined to ensure 
6MTG peaks are fully resolved and correctly integrated. The 6MTG peak in a 
blank sample is automatically subtracted from all subsequent chromatography. 
Quality control samples are included in every run, results of which must be within 
two standard deviations of the target, for both lysate haemoglobin concentration 
and TPMT activity. 
Recovery of a 6MTG calibrator placed at the end of the run must be in the range 
85 – 115%.The calculated mean TPMT activity for all patient samples on the run 
must be within the range 40-55 nmol 6MTG/gHb/hr, excluding a very high or very 
low TPMT result. 
TPMT results are automatically calculated from the 6MTG concentration and the 
lysate haemoglobin concentration, by the laboratory data management system. 
At least three patient results for each run must be manually calculated to check 
this is functioning correctly. 
 
5.1.3 Introduction of changes 
Before being put into routine use, any changes to the method must be fully 
validated to ensure there is no effect on the quality of the result. All relevant 
experimental data is held on record and a FMEA performed to identify any new 
areas of risk. 
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5.1.4 Reagent manufacture 
A log sheet is used to record the manufacture of all reagents used to obtain a 
TPMT result. This includes the name of the operator, lot number of chemicals 
used and the preparation and expiry dates of the manufactured reagents. Each 
reagent is given a unique batch no, so that for any result the reagents used can 
be identified. 
 
5.1.5 Competency checks 
After training, new operators must satisfactorily complete a competency check, 
before being allowed to run the assay unsupervised. For this, they must perform  
a run in which all acceptance criteria are met and a sample analysed five times 
within that run gives an intra-run CV of <5%. 
 
5.1.6 Daily maintenance logs 
Each time an assay is performed the details are recorded e.g. operator, reagents 
/ controls used, incubation temperature, pump pressures. Any calibration details, 
operator comments and whether a run has been accepted or rejected are also 
recorded. 
 
5.1.7 Introducing a new QC 
Control samples are prepared from screened volunteers. These are analysed 
alongside an established QC for a minimum of ten runs. A mean target 
concentration is then calculated and a Levy Jennings chart prepared. 
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5.1.8 Repeat samples 
All patient samples found to have deficient activity are confirmed by repeat 
analysis. A second patient's sample is also requested. 
Samples with confirmed lysate haemoglobin concentrations outside the range  
1.5 - 4.5 g/dL are put for repeat analysis using a fresh, more concentrated or 
dilute lysate as appropriate. 
Patient samples with TPMT activity >89 are checked by repeat analysis. These 
samples are also checked for interfering substances as outlined in 4.1.5. 
 
5.1.9 Genotyping confirmation 
TPMT genotyping is used to confirm the status of patients in the following 
situations: 
 Samples with deficient TPMT activity 
 Recently transfused patients 
 Samples with low TPMT activity 
 Where there is a change of status between present and previous results 
 Patients known to have had an adverse reaction to thiopurine drugs 
 
5.1.10 Reporting 
All new users of the service are sent communication introducing the service. 
Any relevant comments e.g. sample age are added to reports before issue. 
Deficient TPMT activity results are telephoned to the requesting clinician as soon 
as possible, requesting an additional sample for confirmation. 
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5.1.11 Logs 
A user feedback log is in place which provides a summary of all contacts with 
end users. All communications are reviewed at the end of each month. If this 
identifies an area in which the service can be improved a record of action taken 
should be made. 
A TPMT incident log also exists which serves as an important troubleshooting 
guide for operators. All major equipment failures and reasons for rejecting runs 
must be recorded in detail in this log. This is also reviewed every month. 
 
5.2 QC data 
The graphs in Figure 5.3 represent the data from over 800 separate TPMT 
analytical runs. 
The JB and VG controls are blood samples that are collected from two laboratory 
donors, who have been screened negative for hepatitis and HIV. Blood is 
donated approximately every 3 months, aliquoted, frozen, then thawed and 
analysed on every run. Levy-Jennings charts are constructed for each new batch 
of control. 
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Figure 5.3  Plot of TPMT QC April 2006 - September 2008 
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The Levy-Jennings assessment is one of the main criteria when determining 
whether a run is acceptable to report.  
Due to the relatively high numbers of samples analysed, looking at the patient 
mean for each run also gives an indication of the acceptability of the run. Any 
deficient or results over 90 nmol 6MTG/gHb/h are excluded when calculating the 
patient mean. 
It can be clearly seen from these graphs that the QC and patient mean results 
have moved in parallel over the time period studied. Shifts in the graph have 
reflected issues with the assay such as reagent lot changes and problems with 
incubation temperature control. For example, around run 1420 a new lot of one of 
the substrates (SAM) was introduced. This resulted in a considerable shift 
upwards in results. This gave better genotype/phenotype concordance and the 
percentage of low results became more in line with published data. This 
overcame concerns, within the laboratory, that our results had been slightly low 
at that time. 
The JB and VG internal QC results demonstrate the consistency in activity for 
each individual. The data has been looked at in a different way by calculating the 
mean and confidence limits for each batch of QC. This is represented in Figure 
5.4. 
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Figure 5.4 Longitudinal study of TPMT activity in two individuals used as 
Quality Control April 2006 - October 2008 
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5.3 Reducing variability 
Sample handling has been standardised as much as possible to minimise 
operator variance. The whole blood is thoroughly mixed, to give a homogeneous 
sample, before aliquoting. The aliquots are then frozen for a minimum of 15 mins 
to ensure maximum lysis. An experiment was performed to determine the extent 
of blood cell lysis in this time. Cell counts were performed pre and post freeze 
using a Bayer Advia 120. 
 
 
Sample 
 
Pre freeze 
Red blood cell count 
 
Post freeze 
Red blood cell count 
 
 
% RBC lysis 
1 4.65 0.16 96.6 
2 4.57 0.29 93.7 
3 5.09 0.34 93.3 
4 4.84 0.40 91.7 
5 3.95 0.22 94.4 
6 4.21 0.13 96.9 
7 4.90 0.48 90.2 
8 4.43 0.27 93.9 
9 4.77 0.26 94.5 
10 4.56 0.31 93.2 
Mean   93.8 
 
Table 5.1 %  RBC lysis achieved after 15 minutes at -80°C 
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Sample 
 
Pre freeze 
White blood cell count 
 
Post freeze 
White blood cell count 
 
 
% WBC lysis 
1 5.92 4.58 22.6 
2 5.92 5.07 14.4 
3 4.88 4.22 13.5 
4 7.02 5.85 16.7 
5 11.09 8.72 21.4 
6 5.36 3.48 35.1 
7 3.54 2.70 23.7 
8 5.41 4.90 9.4 
9 18.29 14.14 22.7 
10 10.69 8.26 22.7 
Mean   20.2 
 
Table 5.2 %  white blood cell lysis achieved after 15 minutes at -80° 
 
Repeated freeze thaw cycles did not show any further cell lysis. RBC counts are 
very low after freezing and no longer in the usual measuring range. The accuracy 
of these results is questionable as levels are outside the confidence limits of the 
analyser. 
 
5.3.1 Freeze thawing techniques 
Incomplete lysis has been observed in samples that have been covered or stood 
on boxes in the freezer, therefore this practice is avoided.  
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Once removed from the freezer buffer must be added to the aliquots immediately 
to prevent sample degradation. The samples are then allowed to thaw for 
approximately 5 minutes, before mixing thoroughly. Deviations from these 
practices have resulted in unacceptable quality control. 
 
5.3.2 Incubation temperature control 
It has been found that the rate of methylation of 6TG is extremely temperature 
dependent. This has necessitated strict vigilance systems to keep the assay in 
control. The 1 hour 37ºC incubation was initially performed in a water bath; this 
was substituted by a hot block, for convenience, as sample numbers increased. 
The temperature of the blocks is monitored closely and adjusted when necessary 
to maintain the required temperature. Problems with quality control seem to be 
more frequent when the temperature in the laboratory is low. The installation of 
air-conditioning has helped minimise any changes in ambient temperature. 
Ideally, the reaction rate will be linear over the total incubation time. To allow this, 
the test reagent is brought up to 37ºC prior to addition to the sample lysate. This 
reagent preparation is crucial as if the starting temperature is too low an initial lag 
in the reaction will occur. Conversely, if the reagent is over heated, non-
enzymatic methylation of 6TG to 6MTG can occur. This could contribute to a high 
6MTG peak in blank samples. If the pre heating process is unduly long the 
reagent can begin to degrade, with substrates, being seen by visual inspection, 
precipitating out of solution. 
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5.3.3 Sampling errors 
Precise injection volumes of only 2µl are required to be dispensed by the HPLC 
autosampler, therefore a system has been put in place that would detect a ‘short’ 
sample. This risk has been overcome by the addition of L-tryptophan to the 
whole blood suspension buffer. This acts as an internal standard and the L-
tryptophan peak is monitored by the UV detector. Monitoring these peak heights 
will highlight any imprecision in injection volume. 
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6. THIOGUANINE NUCLEOTIDES 
6.1 Thiopurine drug monitoring 
Plasma 6MP levels have been used in an attempt to aid dosing strategies for 
thiopurine drugs, this assay has been limited in its reliability to predict efficacy or 
toxicity. The measurement of urine thiouric acid, the xanthine oxidase pathway 
metabolite has also been tried. This is only useful in assessing compliance, as it 
does not give any indication of therapeutic response.  
More effective monitoring has been achieved, through greater understanding of 
thiopurine metabolic pathways. The 6TGN are the active metabolites of thiopurine 
treatment. They achieve their immunosuppressive effect by virtue of the fact that 
they are incorporated as false bases into DNA, preventing cell proliferation. 
Figure 6.1  Formation of 6-thioguanine nucleotides 
 
 
 
OXIDIZED 
METABOLITES 
6-MERCAPTOPURINE 6-METHYLMERCAPTOPURINE  
TPMT XO 
6-THIOGUANOSINE 5’-MONOPHOSPHATE 
6-THIOGUANOSINE 5’-DIPHOSPHATE 
6-THIOGUANOSINE 5’-TRIPHOSPHATE 
6-THIOGUANINE 
NUCLEOTIDES 
HPRT 
XO= xanthine oxidase, TPMT=thiopurine methyltransferase, 
HPRT=hypoxanthine phosphoribosyltransferase. 
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Another explanation of the immunosuppressive mechanism of thiopurine 
metabolites is induced T cell apoptosis by modulation of Rac1 activation (Tiede 
et al 2003). 
At the moment most 6TGN quantification methods measure nucleotides 
indirectly. Direct measurement is possible using mass spectrometry and ion-
exchange HPLC. These methods can differentiate 6TGN from 6TG and can also 
measure thio-ITP from 6MP which may be useful in studying ITPA deficient 
patients. Other direct assays include enzymatic conversion of 6TGN to 
nucleosides with reverse-phase HPLC measurement.  
Many of the assays developed use erythrocytes as a surrogate pharmacokinetic 
marker, to indicate the intracellular levels of metabolites in the target cells i.e. 
peripheral blood leucocytes or bone marrow pre-cursors. In the measurement of 
RBC 6TGN it is difficult to avoid contamination with white blood cells, which may 
affect results. Further problems arise when considering the degree of possible 
degradation of the labile cell nucleotides between collection and analysis.  
A 6TGN concentration of >235 pmol/108 RBC is associated with therapeutic 
efficacy, while concentrations of >450 pmol/108 are linked with myelotoxicity 
(Dubinsky et al 2000). 
It is important that measurement is performed when a steady state has been 
achieved, after approximately four weeks of treatment, in order to give a reliable 
prediction of response to therapy. 
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6.2 Reasons for testing 
It is argued that TPMT phenotyping, genotyping and measurement of 6TGN all 
have value in the clinical evaluation of patients receiving thiopurine therapy. 
Thiopurine metabolism is complex, with three competing enzyme pathways. Also, 
polymorphisms exist in the TPMT gene and may also exist for genes encoding 
for other metabolic enzymes. These factors result in a wide range of metabolite 
concentrations, for a given dose, in each individual patient. The poor correlation 
between dose and 6TGN concentration supports measurement of 6TGN, to aid 
rational dose adjustment as increased 6TGN has been correlated to reduction in 
disease activity (Hindorf et al 2004). 
The usefulness of 6TGN measurement is to monitor the patient, in response to 
treatment, to help achieve a dosing regime with maximum therapeutic effects and 
minimal toxicity. This quantification allows confident escalation of dose in non-
responders and dose reduction for those with unexpectedly high, potentially 
harmful, 6TGN concentrations. It is particularly useful in assessing:  
 
  patients heterozygous for TPMT activity who may not be receiving    
  standard dosage 
  patients who fail to respond to therapy 
 cases where compliance is questionable. 
 patients receiving the XO inhibitor allopurinol 
 hypermethylators, that have higher than normal TPMT activity, who could 
require treatment with a higher dose to achieve adequate response 
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A study of samples received in our laboratory from patients being treated with 
Azathioprine indicated that a large proportion of patients were being treated with 
a sub-optimal dose. These findings were summarized and presented as a poster 
at the EuroMedLab conference in Amsterdam 2007; a copy is included as 
Appendix 4. 
 
A simplified assay for determination of red blood cell 6-thioguanine 
nucleotides; early evidence suggestions UK patients are receiving sub-
optimal doses of thiopurine drugs                          Graham V, Ford L T, Berg J  
 
Similar findings by Morales et al in 2007 highlighted a high proportion of low 
6TGN level in patients using the standard mg/kg strategy. 
Higher TGN levels have been observed in Crohns disease (CD) patients than in 
those with Ulcerative Colitis (UC), on similar dosing regimes (Hande et al 2006). 
This is unexpected as reduced absorption would be expected in those with 
Crohns disease. This could be indicative of an independent association between 
disease type and nucleotide levels. 
If 6TGN concentrations are low this could indicate abnormal absorption or 
metabolism, this may be warrant measurement of 6MMP concentration. If this is 
also low it would suggest under dosing or non-adherence. While elevated 6MMP 
coupled with low 6TGN indicates preferential metabolism of 6MP to 6MMP by 
TPMT. 
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6.3 Results of provisional study and comparison with New Zealand 
laboratory 
 
In 2006, a 6TGN assay was put into use at City Hospital. This assay was 
adapted from the methods of (Dervieux & Boulieu 1998; Lennard 1987) and was 
performed using washed RBC. Initial comparisons were carried out using RBC 
samples from a laboratory with an established service in New Zealand. 
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Figure 6.2 Initial 6TGN comparison with New Zealand laboratory 
  y = 1.6165x - 35.395    r = 0.99 
 
The City laboratory assay results initially showed a positive bias of 25-30%. It 
was discovered that if the prepared 6TG calibrator was heated alongside the 
samples the 6TG peak height increased. This heating of the calibrator was 
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introduced into the method; this change resulted in a lowering of results, and 
brought the comparison results much more in line with the New Zealand 
laboratory. 
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C
it
y
 6
T
G
N
 p
m
o
l/
8
x
1
0
e
8
 R
B
C
600500400300200
600
500
400
300
200
100
Repeat Comparison with Established Method
 
Figure 6.3 Repeat  6TGN comparison with New Zealand 
  y = 0.8635x + 58.674  r = 0.97 
 
6.4 Method development 
The original method developed liberates 6TGN from RBC, using perchloric acid 
at 95ºC, hydrolysing them back to their parent thiopurine, 6-thioguanine (6TG). 
The 6TG concentration is measured by HPLC, any losses are accounted for by 
inclusion of an internal standard. 
This method requires a relatively large sample volume, as RBC are washed and 
counted prior to analysis. This preparation procedure is laborious and can 
introduce errors in the cell counting step. A radical approach was therefore 
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adopted, similar to that taken with TPMT, to assess the feasibility of measuring 
6TGN using whole blood. 
Whole blood aliquots and red cell counts were taken from 70 patient samples 
before they were prepared for the existing washed red blood cell method. These 
whole blood samples were analysed alongside the routine samples and results 
compared. 
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Figure 6.4 Comparison between 6TGN concentrations measured in 
washed RBC and whole blood  r = 0.978 
 
 
The correlation between washed red cell and whole blood results was excellent 
which is in concordance with a study carried out at the Mayo Foundation in the 
USA (Pike et al 2001). 
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The quality of the chromatography for this method was poor, due to several 
factors including: 
 the low concentrations of solvent in the circulating mobile phase meant the 
system was prone to microbial growth. Resulting in frequent pump 
problems and blocked filters 
 using an isocratic system, the analysis time allotted to each sample, was 
too short to allow complete elution of some unknown compounds. This 
resulted in huge, very late peaks appearing in subsequent 
chromatography, as shown in Figure 6.2 
 
Figure 6.5 Late peaks on 6TGN chromatography 
 
These problems were solved by the introduction of a gradient elution method. 
The theory behind this change was to bring in a more hydrophobic mobile phase 
after elution of the peaks of interest. This was designed to achieve elution of all 
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residual compounds from the column in a relatively short time frame. Then the 
system would return to the original mobile phase in preparation for the next 
sample injection. Several compositions of mobile phase and pump settings were 
trialled to achieve optimum settings, as show in Figures 6.6 - 6.8. The rate of 
introduction and duration of the more hydrophobic mobile phase is as shown. 
Figure 6.6 6TGN chromatography using mobile phase B composition: 
15% Acetonitrile / 5% Methanol / 80%Buffer 
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Figure 6.7 6TGN chromatography using mobile phase B composition: 
30% Acetonitrile / 10% Methanol / 60%Buffer 
 
Figure 6.8 6TGN chromatography using mobile phase B composition: 
15% Acetonitrile / 5% Methanol / 80%Buffer. Increased ramp 
and duration. 
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The intra batch variation for this new method is 8.3% (n=10) and inter batch 
variation 10.2% (n=18). 
A study of 6TGN stability in whole blood has shown levels to fall rapidly after 
around 5 days at room temperature (Figure 6.9). For this reason, results for 
samples that are over 5 days old on receipt are flagged to be interpreted with 
caution. 
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Figure 6.9 6TGN sample stability 
 
The new whole blood assay, developed as part of this research, has taken this 
test forward in several ways: 
 sample preparation is less labour intensive 
 cell counting and pipetting errors are minimised 
 the sample volume required is reduced 
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 the quality of the chromatography is much improved and less failed runs 
are encountered since the change to the gradient method 
 the assay is quicker and more cost effective 
 
A poster summarising some of this work is included as Appendix 5. 
 
Improving a test that has a growing clinical demand; blood 6TGN and its 
role in pharmacogenomics. (2008) Graham V. Berg J. 
 
Now in routine use, this simplified assay will allow more confident escalation of 
dose in non-responders and dose reduction for those with high, potentially 
harmful, 6TGN concentrations. It will be particularly useful in assessing patients 
heterozygous for TPMT activity, who receive a reduced dose and for which 
achieving therapeutic levels can be problematic.  
 
6.5 Use of the 6TGN service 
The number of users of this service is still relatively small, at around 15 
laboratories. Those who do request 6TGN often send a number of samples on 
the same patient. The number of requests received per month has risen by 
approximately 100% in the last year as shown in Figure 6.10. 
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Figure 6.10 Increase in demand for 6TGN analysis 
 
If it becomes common practice to monitor 6TGN levels huge escalation in 
demand for this test could be seen. As unlike TPMT testing, which usually only 
needs to be done once per patient, this is a therapeutic drug monitoring assay, 
where a number of determinations on one patient are more likely. 
TPMT activity was been performed on 166 samples requesting 6TGN and the 
correlation between TPMT activity and 6TGN concentration examined. For 
samples with a high 6TGN concentration (>450 pmol/8x108 RBC), which is 
associated with myelotoxicity, 24% exhibited a low TPMT activity compared to 
only 11% low activity overall. 
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The correlation between 6TGN concentration and mean cell volume was also 
examined for patients samples received for routine analysis. 
6TGN pmol/8x10e8 RBC
M
C
V
 (
fL
)
120010008006004002000
130
120
110
100
90
80
70
60
MCV vs 6TGN
 
Figure 6.11 Mean cell volume / 6TGN level correlation 
No significant correlation was observed but this data is flawed as most of the 
samples analysed were several days old, which can result in falsely high MCVs. 
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7. INDUCTION STUDY 
7.1 Aims 
Many of the enzymes involved in drug metabolism may be up-regulated by 
exposure to drugs and environmental chemicals leading to increased rates of 
metabolism. This phenomenon is known as enzyme induction. Studies on renal 
transplant patients in 2001 showed increases in patient TPMT activity, possibly 
due to induction by Azathioprine (Weyer et al 2001; Thervet et al 2001). More 
recent studies in Sweden do not support this hypothesis (Lindqvist et al 2006) but 
these researchers used RBC TPMT. The research in this chapter looks at 
possible TPMT induction in whole blood.  
Eight patients from within our hospital, which were about to commence on 
Azathioprine were selected at random. Patient details, other than hospital 
number, were not recorded. As haematology samples were received for routine 
monitoring on these patients they were tested for TPMT activity and 6TGN.  
The levels of 6TGN achieved and variation in TPMT activity observed over a 5-6 
month period is represented in Table 7.1, with a graphical representation of 
variation of TPMT activity in Figure 7.1. 
 
 
 
 
 
 
  103 
 
 
 
 
Week 
 
 
TPMT Activity (nmol 6MTG/gHb/h) 
 
Patient 
1 
Patient 
2 
Patient 
3 
Patient 
4 
Patient 
5 
Patient 
6 
Patient 
7 
Patient 
8 
1 38 * * * 42 * * * 
2 * 39 * * * * * * 
3 * * 52 52 * 35 * * 
4 * * * * * * * * 
5 * * * * * * * * 
6 37 43 58 45 39 * 35 * 
7 * * * 48 42 30 * 37 
8 * * * 48 40 37 31 35 
9 35 * 51 * 41 33 * 37 
10 * * * * 51 38 35 44 
11 36 43 * * 48 39 * * 
12 * * * * 49 41 33 42 
13 * * * * 45 42 * * 
14 36 * * 63 * * 37 44 
15 * 42 * * * * * * 
16 * * * * * 43 39 * 
17 * * * * * * * 41 
18 38 * * * * * 40 * 
19 * 41 * * * 42 * 43 
20 * * 50 68 * * 34 * 
21 * * 54 * * * * 44 
22 * * * * * * 35 * 
23 * 46 * 68 42 40 * 41 
24 * * * * * * 36 * 
25 36 * 55 * * * * 41 
 
 
 6TGN level sub-therapeutic 
 
 Therapeutic 6TGN level 
 
 6TGN level above therapeutic range 
 
 
Table  7.1 TPMT and 6TGN levels of patients starting azathioprine 
treatment 
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Figure 7.1  TPMT induction in patients on Azathioprine 
 
 
It can be seen from the data in Table 7.1 that 7 of the 8 patients in this study 
achieved at least therapeutic levels of 6TGN. But it can be seen from Figure 7.1 
that, with the exception of one patient, no increase in TPMT activity was 
observed. The apparent increase in this one patient may have been due to 
factors other than induction e.g. possible fall in patient Hb levels, which could 
give rise to high calculated activity as explained in Chapter 4.3. 
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8. DISCUSSION 
8.1 Introduction 
There is an increasing interest and availability of pharmacogenetic products and 
services, many of which, including TPMT testing, detect polymorphisms 
associated with severe adverse drug reactions. These tests have obvious 
theoretical clinical advantages, some have relatively strong evidence bases and 
there can be a commercial interest in their development. Yet, validation and 
approval can take a very long time. Expense and poorly defined legal 
frameworks have contributed to this ‘logistical challenge’ and this is delaying 
widespread clinical use (Hopkins et al 2006). The thiopurine drugs which are the 
basis of TPMT testing are ‘off patent’, making them open to generic competition. 
Therefore, there is little incentive for manufacturers to invest in pharmacogenetic 
services. Despite these facts, TPMT testing is one service which has become 
well established in the UK and is currently the best example of applied clinical 
phamacogenetics. The work of this thesis has researched and developed the 
pharmacogentic services of City Hospital Birmingham, part of the Sandwell and 
West Birmingham NHS Trust, which is currently a major provider of TPMT 
testing in the UK. 
In a 2007 study, it was found that over two thirds of UK National Health Service 
consultants were requesting determination of TPMT before initiation of 
Azathioprine treatment (Fargher et al 2007). This is compared with virtually zero 
requests in 1997 (Tan BB et al 1997). This increase in testing, which has been 
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demonstrated in this thesis, reflects to a certain extent, changes in national 
guidelines. However, the guidelines are not strictly adhered to and advice 
relating to TPMT testing can be discipline specific, for example resulting in a 
higher uptake from dermatologists, compared with gastroenterologists and 
rheumatologists (Fargher et al 2007b). Pre-treatment and regular measurements 
of full blood count, liver function tests, urea and electrolytes are still strongly 
recommended in all clinical situations.  
Training and education of healthcare professionals in the field of 
pharmacogenetics is taking place (Higgs et al 2008) but this requires escalation 
to meet patients' expectations (Fargher et al 2007). Emerging tests need to be 
explained and interpreted. It has become necessary for clinical pharmacists to 
be able to understand both enzyme level and DNA based TPMT tests in order to 
guide optimal prescribing rather than solely relying on the British National 
Formulary recommended dosing based on mg/kg body weight (between 1 and 3 
mg/kg). The national survey by Fargher et al 2007 shows how well Azathioprine 
is tolerated, with around 67% of patients having good, 17% having reasonable 
and 15% having poor tolerance. With more informed dosing this should continue 
to improve. 
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8.2 Research outcomes 
8.2.1 Whole Blood Assay 
The work in this thesis has helped develop a new TPMT assay that has 
improved clinical utility. This whole blood assay has been introduced after 
comparing RBC TPMT with whole blood TPMT. This work involved comparison 
of the phenotyping for both methods, with genotyping, for 406 patient samples. 
The new whole blood assay is simpler and requires less sample volume. The 
fundamental changes to the method are that whole blood is used rather than 
washed RBC and cell lysis is achieved using freezing rather than using a lysis 
buffer. A strong correlation (r=0.834) was observed between the RBC and whole 
blood phenotyping methods. Both techniques demonstrated 97% genotype 
concordance and 79% concordance between low TPMT results and 
heterozygous genotypes. 
8.2.2 Whole blood assay precision profile 
One of the main reasons for the development of a whole blood TPMT method 
was to improve the relatively high imprecision of the conventional RBC assay. 
This imprecision was shown to be due to the washed cell pellet not being 
homogeneous. This results in varying mixtures of cell type being aliquoted on 
repeat analysis. Variation in activity on repeat analysis may also have been due 
to differences in the amount of old blood cells or white blood cells present in the 
aliquot. Studies by Lennard L et al in 2001 showed that older RBC, which could 
be partially separated during centrifugation, have a lower than average TPMT 
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activity. While in 2008, de Boer et al found extremely high TPMT levels in 
patients that had a high percentage of young RBC. This supports the hypothesis 
that all RBC in a sample do not have similar activity. The activity in the aliquot 
could also be affected by the amount of WBC present. The data from the whole 
blood study shows that whole blood activities are always higher but the degree 
of increase can vary enormously. The higher TPMT activities seen in whole 
blood compared to washed red cell preparations are likely to be due to white cell 
activity. Preliminary studies by ourselves have shown the activity per white cell 
to be very high but considering the haematology of high activity samples in Table 
4.5, there is no obvious correlation between WBC and TPMT activity. WBC 
TPMT activities would be an interesting area of research, but is beyond the 
scope of this thesis. 
8.2.3 Whole blood assay utility 
Another main driver for the whole blood method development was to try to 
eliminate the RBC washing steps. The new method has achieved this, saving 
several hours biomedical scientist time every day, making the assay more cost 
effective. These time and cost savings have impacted positively on the 
turnaround time of results, which has typically been kept to less than two 
working days. This short time frame enables rapid, informed dosing of 
thiopurines for patients that may be extremely ill. The importance of emphasis on 
turnaround is demonstrated by this service now being used by over 200 external 
laboratories. The income the test has generated has allowed development in 
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other areas of the department, including work presented here on the 6TGN 
assay. 
8.2.4  Phenotype / genotype concordance 
Now the whole blood method is in use, all samples with a TPMT of less than 41 
(normal range 35-79) are routinely genotyped (Ford et al 2009). This selective 
genotyping underpins the whole blood phenotyping service providing a valuable 
quality control function. This gives confidence in an assay which can be difficult 
to control, due to in-house reagent production and a number of variables, 
including operator technique.  
Additional samples selected for genotyping include those where the clinical 
details suggest that the patient has been transfused. Genotyping these samples 
overcomes one of the disadvantages of phenotyping where the measurement of 
activity from the donor blood masks the true TPMT status. In a worst case 
scenario, a deficient patient could be missed, as TPMT in a donor’s cells can 
produce a significant amount of reaction product. The transfused blood usually 
contains only a very small percentage of nucleated cells; therefore the 
genotyping should still give a true indication of the patient’s TPMT status. In 
transfusion cases it is suggested that TPMT phenotyping is repeated at least 120 
days after the last transfusion, so that no donor cells remain in circulation. A case 
study where a transfusion masked a deficient patient, tested at City Hospital, is 
described by Ford et al 2004b. After eight weeks treatment with Azathioprine this 
patient developed neutropenic sepsis and staphylococcal skin impetigo. They 
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had become pancytopenic and a bone marrow examination revealed severe 
aplastic anaemia. The azathioprine was stopped after nine weeks and the 
following week blood was analysed for TPMT. The RBC activity was found to be 
low, 16 nmol 6MTG/gHb/h (normal 24-55). At a review eight weeks later the 
patient's TPMT activity was found to be undetectable at <2 nmol6MTG/gHb/h. 
The sample was genotyped and found to be homozygous for *3A, the most 
common TPMT mutation in Caucasians, demonstrating a clear 
phenotype/genotype concordance. Due to the apparent change in TPMT status, 
from low to deficient, the clinical history for the patient was re-examined. It was 
discovered that the patient had received a blood transfusion of one unit of blood 
and two units of platelets six days before the first sample for TPMT measurement 
was taken. In cases like this, the activity detected can be that of the donor cells. 
This is the likely cause of the discrepancy in this case and the cause of the initial 
misleading result. This highlights the importance of interpreting the TPMT results 
with caution in patients who have been transfused. It also highlights one of the 
reasons why our service genotypes all low activity samples and all samples 
where the clinical details indicate a recent transfusion. 
The testing strategy of phenotyping to screen all samples and genotyping for 
selective testing should minimize the risk of missing ‘deficient’ patients which 
may have gone undetected using a single technique.  
As well as genotyping assurance, all aspects of the method have been examined 
and adjusted if necessary to reduce variability and ensure the integrity of the 
results reported. A comprehensive vigilance system has been developed as part 
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of the overall Quality System. This has been necessary to maintain CE marking 
for this assay. 
 
8.2.5  Variability of TPMT activity 
A pre-analytical issue, which may give low results and possible misclassification 
of status, is sample deterioration due to age or storage conditions. Results in 
Chapter 4 show that TPMT is stable for over 10 days at -80°C and 4°C, but 
activity is seen to fall after about 6 days at room temperature. Users of the TPMT 
service are advised to store samples at 4°C prior to posting at ambient 
temperature. It is not known what temperatures the samples are subjected to in 
transit. Therefore, all samples >8 days old are flagged with the comment that the 
result must be interpreted with caution due to enzyme instability. 
The issue of individual variability in TPMT activity was examined in detail. The 
analysis of two donors over period of several years has shown no significant 
fluctuation in their respective activities. Repeat samples from patients also 
suggest that an individual's TPMT activity remains relatively constant. 
The data presented in Table 4.10 gives no indication of gender or age 
differences in TPMT activity. This supports the much smaller study of Keizer-
Garritsen et al (2003) but is contrary to the findings of Klemetsdal et al (1993) 
and Cooper et al (2008), who observed slightly lower activities in females. 
Slightly lower results for children compared with adults were found by Ganiere-
Monteil et al in 2004. 
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The demand for the City Hospital TPMT service has continued to increase, with 
an observed 100% increase over a three year period. This has occurred as it is 
becoming established practice in many NHS Trusts to screen all patients before 
initiating thiopurine therapy. Users switching their business to us, to take 
advantage of the rapid service, have also contributed to the increase in requests. 
The main users of the service continue to be gastroenterology, dermatology and 
rheumatology (Barlow et al 2009). 
 
8.2.6 6TGN assay 
The usefulness of the 6TGN test is still open to debate as it has been suggested 
that erythrocyte 6TGN levels are highly variable, even in the same patient and 
that levels do not reliably provide sufficient information to predict efficacy or 
toxicity (Sandborn 2004; Lennard & Lilleyman 1989; Lowry et al 2001; Mardini et 
al 2003). There does not seem to be a weight/dose correlation with metabolite 
levels (Tani et al 2009). Similarly, Morales in 2007 found the level of 6MP dose 
to be only weakly associated with 6TGN levels, due to individual variability, and 
for this reason supports the use of 6TGN testing. Work by Hindorf et al 2006 has 
shown metabolite monitoring to be cost effective and that of Tani et al 2009 
suggests it is necessary to adequately personalise dosing. Some health 
insurance policies in the USA cover the monitoring of thiopurine metabolite 
levels, as it is considered medically necessary for individuals with inflammatory 
bowel disease (IBD) to guide dose changes in those who have not responded to 
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azathioprine (AZA) and / or 6-mercaptopurine (6-MP) therapy or for those 
suspected of having toxic responses to these medications. 
The level of 6TGN required to achieve therapeutic effect may have an element of 
disease specificity. Lower mean levels have been observed in patients in 
remission for dermatological conditions compared with those having a positive 
response to treatment for inflammatory bowel disease (el-Azhary et al 2009). 
Most 6TGN methods, including that used at City Hospital, are not ideal as they 
do not measure nucleotides directly. Some use enzymatic conversion of TGN to 
nucleosides with reverse-phase HPLC measurement; others depend on the 
hydrolysis back to the thiopurine bases.  In the latter, the efficiency of hydrolysis 
is difficult to ascertain due to the unavailability of TGN standards. Another major 
issue concerns patients being treated with 6TG, where it is impossible to 
distinguish between the hydrolysed derivatives of TGN and the non-metabolised 
drug present in the blood cells. Another issue with the majority of 6TGN testing 
approaches is that RBC are used as a surrogate marker for target cells. This is 
not an ideal, as RBC are not nucleated and therefore lack full purine functionality. 
The enzyme IMP dehydrogenase is required for the conversion of 6MP, a 
hypoxanthine analogue, to thio-GM and TGN, this enzyme is not expressed in 
erythrocytes. Therefore the TGN produced as a result of 6MP metabolism are 
made indirectly, largely in hepatic tissue. For this reason it is suggested that 
erythrocyte TGN levels are more likely to reflect liver cell, rather than target white 
blood cell metabolism (Dulay & Florin 2005). 6TG is a guanine analogue, which 
can be converted to thio-GMP and TGN via HRPT. This direct incorporation of 
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6TG into TGN, compared with the indirect route followed by 6MP, results in 
relatively higher RBC TGN in patients receiving 6TG than those on 6MP. It has 
been recommended that patients who prove intolerant to 6MP may benefit from 
6TG therapy. (Cheung et al 2003, Lennard et al 1993 & 1996). Ideally TGN 
should be measured in non-stimulated target cells. This would be difficult in 
practice as it would involve the laborious purification of leucocytes. 
This work has included comparisons between whole blood 6TGN levels and 
levels in a preparation of washed RBC. Furthermore, research undertaken here 
has enabled a whole blood 6TGN assay to be introduced which is quicker, 
minimizes errors and is more suitable for routine clinical use than previously 
published methods. The actual HPLC analysis has also been improved with the 
introduction of a gradient elution method, which has greatly improved the quality 
of the chromatography, making the method much more suitable for routine use. 
  Work by Decaux et al (2000) and Thomas et al (2003) found a correlation 
between high levels of 6TGN and increased mean cell volume (MCV). Thomas et 
al suggest that MCV measurement is a simple and inexpensive alternative to 
measurement of 6TGN concentrations. No such correlation was found in this 
research although this data is of limited value. Many of the measured MCVs were 
above the reference range but most of the samples analysed were several days 
old, which can result in falsely high MCVs. 
In Chapter 7, eight patients commencing on azathioprine were monitored for any 
apparent TPMT enzyme induction in whole blood. With the exception of one 
patient no significant increase in TPMT activity was observed. This fails to 
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support the hypothesis that induction effects may be more apparent in whole 
blood samples than in washed RBC. The work of Arenas et al in 2004 and 
Hindorf et al, in 2006, saw no increase in TPMT activity during treatment, in 
contrast to that of el-Azhary et al (2009), of the Mayo Clinic, where apparent 
induction was observed. 
 
8.3 Future directions 
Due to the high number of samples analysed by this service, a huge amount of 
valuable data has been available in this study. This has made it relatively easy to 
look at patterns in results. One of the most interesting trends observed has been 
the apparent correlation between low sample haemoglobin concentration and 
high calculated TPMT activity; this is detailed in Chapter 4. Evidence presented 
in this thesis suggests that the convention for reporting TPMT with respect to Hb 
concentration may give a misleading, high result for some patients with abnormal 
haematology, where the Hb measurement is a false indicator of cellular contents. 
These observations are to be followed up with further studies, including 
performing genomic analysis on low Hb samples that have borderline low/normal 
TPMT activity, to compare degree of concordance with routine samples. There is 
the possibility of taking the radical step of reporting TPMT activity in 'units per 
litre'. Recent literature shows a range of units are being used to express TPMT 
activity, many not adjusting for Hb concentration. 
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To give clinicians a better picture of what is happening 'in vivo' a service for 
6MMP is being developed. This assay will be performed alongside 6TGN after 
slight method modifications. It is important to be able to offer quantification of this 
metabolite as increased levels can lead to hepatotoxicity. If a low 6TGN result is 
reported without a 6MMP, this does not give enough information to ascertain 
why. The thiopurine dose maybe too low, the patient may be non-compliant or 
6MP could be being preferentially shunted towards 6MMP, due to high TPMT 
activity or other contributory factors. Such a 6TGN result could lead to 
inappropriate dose escalation; this risk is highlighted in the work of Gardiner et al 
(2008). 
As seen in section 4.4, genotyping underpins this TPMT phenotyping service. In 
the absence of an organized external quality assurance (EQA) scheme. Regular 
audit of phenotype/genotype concordance ensures the validity of the phenotyping 
results.  
City Hospital previously set up a worldwide EQA scheme for TPMT in conjunction 
with UK National External Quality Assessment Service (NEQAS). This was 
difficult to keep running due to difficulty in obtaining suitable material to distribute 
and also due to staffing issues both at City Hospital and NEQAS. A priority area 
for development of the service is to initiate a form of external quality control for 
both TPMT and 6TGN, possibly sample sharing with other laboratories. 
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Thiopurines are widely used as they are an attractive alternative to steroids, both 
in terms of cost and side effects. In 2004 nearly 0.6 million prescriptions for 
Azathioprine were dispensed (The Information Centre NHS 2005). Evidence 
suggests that treating a patient with these drugs, without firstly checking their 
TPMT status is ethically questionable. Such treatment has a 1% risk of death 
from associated bone marrow suppression and there is a four fold increased risk 
of suppression in heterozygotes (Gisbert & Gomollón 2008). Economic evidence 
in New Zealand has highlighted the cost savings of thiopurine treatment versus 
non-treatment of IBD patients (Priest el al 2006). Also, TPMT screening, prior to 
treatment, has been shown to be cost effective, phenotyping more so than 
genotyping (van den Akker-van Marle et al 2006) (Payne et al 2009). But robust 
evidence and accurate costs are difficult to obtain, this is due to reasons such as, 
under reporting of ADR and differences of opinion of what level constitutes 
neutropenia (Compagni et al 2008). In addition, when considering economics, 
phenotyping and metabolite monitoring can facilitate ‘tailored’ dosing. This is 
much more likely to have a favourable outcome, resulting in direct cost savings 
as well as improved quality of life.  
 
Conclusions 
This work has studied the development of a whole blood assay for TPMT and 
monitored it as it took over as the routine test, replacing an earlier more labour 
intensive and less precise assay. This project has confirmed that the new assay 
not only produces more precise and reliable results but that the concordance with 
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genotype is essentially unchanged from the previous test based on a RBC lysate 
preparation.  One feature of this assay, and most others offered by other UK 
providers of TPMT and centres around the world, is expression of the TPMT 
activity in relation to haemoglobin or RBC content of the blood cell lysate. We 
have shown that there is little, if any, advantage to this and that expressing 
patient whole blood activity as U/L will give a result which classifies patients 
equally well against their underlying genotype. Furthermore, in some patients 
with low haemoglobin levels, evidence has been presented that misleading high 
results can be obtained and that this is not seen when results are expressed as 
U/L TPMT.  Bringing the use of U/L expression into routine use would require 
further presentation of our evidence which would ideally encourage other 
providers to move to this reporting format. Such a move is to some extent 
facilitated by a recently launched commercial assay in kit form (BIOLOGIX 
Research Corporation) which disregards the link to haemoglobin and expresses 
a semi-quantitative result in U/L. 
Our concept of a whole blood assay rather than using a sample based on 
washed RBC has also been applied to develop an assay for thioguanine 
nucleotides, another important outcome of this project has been bringing this into 
routine use.  Again this has produced an assay which is much more suited to 
routine analysis as it reduces the analytical steps considerably. As the interest in 
therapeutic drug monitoring using 6TGN grows, this is a very useful 
development.  
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Alongside the timeline of this research project interest in TPMT analysis prior to 
starting treatment with thiopurines has grown considerably. Indeed in January 
2009 the Drugs and Therapeutics Bulletin recommend that patients should be 
pre-screened with TPMT before commencing therapy. The provision of a service 
at City Hospital, which has always been able to maintain a 1-2 working day 
turnaround, is to a great part related to the process of continuous development 
and quality improvement that has been the foundation of the work in this thesis. 
This work has aided UK clinicians prescribing thiopurines, by offering a timely 
service for determination of TPMT status in patients commencing therapy, which 
can only impact positively on patient care.  
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9. APPENDICES 
 
 
Appendix 1  Consumable and Equipment Suppliers 
 
General 
 
Camlab  Gilson pipettes 
VWR   ART 10µl sterile pipette tips with filter 
   ART 20µl sterile pipette gel tips with filter 
   ART 200µ sterile pipette tips with filter 
   ART 1000 sterile pipette tips with filter 
Alpha Labs  1.5 ml sterile micro-centrifuge tubes 
   Pastettes 
   Micro-pastettes 
 
 
TPMT Phenotyping 
 
Hettich   Rotanda 460 Centrifuge 
Grant    UBD Dri Incubation Blocks 
Shimadzu   SCL-10AVP System Controller 
SIL-10ADVP Autosampler 
LC-10ADVP LC Pump 
DGU-14A Degasser 
CTO-10ASVP Column Oven with Phenomenex Kingsorb 
column 
SPD-10 AVP UV Detector 
RF-10AXL Fluorescence Detector 
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TPMT Genotyping 
 
Grant    Water Bath 
LEC    Automatic Ice Maker 
Unicam   UV/visible spectrophotometer quartz micro-cuvettes (10mm) 
Abgene   0.2 ml Thermo-tube, thin walled tubes with flat caps 
Techne   96 well plate Genius thermal cycler  
Eppendorf   5415D Micro-centrifuge   
Thermo   EC330 Midicell Primo Submarine Gel System 
EC135-90 Power Pack 
Syngene  GeneGenius Gel Documentation System 
Consisting of: Gel Documentation Analysis System (IBM Thinkpad 
Computer) 
Bio Imaging System 
GelVue UV Transilluminator 
Slim Light Panel 
Sony    Digital Graphic Printer UDP-D895-MD 
Sony    Printing Paper Type IV (Enhanced) UPP-110HA 
 
6TGN 
 
Shimadzu  CTO -20A Column Oven Phenomenex Prodigy 5uODS(2)  
column 
LC20 -AD HPLC Pump 
SIL -20A Autosampler 
SPD -20A UV/Vis Absorbance Detector 
Hettich   MIKRO 200 Eppendorf Microcentrifuge   
Stuart Scientific  SHT 100D Dri Block Unit  
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Appendix 2 Whole blood TPMT study raw data 
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 RBC Lysate 1  RBC Lysate 2  Mean RBC Lysate  Whole Blood 1  Whole Blood 2  Mean WB         
Sample Peak Ht. Activity Peak Ht. Activity Peak Ht. Activity Peak Ht. Activity Peak Ht. Activity Peak Ht. Activity Genotype 
219424 9.2 33 6.6 35 7.9 34 11.1 47 11.3 48 11.2 48 TPMT*1/1 
219425 2.5 9 2.8 11 2.7 10 2.4 9 3.3 12 2.9 11 TPMT*1/3 
219426 4.8 23 2.0 21 3.4 22 11.6 46 11.4 43 11.5 45 TPMT*1/1 
219427 6.4 26 7.9 32 7.2 29 11.0 58 9.8 49 10.4 54 TPMT*1/1 
219428 7.8 24 7.3 22 7.6 23 7.5 36 8.3 35 7.9 36 TPMT*1/1 
219414 8.0 29 9.8 28 8.9 29 9.5 45 9.7 40 9.6 43 TPMT*1/1 
219415 9.5 28 9.8 43 9.7 36 7.4 35 7.6 33 7.5 34 TPMT*1/1 
219416 8.7 32 10.5 33 9.6 33 7.5 37 7.8 36 7.7 37 TPMT*1/1 
219417 9.7 25 12.6 36 11.2 31 8.3 37 8.6 35 8.5 36 TPMT*1/1 
219418 11.0 34 8.9 28 10.0 31 9.6 44 9.9 42 9.8 43 TPMT*1/1 
219419 16.3 44 16.2 45 16.3 45 10.5 44 11.3 44 10.9 44 TPMT*1/1 
219420 10.1 38 * * 10.1 38 12.4 41 * * 12.4 41 TPMT*1/1 
219421 9.1 32 10.4 34 9.8 33 8.2 35 10.4 42 9.3 39 TPMT*1/1 
219422 15.2 56 * * 15.2 56 14.5 59 * * 14.5 59 TPMT*1/1 
219423 11.9 40 12.5 37 12.2 39 8.4 40 9.1 42 8.8 41 TPMT*1/1 
219429 8.1 33 10.5 34 9.3 34 12.0 46 12.0 47 12.0 47 TPMT*1/1 
219431 13.6 35 12.3 31 13.0 33 12.4 43 11.7 40 12.1 42 TPMT*1/1 
219432 16.0 37 8.8 37 12.4 37 11.9 55 11.0 55 11.5 55 TPMT*1/1 
219433 13.7 47 16.0 57 14.9 52 15.2 60 14.1 57 14.7 59 TPMT*1/1 
219434 14.0 50 16.2 59 15.1 55 14.5 66 14.0 64 14.3 65 TPMT*1/1 
219435 10.2 31 12.6 36 11.4 34 11.7 46 10.8 46 11.3 46 TPMT*1/1 
219436 6.9 28 9.4 33 8.2 31 12.1 43 12.3 44 12.2 44 TPMT*1/1 
219437 8.1 31 12.6 36 10.4 34 9.8 45 9.4 45 9.6 45 TPMT*1/1 
219438 6.9 20 4.0 23 5.5 22 11.8 46 11.7 48 11.8 47 TPMT*1/1 
219440 7.2 26 3.0 22 5.1 24 7.8 34 7.1 35 7.5 35 TPMT*1/1 
219442 7.2 25 9.8 27 8.5 26 8.5 36 7.8 34 8.2 35 TPMT*1/1 
219443 9.8 35 * * 9.8 35 11.1 41 11.0 42 11.1 42 TPMT*1/1 
219444 9.4 33 9.5 34 9.5 34 10.0 38 10.2 42 10.1 40 TPMT*1/1 
219445 7.4 20 10.9 32 9.2 26 9.2 37 9.0 40 9.1 39 TPMT*1/1 
219446 9.2 37 13.8 41 11.5 39 12.7 48 12.7 48 12.7 48 TPMT*1/1 
219447 5.0 15 5.4 16 5.2 16 5.9 21 5.7 22 5.8 22 TPMT*1/3 
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 RBC Lysate 1  RBC Lysate 2  Mean RBC Lysate  Whole Blood 1  Whole Blood 2  Mean WB         
Sample Peak Ht. Activity Peak Ht. Activity Peak Ht. Activity Peak Ht. Activity Peak Ht. Activity Peak Ht. Activity Genotype 
219448 9.0 30 13.4 35 11.2 33 9.7 44 9.4 45 9.6 45 TPMT*1/1 
219449 11.5 57 5.8 49 8.7 53 11.2 56 10.2 51 10.7 54 TPMT*1/1 
219450 12.7 58 18.5 64 15.6 61 12.3 80 17.9 76 15.1 78 TPMT*1/1 
219451 5.4 17 6.2 18 5.8 18 5.9 26 6.0 28 6.0 27 TPMT*1/3 
219452 9.4 29 11.7 32 10.6 31 11.3 48 12.2 48 11.8 48 TPMT*1/1 
219453 5.3 23 7.6 26 6.5 25 8.4 40 8.4 39 8.4 40 TPMT*1/1 
219454 4.5 15 5.7 17 5.1 16 5.6 21 5.9 22 5.8 22 TPMT*1/3 
219455 5.0 39 9.5 42 7.3 41 14.1 50 13.8 52 14.0 51 TPMT*1/1 
219456 11.1 34 12.2 37 11.7 36 3.1 53 14.2 54 8.7 54 TPMT*1/1 
219457 12.9 35 8.7 26 10.8 31 10.9 52 10.1 53 10.5 53 TPMT*1/1 
219459 13.6 36 12.7 37 13.2 37 13.6 50 13.3 54 13.5 52 TPMT*1/1 
219460 10.9 39 10.4 39 10.7 39 12.2 48 12.1 49 12.2 49 TPMT*1/1 
219461 5.4 33 7.8 37 6.6 35 10.2 42 9.7 41 10.0 42 TPMT*1/1 
219462 15.3 43 13.6 44 14.5 44 13.6 55 13.3 59 13.5 57 TPMT*1/1 
219463 16.0 44 14.2 43 15.1 44 11.5 55 10.9 52 11.2 54 TPMT*1/1 
219464 6.6 32 9.9 31 8.3 32 9.8 36 9.8 39 9.8 38 TPMT*1/1 
219465 11.0 39 16.2 48 13.6 44 8.9 51 11.2 54 10.1 53 TPMT*1/1 
219466 15.3 54 14.8 58 15.1 56 14.7 67 13.5 62 14.1 65 TPMT*1/1 
219468 9.0 30 15.0 37 12.0 34 13.4 51 12.1 44 12.8 48 TPMT*1/1 
219469 10.0 39 12.6 40 11.3 40 12.6 58 11.3 52 12.0 55 TPMT*1/1 
219476 11.0 36 16.3 44 13.7 40 13.1 53 12.5 55 12.8 54 TPMT*1/1 
219477 10.6 26 13.3 32 12.0 29 11.1 49 10.4 48 10.8 49 TPMT*1/1 
219478 18.0 44 * * 18.0 44 11.5 51 10.3 45 10.9 48 TPMT*1/1 
219479 7.5 29 9.3 34 8.4 32 11.4 48 12.0 49 11.7 49 TPMT*1/1 
219480 11.8 35 15.4 39 13.6 37 14.3 49 13.8 51 14.1 50 TPMT*1/1 
219481 6.5 17 8.7 24 7.6 21 6.3 36 6.3 36 6.3 36 TPMT*1/1 
219482 5.6 17 6.9 19 6.3 18 4.4 25 4.5 25 4.5 25 TPMT*1/3 
219483 11.1 38 15.5 34 13.3 36 11.8 46 12.7 48 12.3 47 TPMT*1/1 
219484 13.7 40 17.8 42 15.8 41 13.0 53 12.2 50 12.6 52 TPMT*1/1 
219485 8.5 33 13.3 39 10.9 36 18.1 77 14.5 61 16.3 69 TPMT*1/1 
219486 13.9 44 18.7 53 16.3 49 14.6 59 13.9 64 14.3 62 TPMT*1/1 
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 RBC Lysate 1  RBC Lysate 2  Mean RBC Lysate  Whole Blood 1  Whole Blood 2  Mean WB         
Sample Peak Ht. Activity Peak Ht. Activity Peak Ht. Activity Peak Ht. Activity Peak Ht. Activity Peak Ht. Activity Genotype 
219487 16.0 57 10.7 44 13.4 51 * * 12.2 71 12.2 71 TPMT*1/1 
219488 13.9 44 15.5 47 14.7 46 20.0 69 18.0 66 19.0 68 TPMT*1/1 
219489 6.0 44 5.0 46 5.5 45 11.4 55 10.6 58 11.0 57 TPMT*1/1 
219490 3.4 29 2.9 29 3.2 29 12.5 51 12.0 53 12.3 52 TPMT*1/1 
219491 6.9 42 4.6 40 5.8 41 7.8 48 7.3 45 7.6 47 TPMT*1/1 
219492 5.2 30 4.6 39 4.9 35 10.7 44 10.2 43 10.5 44 TPMT*1/1 
219493 4.7 34 4.1 32 4.4 33 17.1 82 17.4 87 17.3 85 TPMT*1/1 
219494 5.2 36 2.8 34 4.0 35 10.2 36 9.9 36 10.1 36 TPMT*1/1 
219495 6.5 55 4.4 60 5.5 58 16.0 73 15.3 76 15.7 75 TPMT*1/1 
219496 7.0 45 5.4 42 6.2 44 10.2 45 10.2 47 10.2 46 TPMT*1/1 
219497 3.3 28 4.1 30 3.7 29 12.2 45 12.3 48 12.3 47 TPMT*1/1 
219498 3.6 30 2.5 31 3.1 31 12.0 44 11.4 43 11.7 44 TPMT*1/1 
219499 4.7 32 3.2 32 4.0 32 9.6 48 9.3 46 9.5 47 TPMT*1/1 
219500 4.4 32 3.4 34 3.9 33 15.9 53 15.8 51 15.9 52 TPMT*1/1 
219501 2.3 42 2.9 35 2.6 39 14.5 57 14.9 63 14.7 60 TPMT*1/1 
219502 5.1 51 3.5 48 4.3 50 12.4 51 11.7 51 12.1 51 TPMT*1/1 
219503 4.0 29 2.9 32 3.5 31 9.9 50 9.4 49 9.7 50 TPMT*1/1 
219504 2.1 23 1.6 20 1.9 22 6.6 27 6.8 29 6.7 28 TPMT*1/3 
219505 7.0 45 3.4 27 5.2 36 7.8 43 7.2 38 7.5 41 TPMT*1/1 
219470 9.6 29 15.6 40 12.6 35 11.1 47 11.8 48 11.5 48 TPMT*1/1 
219471 7.7 26 8.0 31 7.9 29 10.3 40 11.0 42 10.7 41 TPMT*1/1 
219472 5.1 19 9.0 24 7.1 22 6.2 31 7.5 36 6.9 34 TPMT*1/3 
219473 12.9 38 15.8 49 14.4 44 13.6 53 14.3 54 14.0 54 TPMT*1/1 
219474 5.9 17 9.9 25 7.9 21 6.9 30 6.9 30 6.9 30 TPMT*1/3 
219475 10.7 32 20.8 67 15.8 50 12.8 61 13.2 61 13.0 61 TPMT*1/1 
219506 5.6 19 9.0 32 7.3 26 7.7 40 8.0 40 7.9 40 TPMT*1/1 
219507 6.1 20 10.2 33 8.2 27 9.5 55 9.4 54 9.5 55 TPMT*1/1 
219508 6.4 23 10.0 35 8.2 29 8.6 45 8.4 44 8.5 45 TPMT*1/1 
219509 8.1 32 12.3 50 10.2 41 11.2 56 10.1 53 10.7 55 TPMT*1/1 
219510 5.7 18 9.2 32 7.5 25 9.7 44 9.2 44 9.5 44 TPMT*1/1 
219511 9.1 29 12.3 41 10.7 35 10.4 46 9.8 43 10.1 45 TPMT*1/1 
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 RBC Lysate 1  RBC Lysate 2  Mean RBC Lysate  Whole Blood 1  Whole Blood 2  Mean WB         
Sample Peak Ht. Activity Peak Ht. Activity Peak Ht. Activity Peak Ht. Activity Peak Ht. Activity Peak Ht. Activity Genotype 
219512 7.6 33 11.1 37 9.4 35 11.6 51 11.1 49 11.4 50 TPMT*1/1 
219513 9.0 34 10.8 40 9.9 37 14.2 52 14.4 53 14.3 53 TPMT*1/1 
219518 6.1 23 8.3 28 7.2 26 8.3 35 8.1 36 8.2 36 TPMT*1/1 
219519 17.5 69 19.7 66 18.6 68 13.4 74 12.3 68 12.9 71 TPMT*1/1 
219520 9.4 30 9.1 30 9.3 30 10.2 47 9.3 46 9.8 47 TPMT*1/1 
219521 7.5 28 10.9 33 9.2 31 9.6 44 9.2 42 9.4 43 TPMT*1/1 
219522 12.2 41 13.6 43 12.9 42 13.8 56 14.7 54 14.3 55 TPMT*1/1 
219523 7.9 33 14.7 34 11.3 34 13.2 48 13.2 47 13.2 48 TPMT*1/1 
219524 18.4 70 18.3 59 18.4 65 18.0 91 20.4 94 19.2 93 TPMT*1/1 
219515 10.4 24 11.7 27 11.1 26 5.7 37 7.2 36 6.5 37 TPMT*1/1 
219516 16.1 52 * * 16.1 52 16.0 61 * * 16.0 61 TPMT*1/1 
219517 10.4 26 8.9 38 9.7 32 8.9 38 10.6 45 9.8 42 TPMT*1/1 
219525 5.8 16 8.3 19 7.1 18 5.5 23 6.4 26 6.0 25 TPMT*1/3 
219527 13.0 31 13.6 34 13.3 33 9.4 40 9.0 37 9.2 39 TPMT*1/1 
219528 14.2 65 21.2 65 17.7 65 16.0 73 17.0 72 16.5 73 TPMT*1/1 
219529 6.6 21 9.4 25 8.0 23 11.9 55 12.3 52 12.1 54 TPMT*1/1 
219530 8.7 27 11.0 33 9.9 30 9.3 46 10.2 47 9.8 47 TPMT*1/1 
219531 4.6 13 5.1 15 4.9 14 5.3 22 5.8 22 5.6 22 TPMT*1/1 
219532 13.4 43 15.1 46 14.3 45 10.9 60 11.6 58 11.3 59 TPMT*1/1 
219533 8.4 26 10.1 30 9.3 28 8.8 39 9.3 39 9.1 39 TPMT*1/1 
219534 9.8 31 15.5 42 12.7 37 11.0 58 12.6 63 11.8 61 TPMT*1/1 
219535 11.8 31 12.4 35 12.1 33 14.0 51 15.1 52 14.6 52 TPMT*1/1 
219536 5.3 25 8.0 30 6.7 28 12.4 51 14.2 58 13.3 55 TPMT*1/1 
219537 9.7 31 12.5 40 11.1 36 10.4 67 12.0 66 11.2 67 TPMT*1/1 
219538 12.1 43 17.8 53 15.0 48 12.4 68 12.9 68 12.7 68 TPMT*1/1 
219539 15.8 45 19.1 58 17.5 52 14.7 65 15.7 64 15.2 65 TPMT*1/1 
219540 17.4 46 * * 17.4 46 11.7 56 * * 11.7 56 TPMT*1/1 
219541 12.4 40 16.9 50 14.7 45 13.7 66 13.0 62 13.4 64 TPMT*1/1 
219542 15.4 56 14.0 48 14.7 52 14.1 55 15.1 66 14.6 61 TPMT*1/1 
219543 16.8 58 18.1 51 17.5 55 12.3 61 11.9 62 12.1 62 TPMT*1/1 
219544 7.7 24 9.6 28 8.7 26 13.9 44 13.5 45 13.7 45 TPMT*1/1 
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 RBC Lysate 1  RBC Lysate 2  Mean RBC Lysate  Whole Blood 1  Whole Blood 2  Mean WB         
Sample Peak Ht. Activity Peak Ht. Activity Peak Ht. Activity Peak Ht. Activity Peak Ht. Activity Peak Ht. Activity Genotype 
219545 7.9 24 8.0 30 8.0 27 8.8 36 8.5 36 8.7 36 TPMT*1/3 
219546 10.8 52 8.0 33 9.4 43 10.8 42 10.8 48 10.8 45 TPMT*1/1 
219547 9.1 29 13.1 38 11.1 34 12.4 52 11.8 52 12.1 52 TPMT*1/1 
219548 7.6 30 11.3 30 9.5 30 11.4 42 11.3 44 11.4 43 TPMT*1/1 
219549 12.8 38 14.2 42 13.5 40 14.1 55 14.2 56 14.2 56 TPMT*1/1 
219550 11.4 34 11.9 34 11.7 34 12.3 45 11.7 44 12.0 45 TPMT*1/1 
219551 7.0 28 7.5 32 7.3 30 10.8 40 10.7 42 10.8 41 TPMT*1/1 
219552 10.6 28 11.6 36 11.1 32 11.8 52 11.5 51 11.7 52 TPMT*1/1 
219553 5.8 16 7.0 20 6.4 18 7.5 27 8.0 29 7.8 28 TPMT*1/3 
219554 10.7 29 9.9 38 10.3 34 15.1 69 16.9 60 16.0 65 TPMT*1/1 
219555 6.6 21 7.8 28 7.2 25 10.6 47 10.3 47 10.5 47 TPMT*1/1 
219556 15.9 50 22.2 53 19.1 52 17.0 69 16.8 71 16.9 70 TPMT*1/1 
219557 5.2 36 14.5 39 9.9 38 10.3 54 10.0 52 10.2 53 TPMT*1/1 
219558 9.5 33 7.5 27 8.5 30 10.6 45 10.3 45 10.5 45 TPMT*1/1 
219559 15.9 42 11.2 33 13.6 38 15.3 56 16.1 55 15.7 56 TPMT*1/1 
219560 13.4 38 15.6 42 14.5 40 14.9 59 16.0 61 15.5 60 TPMT*1/1 
219561 11.6 35 10.1 32 10.9 34 8.8 57 9.2 53 9.0 55 TPMT*1/1 
219562 8.1 28 8.9 30 8.5 29 9.8 47 10.3 54 10.1 51 TPMT*1/1 
219563 11.9 31 14.0 28 13.0 30 14.9 55 15.8 54 15.4 55 TPMT*1/1 
219565 10.4 34 13.4 33 11.9 34 10.6 42 9.1 39 9.9 41 TPMT*1/1 
219567 13.7 38 15.6 40 14.7 39 13.6 53 14.0 53 13.8 53 TPMT*1/1 
219568 19.3 66 14.2 68 16.8 67 15.5 81 15.3 99 15.4 90 TPMT*1/1 
219569 15.5 41 15.6 39 15.6 40 13.2 52 14.1 53 13.7 53 TPMT*1/1 
219570 12.8 45 5.7 57 9.3 51 8.7 60 10.0 61 9.4 61 TPMT*1/1 
219571 8.9 33 * * 8.9 33 8.9 39 9.3 39 9.1 39 TPMT*1/1 
219572 8.8 25 7.5 23 8.2 24 7.7 37 5.6 26 6.7 32 TPMT*1/1 
219573 5.6 15 6.2 15 5.9 15 6.6 24 6.8 25 6.7 25 TPMT*1/2 
219577 4.8 14 * * 4.8 14 6.3 22 6.7 22 6.5 22 TPMT*1/3 
219578 15.0 50 14.4 50 14.7 50 13.1 85 13.4 82 13.3 84 TPMT*1/1 
219579 11.2 32 13.9 35 12.6 34 11.4 48 12.3 48 11.9 48 TPMT*1/1 
219580 11.9 35 13.3 37 12.6 36 12.6 50 13.6 52 13.1 51 TPMT*1/1 
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 RBC Lysate 1  RBC Lysate 2  Mean RBC Lysate  Whole Blood 1  Whole Blood 2  Mean WB         
Sample Peak Ht. Activity Peak Ht. Activity Peak Ht. Activity Peak Ht. Activity Peak Ht. Activity Peak Ht. Activity Genotype 
219581 13.5 51 10.5 52 12.0 52 13.1 53 16.4 60 14.8 57 TPMT*1/1 
219582 15.3 41 15.6 42 15.5 42 18.1 59 19.6 58 18.9 59 TPMT*1/1 
219583 12.7 36 13.3 35 13.0 36 15.3 58 15.3 50 15.3 54 TPMT*1/1 
219584 9.8 31 5.6 34 7.7 33 10.7 44 12.3 47 11.5 46 TPMT*1/1 
219687 8.1 25 7.0 25 7.6 25 9.7 44 9.7 44 9.7 44 TPMT*1/1 
219688 10.5 29 12.9 34 11.7 32 10.3 49 11.1 49 10.7 49 TPMT*1/1 
219689 14.7 29 12.7 32 13.7 31 9.7 41 10.3 40 10.0 41 TPMT*1/1 
219690 10.3 31 12.1 32 11.2 32 10.7 44 11.6 44 11.2 44 TPMT*1/1 
219691 11.0 31 * * 11.0 31 8.3 40 8.9 40 8.6 40 TPMT*1/1 
219692 12.3 36 13.3 38 12.8 37 8.9 36 9.4 38 9.2 37 TPMT*1/1 
219693 11.1 29 10.6 30 10.9 30 10.4 39 10.8 38 10.6 39 TPMT*1/1 
219694 7.9 24 6.1 25 7.0 25 7.5 38 7.7 35 7.6 37 TPMT*1/1 
219695 10.2 28 10.5 26 10.4 27 7.7 35 8.3 34 8.0 35 TPMT*1/1 
219696 12.2 34 12.3 34 12.3 34 11.3 48 11.9 48 11.6 48 TPMT*1/1 
219697 11.5 28 11.9 30 11.7 29 9.2 37 9.9 39 9.6 38 TPMT*1/1 
219698 11.2 29 10.4 29 10.8 29 11.8 50 12.4 54 12.1 52 TPMT*1/1 
219699 10.2 32 10.9 32 10.6 32 8.0 30 8.6 30 8.3 30 TPMT*1/1 
219700 3.7 11 4.5 13 4.1 12 4.8 20 4.8 21 4.8 21 TPMT*1/3 
219701 8.8 24 9.2 25 9.0 25 11.6 44 12.0 41 11.8 43 TPMT*1/1 
219702 9.3 27 9.8 28 9.6 28 9.8 41 10.6 42 10.2 42 TPMT*1/1 
219703 10.2 30 9.4 32 9.8 31 8.3 48 7.4 48 7.9 48 TPMT*1/1 
219704 9.1 29 9.3 27 9.2 28 10.3 38 12.1 42 11.2 40 TPMT*1/1 
219705 8.5 25 9.3 26 8.9 26 10.5 50 10.4 48 10.5 49 TPMT*1/1 
219706 6.4 19 6.7 20 6.6 20 9.3 38 10.3 39 9.8 39 TPMT*1/1 
219707 11.0 35 12.0 38 11.5 37 11.4 48 11.7 50 11.6 49 TPMT*1/1 
219708 7.1 27 7.4 27 7.3 27 8.0 42 9.1 40 8.6 41 TPMT*1/1 
219709 5.0 13 7.2 23 6.1 18 4.3 19 5.1 20 4.7 20 TPMT*1/3 
219710 10.1 35 6.6 38 8.4 37 7.4 45 7.8 45 7.6 45 TPMT*1/1 
219711 15.6 42 16.6 46 16.1 44 14.6 53 18.3 54 16.5 54 TPMT*1/1 
219712 13.6 39 14.1 43 13.9 41 11.9 57 13.5 55 12.7 56 TPMT*1/1 
219713 10.0 42 10.7 39 10.4 41 9.7 44 9.1 48 9.4 46 TPMT*1/1 
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 RBC Lysate 1  RBC Lysate 2  Mean RBC Lysate  Whole Blood 1  Whole Blood 2  Mean WB         
Sample Peak Ht. Activity Peak Ht. Activity Peak Ht. Activity Peak Ht. Activity Peak Ht. Activity Peak Ht. Activity Genotype 
219714 15.0 59 15.3 56 15.2 58 15.2 67 15.6 75 15.4 71 TPMT*1/1 
219715 11.9 41 12.0 41 12.0 41 13.4 55 12.9 55 13.2 55 TPMT*1/1 
219716 8.0 25 11.4 26 9.7 26 8.5 42 8.7 43 8.6 43 TPMT*1/1 
219717 5.5 20 6.3 21 5.9 21 7.3 36 8.0 38 7.7 37 TPMT*1/1 
219718 8.4 23 9.3 24 8.9 24 10.5 39 9.6 39 10.1 39 TPMT*1/1 
219719 13.8 56 19.5 56 16.7 56 12.2 84 12.8 83 12.5 84 TPMT*1/1 
219720 5.7 17 7.0 19 6.4 18 5.6 21 6.1 21 5.9 21 TPMT*1/3 
219721 11.7 35 12.1 34 11.9 35 11.7 43 11.0 45 11.4 44 TPMT*1/1 
219722 5.3 25 9.3 27 7.3 26 9.5 37 10.2 37 9.9 37 TPMT*1/1 
219723 11.7 33 12.3 33 12.0 33 11.3 46 12.2 48 11.8 47 TPMT*1/1 
219724 9.3 29 9.3 29 9.3 29 8.3 40 8.4 40 8.4 40 TPMT*1/1 
219725 12.5 43 12.1 43 12.3 43 13.6 53 14.7 54 14.2 54 TPMT*1/1 
219726 7.5 26 10.1 25 8.8 26 8.9 43 8.5 37 8.7 40 TPMT*1/1 
219727 9.8 33 12.1 35 11.0 34 12.5 55 13.7 56 13.1 56 TPMT*1/1 
219728 4.9 15 6.0 15 5.5 15 4.8 23 4.9 22 4.9 23 TPMT*1/3 
219729 10.7 36 9.9 39 10.3 38 10.3 47 11.7 44 11.0 46 TPMT*1/1 
219730 14.5 39 16.6 42 15.6 41 11.8 52 12.4 49 12.1 51 TPMT*1/1 
219731 10.3 28 12.7 30 11.5 29 10.2 42 10.7 42 10.5 42 TPMT*1/1 
219732 10.9 33 8.2 25 9.6 29 11.9 59 12.8 52 12.4 56 TPMT*1/1 
219733 10.9 29 12.3 31 11.6 30 10.2 42 11.1 42 10.7 42 TPMT*1/1 
219734 11.8 36 12.1 33 12.0 35 11.4 50 12.2 50 11.8 50 TPMT*1/1 
219735 7.7 24 7.0 24 7.4 24 7.1 34 7.1 34 7.1 34 TPMT*1/1 
219736 8.1 29 7.8 29 8.0 29 6.9 45 7.5 43 7.2 44 TPMT*1/1 
219738 10.1 31 12.1 33 11.1 32 9.3 43 9.8 41 9.6 42 TPMT*1/1 
219737 7.8 50 10.7 56 9.3 53 14.3 66 14.1 70 14.2 68 TPMT*1/1 
219739 8.0 46 9.6 46 8.8 46 12.3 59 13.2 63 12.8 61 TPMT*1/1 
219740 4.3 43 6.2 36 5.3 40 9.0 50 9.4 49 9.2 50 TPMT*1/1 
219741 4.4 48 5.6 44 5.0 46 12.2 52 11.9 48 12.1 50 TPMT*1/1 
219743 3.9 43 4.2 39 4.1 41 10.8 50 10.6 47 10.7 49 TPMT*1/1 
219744 16.1 52 16.8 58 16.5 55 16.8 64 18.0 66 17.4 65 TPMT*1/1 
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219745 11.2 49 7.1 60 9.2 55 13.8 72 14.4 72 14.1 72 TPMT*1/1 
219746 10.5 41 10.8 44 10.7 43 9.1 56 10.6 65 9.9 61 TPMT*1/1 
219747 12.7 42 12.3 45 12.5 44 13.1 53 12.1 56 12.6 55 TPMT*1/1 
219748 9.4 45 11.3 44 10.4 45 10.0 58 10.7 59 10.4 59 TPMT*1/1 
219749 4.8 23 4.9 20 4.9 22 7.4 41 7.2 38 7.3 40 TPMT*1/3 
219750 9.0 47 12.3 45 10.7 46 17.4 74 18.5 73 18.0 74 TPMT*1/1 
219752 13.4 48 13.0 48 13.2 48 10.9 52 11.7 56 11.3 54 TPMT*1/1 
219753 12.9 46 15.1 55 14.0 51 13.8 63 12.3 59 13.1 61 TPMT*1/1 
219754 9.0 66 10.4 60 9.7 63 14.6 64 17.1 70 15.9 67 TPMT*1/1 
219755 10.8 48 10.1 50 10.5 49 13.9 53 14.0 57 14.0 55 TPMT*1/1 
219756 9.5 39 8.7 43 9.1 41 12.6 53 14.0 59 13.3 56 TPMT*1/1 
219757 7.2 27 * * 7.2 27 10.3 42 10.7 51 10.5 47 TPMT*1/1 
219759 1.2 4 1.3 4.9 1.3 4 1.6 7.7 1.3 5.9 1.5 7 TPMT*3/3 
219760 8.0 28 5.4 33 6.7 31 9.7 44 11.3 46 10.5 45 TPMT*1/1 
219761 8.5 31 9.0 33 8.8 32 10.4 44 11.2 44 10.8 44 TPMT*1/1 
219762 8.7 34 11.2 37 10.0 36 10.8 48 14.7 60 12.8 54 TPMT*1/1 
219763 10.3 49 12.0 48 11.2 49 10.4 60 13.0 55 11.7 58 TPMT*1/1 
219764 10.2 36 10.6 42 10.4 39 12.3 52 12.3 50 12.3 51 TPMT*1/1 
219765 10.3 45 6.3 53 8.3 49 14.5 59 15.9 58 15.2 59 TPMT*1/1 
219922 9.2 56 9.6 59 9.4 58 11.9 57 13.8 58 12.9 58 TPMT*1/1 
219925 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 TPMT*3/3 
219926 9.3 33 10.8 33 10.1 33 9.3 43 9.5 44 9.4 44 TPMT*1/1 
219927 11.0 34 12.8 39 11.9 37 10.1 40 10.8 44 10.5 42 TPMT*1/1 
219928 20.8 67 21.2 67 21.0 67 13.9 80 13.9 85 13.9 83 TPMT*1/1 
219929 11.0 42 11.4 36 11.2 39 11.3 48 12.5 51 11.9 50 TPMT*1/1 
219930 20.9 62 21.7 68 21.3 65 13.5 57 13.6 62 13.6 60 TPMT*1/1 
219931 12.4 40 13.6 40 13.0 40 11.4 45 11.6 49 11.5 47 TPMT*1/1 
219932 13.3 38 10.5 40 11.9 39 13.3 56 13.0 49 13.2 53 TPMT*1/1 
219933 12.5 38 11.1 41 11.8 40 12.2 52 13.5 62 12.9 57 TPMT*1/1 
219934 8.2 50 12.5 53 10.4 52 10.9 57 11.2 65 11.1 61 TPMT*1/1 
219935 11.1 39 11.1 37 11.1 38 11.8 50 11.3 48 11.6 49 TPMT*1/1 
  131 
 RBC Lysate 1  RBC Lysate 2  Mean RBC Lysate  Whole Blood 1  Whole Blood 2  Mean WB         
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219936 8.6 50 11.7 50 10.2 50 10.2 49 11.0 53 10.6 51 TPMT*1/1 
219937 8.5 36 7.8 34 8.2 35 6.9 40 7.8 43 7.4 42 TPMT*1/3 
219938 7.9 24 8.2 25 8.1 25 8.0 32 8.5 34 8.3 33 TPMT*1/3 
219939 14.3 48 17.3 58 15.8 53 12.0 63 31.1 72 21.6 68 TPMT*1/1 
219940 11.5 38 14.9 40 13.2 39 12.3 59 12.5 60 12.4 60 TPMT*1/3 
219941 14.2 49 14.6 50 14.4 50 10.5 64 11.4 66 11.0 65 TPMT*1/1 
219942 13.5 46 16.2 45 14.9 46 11.9 69 12.7 74 12.3 72 TPMT*1/1 
219943 15.7 48 11.9 44 13.8 46 14.8 54 16.7 56 15.8 55 TPMT*1/1 
219944 13.8 45 13.9 45 13.9 45 13.2 56 15.5 55 14.4 56 TPMT*1/1 
219945 11.3 37 11.3 34 11.3 36 12.4 55 14.1 60 13.3 58 TPMT*1/1 
219946 5.5 25 5.4 25 5.5 25 7.2 42 8.3 48 7.8 45 TPMT*1/3 
219947 11.4 38 12.4 40 11.9 39 13.8 61 14.9 68 14.4 65 TPMT*1/1 
219948 10.2 32 10.7 29 10.5 31 11.3 46 12.3 52 11.8 49 TPMT*1/1 
219949 17.6 55 18.8 63 18.2 59 17.1 94 19.5 107 18.3 101 TPMT*1/1 
219950 11.9 48 11.6 47 11.8 48 14.2 62 14.8 63 14.5 63 TPMT*1/1 
219951 10.8 29 7.7 37 9.3 33 11.1 64 12.2 58 11.7 61 TPMT*1/1 
219360 10.5 40 11.5 40 11.0 40 11.6 53 11.6 51 11.6 52 TPMT*1/1 
219953 5.9 25 5.5 25 5.7 25 11.4 50 11.7 50 11.6 50 TPMT*1/1 
219955 11.6 40 12.7 40 12.2 40 13.5 59 12.3 61 12.9 60 TPMT*1/1 
219956 8.7 29 8.8 29 8.8 29 9.5 42 10.0 44 9.8 43 TPMT*1/1 
219957 10.6 39 11.5 38 11.1 39 13.0 65 12.7 66 12.9 66 TPMT*1/1 
219958 10.3 44 11.5 44 10.9 44 12.1 70 12.5 65 12.3 68 TPMT*1/1 
219959 6.2 24 6.3 22 6.3 23 4.1 50 4.8 48 4.5 49 TPMT*1/1 
219952 5.8 38 7.0 41 6.4 40 11.2 47 13.7 46 12.5 47 TPMT*1/1 
219961 9.5 52 8.7 48 9.1 50 13.9 53 15.0 53 14.5 53 TPMT*1/1 
219962 9.7 41 9.8 40 9.8 41 12.1 63 12.8 61 12.5 62 TPMT*1/1 
219963 8.1 37 8.1 34 8.1 36 10.3 42 11.0 42 10.7 42 TPMT*1/1 
219964 7.5 33 9.1 33 8.3 33 10.6 65 11.1 64 10.9 65 TPMT*1/1 
219965 8.1 34 8.3 34 8.2 34 12.5 51 13.2 50 12.9 51 TPMT*1/1 
219973 11.3 40 10.3 38 10.8 39 9.9 47 10.0 48 10.0 48 TPMT*1/1 
219974 5.5 30 6.1 32 5.8 31 8.1 36 8.9 39 8.5 38 TPMT*1/1 
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219975 8.2 31 8.5 35 8.4 33 12.0 49 12.5 62 12.3 56 TPMT*1/1 
219976 5.6 39 5.0 37 5.3 38 14.3 63 15.2 64 14.8 64 TPMT*1/1 
219977 11.7 54 14.0 53 12.9 54 13.6 68 15.4 74 14.5 71 TPMT*1/1 
219978 6.6 38 8.4 37 7.5 38 11.4 48 12.1 49 11.8 49 TPMT*1/1 
219979 5.0 42 7.1 46 6.1 44 13.3 56 13.8 58 13.6 57 TPMT*1/1 
219980 3.3 33 5.2 34 4.3 34 11.4 52 11.7 51 11.6 52 TPMT*1/1 
219981 3.7 34 8.6 31 6.2 33 7.3 47 7.6 46 7.5 47 TPMT*1/1 
219960 2.9 15 3.6 16 3.3 16 5.3 21 5.3 21 5.3 21 TPMT*1/3 
219971 11.1 41 11.5 42 11.3 42 13.6 53 12.5 51 13.1 52 TPMT*1/1 
219966 9.6 38 10.6 38 10.1 38 9.6 75 10.4 76 10.0 76 TPMT*1/1 
219968 5.8 32 7.6 33 6.7 33 11.2 44 12.4 52 11.8 48 TPMT*1/1 
219969 9.8 40 7.2 40 8.5 40 10.5 44 11.6 51 11.1 48 TPMT*1/1 
219982 7.6 31 8.7 31 8.2 31 10.8 38 11.6 40 11.2 39 TPMT*1/1 
219983 9.5 28 7.6 28 8.6 28 9.4 41 9.7 43 9.6 42 TPMT*1/1 
219984 5.3 25 7.2 28 6.3 27 13.9 42 15.3 47 14.6 45 TPMT*1/1 
219985 3.8 14 4.7 16 4.3 15 5.2 21 5.9 24 5.6 23 TPMT*1/3 
219986 4.1 15 4.8 17 4.5 16 5.9 22 5.8 21 5.9 22 TPMT*1/3 
219987 4.5 18 5.4 17 5.0 18 7.4 26 7.7 26 7.6 26 TPMT*1/3 
219988 5.8 30 8.8 35 7.3 33 11.4 46 11.5 45 11.5 46 TPMT*1/1 
219989 8.6 31 8.6 32 8.6 32 8.1 45 8.9 49 8.5 47 TPMT*1/1 
219990 4.2 17 4.6 17 4.4 17 8.2 28 8.5 29 8.4 29 TPMT*1/3 
219991 6.4 24 6.6 27 6.5 26 12.2 67 13.1 72 12.7 70 TPMT*1/1 
219992 8.8 32 9.1 33 9.0 33 12.4 52 13.0 55 12.7 54 TPMT*1/1 
219993 7.8 32 8.2 32 8.0 32 9.5 50 11.9 50 10.7 50 TPMT*1/1 
219994 7.3 27 4.6 23 6.0 25 8.5 42 8.9 44 8.7 43 TPMT*1/1 
219995 13.0 43 15.7 44 14.4 44 13.5 59 11.9 59 12.7 59 TPMT*1/1 
219996 14.7 43 8.7 46 11.7 45 13.0 55 12.1 53 12.6 54 TPMT*1/1 
219997 6.1 21 6.6 19 6.4 20 6.3 26 6.4 28 6.4 27 TPMT*1/3 
219998 11.5 38 15.3 41 13.4 40 14.5 47 14.0 48 14.3 48 TPMT*1/1 
219999 15.9 46 14.8 43 15.4 45 13.3 50 12.6 51 13.0 51 TPMT*1/1 
210000 13.4 41 17.9 50 15.7 46 15.8 58 15.3 58 15.6 58 TPMT*1/1 
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Sample Peak Ht. Activity Peak Ht. Activity Peak Ht. Activity Peak Ht. Activity Peak Ht. Activity Peak Ht. Activity Genotype 
229001 15.9 44 16.7 46 16.3 45 14.6 59 16.6 55 15.6 57 TPMT*1/1 
229002 15.6 52 16.3 50 16.0 51 12.7 74 13.2 73 13.0 74 TPMT*1/1 
229003 12.2 35 12.3 35 12.3 35 11.2 49 13.0 53 12.1 51 TPMT*1/1 
229005 13.6 36 15.3 40 14.5 38 13.4 59 14.4 59 13.9 59 TPMT*1/1 
229006 14.3 41 10.5 41 12.4 41 13.5 67 13.5 62 13.5 65 TPMT*1/1 
229007 8.4 36 12.4 43 10.4 40 12.9 55 17.0 53 15.0 54 TPMT*1/1 
229008 13.6 58 15.3 50 14.5 54 15.3 70 15.4 68 15.4 69 TPMT*1/1 
229009 12.1 35 10.3 49 11.2 42 12.2 52 13.3 50 12.8 51 TPMT*1/1 
229010 9.7 40 16.5 47 13.1 44 16.1 61 16.9 62 16.5 62 TPMT*1/1 
229011 12.9 43 15.4 42 14.2 43 13.2 54 13.9 53 13.6 54 TPMT*1/1 
229012 15.1 45 17.2 46 16.2 46 13.5 57 14.0 55 13.8 56 TPMT*1/1 
229013 11.8 33 12.8 35 12.3 34 11.7 54 12.2 54 12.0 54 TPMT*1/1 
229014 11.3 32 11.4 32 11.4 32 12.7 56 13.6 58 13.2 57 TPMT*1/1 
229015 13.8 37 14.7 38 14.3 38 13.0 51 13.0 51 13.0 51 TPMT*1/1 
229016 13.6 48 15.8 54 14.7 51 14.2 74 14.6 73 14.4 74 TPMT*1/1 
229017 6.4 31 4.7 30 5.6 31 11.3 48 12.4 49 11.9 49 TPMT*1/1 
229018 6.5 34 8.9 34 7.7 34 12.0 55 14.5 61 13.3 58 TPMT*1/1 
229019 7.3 28 7.1 27 7.2 28 7.1 37 7.5 36 7.3 37 TPMT*1/3 
229020 7.7 37 8.8 36 8.3 37 11.3 44 12.3 45 11.8 45 TPMT*1/1 
229021 5.0 25 6.2 30 5.6 28 11.9 45 11.6 43 11.8 44 TPMT*1/1 
229022 9.2 36 9.9 38 9.6 37 11.4 46 12.0 47 11.7 47 TPMT*1/1 
229024 4.5 38 7.2 33 5.9 36 8.5 47 10.6 58 9.6 53 TPMT*1/1 
229025 9.0 33 9.9 34 9.5 34 11.0 55 11.3 54 11.2 55 TPMT*1/1 
229026 9.0 34 9.4 36 9.2 35 13.2 52 13.6 50 13.4 51 TPMT*1/1 
229027 7.9 30 7.3 31 7.6 31 8.9 47 9.1 44 9.0 46 TPMT*1/1 
229028 7.2 26 7.4 27 7.3 27 11.3 41 11.9 42 11.6 42 TPMT*1/1 
229029 10.5 40 11.2 41 10.9 41 11.4 46 11.4 48 11.4 47 TPMT*1/1 
229030 6.0 33 7.0 31 6.5 32 11.7 44 13.4 46 12.6 45 TPMT*1/1 
229036 14.2 50 14.5 50 14.4 50 13.3 50 15.6 55 14.5 53 TPMT*1/1 
229038 12.1 44 12.3 47 12.2 46 12.9 51 14.2 50 13.6 51 TPMT*1/1 
229039 16.5 61 17.6 61 17.1 61 15.0 69 16.1 68 15.6 69 TPMT*1/1 
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Sample Peak Ht. Activity Peak Ht. Activity Peak Ht. Activity Peak Ht. Activity Peak Ht. Activity Peak Ht. Activity Genotype 
229040 8.5 42 13.9 42 11.2 42 12.6 53 13.0 49 12.8 51 TPMT*1/1 
229041 4.8 29 6.3 30 5.6 30 10.9 50 10.5 44 10.7 47 TPMT*1/1 
229042 11.2 32 13.5 34 12.4 33 11.2 47 11.3 48 11.3 48 TPMT*1/1 
229043 10.0 32 9.5 32 9.8 32 6.7 37 6.8 34 6.8 36 TPMT*1/3 
229044 11.9 31 12.8 34 12.4 33 10.1 38 11.2 42 10.7 40 TPMT*1/1 
229045 14.0 44 15.1 40 14.6 42 13.6 55 13.7 54 13.7 55 TPMT*1/1 
229046 10.1 25 11.2 26 10.7 26 10.5 46 11.0 45 10.8 46 TPMT*1/1 
229047 11.2 40 12.6 42 11.9 41 10.4 60 10.8 59 10.6 60 TPMT*1/1 
229048 8.0 28 11.6 39 9.8 34 12.4 47 13.3 47 12.9 47 TPMT*1/1 
229049 5.2 25 6.1 22 5.7 24 6.7 31 6.7 29 6.7 30 TPMT*1/1 
229050 15.7 47 18.0 51 16.9 49 13.7 75 12.5 76 13.1 76 TPMT*1/1 
229051 11.2 32 13.0 38 12.1 35 11.1 53 18.1 42 14.6 48 TPMT*1/1 
229052 8.1 25 9.2 26 8.7 26 9.6 56 10.2 59 9.9 58 TPMT*1/1 
229053 8.0 26 10.5 32 9.3 29 11.9 48 10.9 43 11.4 46 TPMT*1/1 
229054 3.6 13 5.8 18 4.7 16 5.2 20 4.6 22 4.9 21 TPMT*1/2 
229055 11.1 39 10.8 35 11.0 37 9.0 50 9.4 49 9.2 50 TPMT*1/1 
229031 11.0 38 11.8 38 11.4 38 11.0 50 10.5 48 10.8 49 TPMT*1/1 
229033 10.4 41 10.9 40 10.7 41 12.6 48 10.3 47 11.5 48 TPMT*1/1 
229034 5.7 26 6.2 27 6.0 27 10.0 48 9.2 51 9.6 50 TPMT*1/1 
229035 11.3 44 12.6 43 12.0 44 13.1 53 8.7 53 10.9 53 TPMT*1/1 
229056 9.0 38 12.0 38 10.5 38 9.2 51 4.0 49 6.6 50 TPMT*1/1 
229057 6.7 29 7.3 28 7.0 29 10.2 51 11.2 51 10.7 51 TPMT*1/1 
229058 9.7 43 8.4 42 9.1 43 11.7 58 12.0 53 11.9 56 TPMT*1/1 
229059 3.9 21 9.2 39 6.6 30 11.7 51 12.3 50 12.0 51 TPMT*1/1 
229060 5.4 20 4.7 18 5.1 19 4.0 22 4.3 24 4.2 23 TPMT*1/3 
229061 4.8 16 4.9 15 4.9 16 6.2 25 6.7 29 6.5 27 TPMT*1/3 
229062 5.0 15 5.0 17 5.0 16 5.4 28 5.3 29 5.4 29 TPMT*1/2 
229063 10.2 36 9.2 35 9.7 36 10.1 53 10.6 58 10.4 56 TPMT*1/1 
229064 9.9 36 5.8 34 7.9 35 9.6 46 69.0 40 39.3 43 TPMT*1/1 
229065 10.6 38 11.6 39 11.1 39 12.7 58 12.7 63 12.7 61 TPMT*1/1 
229066 29.5 83 32.4 81 31.0 82 19.4 101 18.6 102 19.0 102 TPMT*1/1 
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Sample Peak Ht. Activity Peak Ht. Activity Peak Ht. Activity Peak Ht. Activity Peak Ht. Activity Peak Ht. Activity Genotype 
229067 13.9 40 15.9 43 14.9 42 21.4 67 21.8 69 21.6 68 TPMT*1/1 
229068 16.1 45 15.6 48 15.9 47 13.8 61 13.4 61 13.6 61 TPMT*1/1 
229069 13.0 38 13.4 35 13.2 37 12.0 60 12.7 66 12.4 63 TPMT*1/1 
229070 13.2 44 15.9 45 14.6 45 16.2 59 15.3 60 15.8 60 TPMT*1/1 
229071 5.8 49 9.3 49 7.6 49 16.2 61 16.0 61 16.1 61 TPMT*1/1 
229072 8.0 28 11.8 35 9.9 32 17.6 61 17.3 61 17.5 61 TPMT*1/1 
229073 13.8 41 14.0 41 13.9 41 12.8 59 12.9 62 12.9 61 TPMT*1/1 
229074 13.3 39 13.4 40 13.4 40 11.7 50 8.6 59 10.2 55 TPMT*1/1 
229076 17.4 48 12.8 49 15.1 49 18.5 70 18.0 71 18.3 71 TPMT*1/1 
229077 12.6 42 13.1 44 12.9 43 16.1 61 11.8 65 14.0 63 TPMT*1/1 
229078 14.7 40 14.3 41 14.5 41 11.6 61 11.3 62 11.5 62 TPMT*1/1 
229079 6.2 30 9.4 29 7.8 30 10.3 47 10.6 51 10.5 49 TPMT*1/1 
229080 10.8 34 11.6 38 11.2 36 13.6 60 13.0 62 13.3 61 TPMT*1/1 
229081 13.3 56 11.3 56 12.3 56 19.5 65 18.9 69 19.2 67 TPMT*1/1 
229082 13.8 39 15.9 42 14.9 41 14.0 57 13.5 57 13.8 57 TPMT*1/1 
229083 5.7 39 13.0 38 9.4 39 16.0 53 14.8 51 15.4 52 TPMT*1/1 
229084 13.2 45 15.9 43 14.6 44 15.6 57 15.5 61 15.6 59 TPMT*1/1 
229086 19.2 62 21.6 61 20.4 62 17.3 73 16.9 69 17.1 71 TPMT*1/1 
229087 14.6 46 13.4 42 14.0 44 15.0 66 15.7 72 15.4 69 TPMT*1/1 
229088 9.2 28 10.0 28 9.6 28 9.1 39 8.4 37 8.8 38 TPMT*1/3 
229089 15.3 50 16.4 49 15.9 50 20.1 74 18.6 71 19.4 73 TPMT*1/1 
229090 13.6 50 16.3 45 15.0 48 16.2 59 15.9 65 16.1 62 TPMT*1/1 
229091 16.0 48 16.1 47 16.1 48 17.6 81 17.5 77 17.6 79 TPMT*1/1 
229094 14.2 56 15.2 54 14.7 55 17.0 72 16.3 72 16.7 72 TPMT*1/1 
229095 18.0 57 17.4 53 17.7 55 14.7 67 14.3 68 14.5 68 TPMT*1/1 
229096 14.5 46 16.0 45 15.3 46 16.6 65 15.6 64 16.1 65 TPMT*1/1 
229097 23.0 63 24.2 61 23.6 62 18.5 73 17.3 70 17.9 72 TPMT*1/1 
229098 16.3 45 19.7 46 18.0 46 13.4 61 13.4 61 13.4 61 TPMT*1/1 
229099 18.0 52 19.1 51 18.6 52 17.2 79 16.5 83 16.9 81 TPMT*1/1 
229100 21.9 67 21.8 63 21.9 65 16.5 73 16.8 74 16.7 74 TPMT*1/1 
229101 13.6 38 13.6 36 13.6 37 15.6 64 14.7 62 15.2 63 TPMT*1/1 
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A simplified assay for determination of red blood cell 6-thioguanine 
nucleotides; early evidence suggestions UK patients are receiving sub-optimal 
doses of thiopurine drugs 
 
 
V Graham, Dr L T Ford, Dr J Berg 
Department of Clinical Biochemistry, City Hospital, Birmingham, B18 7QH 
Improving a test that has a growing clinical demand; blood 6TGN and 
it's role in pharmacogenomics
Valerie Graham, Dr. Jonathan Berg
Department of Clinical Biochemistry, City Hospital, Birmingham B18 7QH
Sandwell and West Birmingham Hospitals
NHS Trust NHS
Introduction
Pharmacogenetics links differences in gene expression
to drug response. Advances in this field are helping to
predict drug efficacy and toxicity. These developments
have major medical benefits as they aid optimisation of
drug dosage.
Currently, the measurement of thiopurine methyl
transferase (TPMT) is the best clinically applied example
of pharmacogenetics. This enzyme is involved in the
metabolism of the widely used Thiopurine drugs. The
quantitative determination of the active metabolites of
these drugs, the 6-thioguanine nucleotides (6TGN),
helps monitor a patient's response to treatment.
6TGN monitoring has not yet become routine practice in
the UK, in part because methods have involved time
consuming washed cell preparations, as conventionally
6TGN has been estimated in erythrocytes.
Results
Our new whole blood method results were compared
to those from conventional RBC analysis in 70 patient
samples.
Method
We have improved our method for 6TGN, estimating
metabolite levels in whole blood rather than washed
cells, making it more suitable for routine clinical use. The
method liberates 6TGN from red blood cells (RBC).
Perchloric acid at 95ºC hydrolyses the nucleotides back
to their parent thiopurine, 6-thioguanine (6TG) which is
measured by HPLC.
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Conclusions
Our whole blood 6-TGN method shows excellent
correlation between whole blood and washed RBC.
The whole blood assay is less labour intensive and
cell counting and pipetting errors are minimised. The
sample volume required is also reduced. This quick,
cost effective, simplified assay is now being
introduced into routine clinical use.
This quantification will allow more confident
escalation of dose in non-responders and dose
reduction for those with high, potentially harmful,
6TGN concentrations. It will be particularly useful in
assessing patients heterozygous for TPMT activity,
who receive a reduced dose and for which achieving
therapeutic levels can be problematic.
Appendix 5
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Appendix 6 
Patients with high-normal TPMT activity identified during routine phenotypic 
testing: What is going on? 
L T Ford, V Graham, J D Berg (Focus 2006 Poster)  
Department of Clinical Biochemistry, City Hospital, Birmingham B18 7QH 
In addition to individuals with undetectable and low TPMT activity at risk of adverse 
reactions to thiopurine drug treatment, there is also evidence of a group of patients with 
very high TPMT activity. These patients may not respond to standard doses of thiopurine 
drugs, and are at risk of hepatotoxicity from increased production of methylated-thiopurine 
metabolites and it is important to be able to identify this patient group. Approximately 2% 
of the patient samples sent to our TPMT phenotyping service have very high TPMT 
activity defined as greater than 60 nmol/gHb/hour. To determine if there is a pre-analytical 
cause in 2005 we sent out audit forms with all high TPMT activity results and received 42 
returns.The mean patient age was 46 years and there were an equal number of males 
and females. The mean TPMT activity was 71 nmol/gHb/hour (range 60-92 
nmol/gHb/hour). The mean patient haemoglobin concentration at the time of analysis was 
10.5 g/dL (range 7-14 g/dL). Prior to measuring TPMT activity a red blood cell lysate is 
prepared. The haemoglobin concentration of this lysate is used to determine the 
concentration of TPMT enzyme present, and could result in over-estimation of TPMT 
activity. However, no correlation was found between haemoglobin concentration and 
TPMT activity. On average patients were receiving 5 different drugs at the time of testing, 
one patient was on 12 different drugs. The most common drug treatment was 
prednisolone with 79% of patients receiving therapy of between 10-100 mg 
od daily. No correlation was found between prednisolone dose and TPMT activity. 
Thiopurine drug treatment can itself induce TPMT activity but only 5 patients were 
receiving azathioprine at the time of testing. We could identify no pre-analytical factors 
responsible for the high TPMT activity measured in some patientsamples using TPMT 
phenotyping. 
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Appendix 7 
Routine thiopurine drug monitoring by rapid determination of whole blood 
metabolite levels  
 
V Graham, L Ford, J Berg (2008) Focus Poster 
Department of Clinical Biochemistry, City Hospital, Birmingham B18 7QH 
 
Thiopurine drugs are widely used to treat auto-immune disease.Quantitative 
determination of the thiopurine active metabolites, 6-thioguanine nucleotides (6TGN), can 
guide treatment, increasing drug efficacy and reducing likelihood of side effects. 
Monitoring is particularly useful for individuals heterozygous for TPMT, who usually 
require a lower than normal dose to achieve therapeutic levels. Despite the potential 
benefits of 6TGN monitoring, it has not yet become an established test. Complex 
methods involving time consuming manufacture of washed cell preparations have clearly 
not been easy to apply in the routine laboratory.  
Method: We have compared levels of 6TGN in both wholeblood and washed red blood 
cells after conversion of thiopurine metabolites back to 6TGN. The lystate method starts 
by preparing washed RBC. The whole blood assay does not 
undertake this preparative step. The 6TGNs are hydrolysed to 6-thioguanine (6TG) by 
incubation with perchloric acid and dithiothretiol at 95°C for 1 hour. The concentration of 
6TG is then measured using isocratic HPLC with UV detection at 304 nm. 
Results: A comparison was made between the conventional washed red blood cell 
method and the new whole blood method. Results from whole blood were significantly 
higher than lysate preparations with a Mann Whitney U Test giving p=0.61. Regression 
analysis for patient samples prepared by the two methods gave the regression line: 
Whole Blood TGN = 16.4 + Lysate TGN x 0.977. Conclusion: The whole blood procedure 
is much less labour intensive and errors in cell counting and pipetting are also minimised. 
Our whole blood approach offers a simplified assay, which is quick and cost effective 
making it suitable for routine clinical use. Whole blood results are slightly higher but as 
application of the 6TGN assay has been limited, establishing reference intervals for the 
whole blood assay would be ideal at this stage. 
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Appendix 8  6TGN / Mean cell volume correlation data 
 
 
 
6TGN 
Therapeutic range 
235-450 pmol 
6TG/8x108 rbc 
MCV 
Normal range 
77-99 fl 
 
  
6TGN 
Therapeutic range 
235-450 pmol 
6TG/8x108 rbc 
MCV 
Normal range 
77-99 fl 
 
<50 83.0  335 107.0 
<50 94.5  336 92.8 
<50 107.5  339 108.7 
<50 99.1  357 96.8 
<50 91.6  408 112.6 
97 100.6  432 99.4 
109 107.7  436 85.2 
115 67.0  460 98.8 
116 91.4  472 103.8 
132 102.1  479 106.2 
147 88.5  481 90.4 
147 107.1  482 101.7 
157 92.1  483 88.0 
161 105.7  485 107.2 
174 98.4  501 81.6 
178 76.2  508 78.3 
186 93.2  508 113.0 
186 114.2  513 111.8 
191 101.9  541 90.0 
197 107.0  567 108.8 
210 96.9  581 104.9 
215 110.2  581 89.6 
217 102.7  620 121.0 
230 115.7  620 111.8 
261 99.4  665 79.8 
282 82.9  672 89.5 
292 109.2  705 102.6 
297 113.4  789 110.3 
302 109.8  802 109.0 
304 103.0  888 123.6 
312 87.7  911 113.1 
325 103.3  1043 90.0 
327 113.3  1116 101.0 
327 113.4    
 
 
 147 
10. REFERENCES 
              
              
1. Alves S, Prata MJ, Ferreira F, Amorim A. (2000) Screening of thiopurine S-
methyltransferase mutations by horizontal conformation-sensitive gel 
electrophoresis. Hum Mutat, 15(3):246-53 
 
2. Ames MM, Selassie CD, Woodson LC, Van Loon JA, Hansch C, Weinshilboum 
RM. (1986) Thiopurine methyltransferase: structure-activity relationships for 
benzoic acid inhibitors and thiophenol substrates. J Med Chem, Mar;29(3):354-8 
 
3. Ansari A, Elliott T, Baburajan B, Mayhead P, O'Donohue J, Chocair P, 
Sanderson J, Duley J. (2008) Long term outcome of using allopurinol co-therapy 
as a strategy for overcoming thiopurine hepatotoxicity in treating inflammatory 
bowel disease. Aliment Pharmacol Ther, Jun 2 
 
4. Anstey A, Lennard L, Mayou SC, Kirby JD. (1992)  Pancytopenia related to 
azathioprine – an enzyme deficiency caused by a common genetic polymorphism. 
J. Royal Soc. Med, 85: 752-756 
 
5. Anstey AV, Wakelin S, Reynolds NJ. (2004) Guidelines for prescribing 
azathioprine in dermatology. British J Derm, 151: 1123-1132 
 
6. Arenas M, Duley JA, Ansari A, Shobowale-Bakre EA, Fairbanks L, Soon SY, 
Sanderson J, Marinaki AM. (2004) Genetic determinants of the pre- and post-
azathioprine therapy thiopurine methyltransferase activity phenotype. Nucleosides 
Nucleotides Nucleic Acids, Oct;23(8-9):1403-5 
 
7. N Barlow, R Adams, P Bangh, J D Berg (2009) Who is using the TPMT test in the 
UK? A review of requests sent to a national referral centre Ann Clin Biochem, 
Focus Poster 
 
8. Bruunshuus I, Schmiegelow K. (1989) Analysis of 6-mercaptopurine, 6-
thioguanine nucleotides, and 6-thiouric acid in biological fluids by high-
performance liquid chromatography. Scand J Clin Lab Invest, Dec;49(8):779-84 
 
9. Cheung TK, Florin TH. (2003) 6-thioguanine: a new old drug to procure remission 
in inflammatory bowel disease. Intern Med J. Jan-Feb;33(1-2):44-6 
 
10. Clunie G, Lennard L. (2004) Relevance of thiopurine methyl transferase status in 
rheumatology patients receiving azathioprine. Rheumatology, 43: 13-18 
 
11. Collie-Duguid ES, Pritchard SC, Powrie RH, Sludden J, Collier DA, Li T, McLeod 
HL. (1999)  The frequency and distribution of thiopurine methyltransferase alleles 
in Caucasian and Asian populations. Pharmacogenetics. Feb;9(1):37-42 
12. Compagni A, Bartoli S, Buehrlen B, Fattore G, Ibarreta D, de Mesa EG. (2008) 
Avoiding adverse drug reactions by pharmacogenetic testing: a systematic review 
of the economic evidence in the case of TPMT and AZA-induced side effects. Int J 
Technol Assess Health Care. Summer;24(3):294-302 
 148 
13. Cooper SC, Ford LT, Berg JD, Lewis MJ. (2008) Ethnic variation of thiopurine S-
methyltransferase activity; a large, prospective population study. 
Pharmacogenomics. Mar;9(3):303-9. 
 
14. Coulthard SA, Hogarth LA, Little M, Mathieson EC, Redfern CPF, Minto L, Hall 
AG. (2002) The effect of methyl transferase expression on sensitivity to thiopurine 
drugs. Molecular Pharmacology, 62:102-109 
 
15. Cuffari C, Dassopoulos T, Turnbough L, Thompson RE, Bayless TM. (2004) 
Thiopurine methyltransferase activity influences clinical response to azathioprine in 
inflammatory bowel disease. Clin Gastroenterol Hepatol, May;2(5):410-7 
 
16. Cuffari C, Hunt S, Bayless T (2001) Utilisation of erythrocyte 6-thioguanine 
metabolite levels to optimise azathioprine therapy in patients with inflammatory 
bowel disease Gut. May;48(5):642-6 
17. de Boer NK, van Bodegraven AA, de Graaf P, van der Hulst RW, Zoetekouw L, 
van Kuilenburg AB. (2008) Paradoxical elevated thiopurine S-methyltransferase 
activity after pancytopenia during azathioprine therapy: potential influence of red 
blood cell age. Ther Drug Monit. Jun;30(3):390-3 
18. Decaux G, Prospert F, Horsmans Y, Desager JP. (2000) Relationship between 
red cell mean corpuscular volume and 6-thioguanine nucleotides in patients 
treated with azathioprine. J Lab Clin Med,  Mar;135(3):256-62 
19. Department of Health (2003) Our inheritance, our future.  Realising the potential 
of genetics in the NHS.  
20. Dervieux T, Boulieu R. (1998) Simultaneous determination of 6-thioguanine and 
methyl 6-mercaptopurine nucleotides of azathioprine in red blood cells by HPLC. 
Clin Chem, Mar;44(3):551-5 
 
21. Dewit O, Vanheuverzwyn R, Desager JP, Horsmans Y. (2002) Interaction 
between azathioprine and aminosalicylates: an in vivo study in patients with 
Crohns disease. Aliment Pharmacol Ther,  Jan;16(1):79-85 
 
22. Drug and Therapeutics Bulletin TPMT testing before azathioprine therapy? 
DTB, January 2009; 47: 9-12 
 
23. Dubinsky MC. (2004) Azathioprine, 6-mercaptopurine in inflammatory bowel 
disease: pharmacology, efficacy, and safety. Clin Gastroenterol Hepatol, 
Sep;2(9):731-43 
 
24. Dubinsky MC, Lamothe S, Yang HY, Targan SR, Sinnett D, Théorêt Y, Seidman 
EG.(2000) Pharmacogenomics and metabolite measurement for 6-mercaptopurine 
therapy in inflammatory bowel disease. Gastroenterology,  Apr;118(4):705-13 
 
25. Dubinsky MC, Reyes E, Ofman J, Chiou CF, Wade S, Sandborn WJ.( 2005) A 
cost-effectiveness analysis of alternative disease management strategies in 
patients with Crohns disease treated with azathioprine or 6-mercaptopurine. Am J 
Gastroenterol,  Oct;100(10):2239-47 
 149 
26. Duley JA, Florin TH. (2005)   Thiopurine therapies: problems, complexities, and 
progress with monitoring thioguanine nucleotides. Ther Drug Monit, 
Oct;27(5):647-54 
 
27. el-Azhary RA, Farmer SA, Drage LA, Rogers RS 3rd, McEvoy MT, Davis MD, 
Bridges AG, Gibson LE. (2009) Thioguanine nucleotides and thiopurine 
methyltransferase in immunobullous diseases: optimal levels as adjunctive tools 
for azathioprine monitoring. Arch Dermatol. Jun;145(6):644-52 
 
28. Engen RM, Marsh S, Van Booven DJ, McLeod HL. (2006) Ethnic differences in 
pharmacogenetically relevant genes. Curr Drug Targets,  Dec;7(12):1641-8 
 
29. Ernest G, Seidman MD. (2003) Clinical use and practical application of TPMT 
enzyme and 6-mercaptopurine metabolite monitoring in IBD. Rev Gastroenterol 
Disord,  3: S30-S38 
 
30. Fargher EA, Eddy C, Newman W, Qasim F, Tricker K, Elliott RA, Payne K (2007) 
Patients' and healthcare professionals' views on pharmacogenetic testing and its 
future delivery in the NHS. Pharmacogenomics. Nov;8(11):1511-9 
 
31. Fargher EA, Tricker K, Newman W, Elliott R, Roberts SA, Shaffer JL, Bruce I, 
Payne K (2007) Current use of pharmacogenetic testing: a national survey of 
thiopurine methyltransferase testing prior to azathioprine prescription. J Clin 
Pharm Ther. Apr;32(2):187-95 
 
32. Ford LT, Berg JD. (2003)  Determination of thiopurine S-methyltransferase 
activity in erythrocytes using 6- thioguanine as substrate and a non-extraction 
liquid chromatographic technique. J Chrom B, 798: 111-115 
 
33. Ford LT, Cooper SC, Lewis MJ, Berg JD (2004a) Reference intervals for 
thiopurine S-methyltransferase activity in red blood cells using 6-thioguanine as 
substrate and rapid non-extraction liquid chromatography.  Ann Clin Biochem, 
Jul;41(Pt 4):303-8  
 
34. Ford L, Graham V, Berg J. (2006) Whole-blood thiopurine S-methyltransferase 
activity with genotype concordance: a new, simplified phenotyping assay. Ann 
Clin Biochem. Sep;43(Pt 5):354-60  
 
35. Ford LT, Graham V, Berg JD (2006) Patients with high-normal TPMT activity 
identified during routine phenotypic testing: What is going on? Ann Clin Biochem 
Focus Poster 
 
36. Ford L, Kampanis P, Berg J. (2009) Thiopurine S-methyltransferase genotype-
phenotype concordance: used as a quality assurance tool to help control the 
phenotype assay. Ann Clin Biochem, Mar;46(Pt 2):152-4 
37. Ford L, Prout C, Gaffney D, Berg J. (2004b) Whose TPMT activity is it anyway? 
Ann Clin Biochem,  Nov;41(Pt 6):498-500 
 
 150 
38. Ganiere-Monteil C, Medard Y, Lejus C, Bruneau B, Pineau A, Fenneteau O, 
Bourin M, Jacqz-Aigrain E. (2004) Phenotype and genotype for thiopurine 
methyltransferase activity in the French Caucasian population: impact of age. Eur 
J Clin Pharmacol. Apr;60(2):89-96 
39. Gardiner SJ, Gearry RB, Barclay ML, Begg EJ. (2006) Two cases of thiopurine 
methyltransferase (TPMT) deficiency - a lucky save and a near miss with 
azathioprine. Br J Clin Pharmacol, Oct;62(4):473-6 
40. Gardiner SJ, Gearry RB, Burt MJ, Ding SL, Barclay ML. (2008) Severe 
hepatotoxicity with high 6-methylmercaptopurine nucleotide concentrations after 
thiopurine dose escalation due to low 6-thioguanine nucleotides. Eur J 
Gastroenterol Hepatol,  Dec;20(12):1238-42 
41. Gearry RB, Barclay ML, Roberts RL, Harraway J, Zhang M, Pike LS, George PM, 
Florkowski CM. (2005) Thiopurine methyltransferase and 6-thioguanine nucleotide 
measurement: early experience of use in clinical practice. Intern Med J, 
Oct;35(10):580-5 
42. Gisbert JP, Gomollón F. (2008) Thiopurine-induced myelotoxicity in patients with 
inflammatory bowel disease: a review. Am J Gastroenterol. Jul;103(7):1783-800 
43. Guerciolini R, Szumlanski C, Weinshilboum RM. (1991) Human liver xanthine 
oxidase: nature and extent of individual variation. Clin Pharmacol Ther, 
Dec;50(6):663-72 
 
44. Hande S, Wilson-Rich N, Bousvaros A, Zholudev A, Maurer R, Banks P, 
Makrauer F, Reddy S, Burakoff R, Friedman S. (2006) 5-aminosalicylate therapy is 
associated with higher 6-thioguanine levels in adults and children with 
inflammatory bowel disease in remission on 6-mercaptopurine or azathioprine. 
Inflamm Bowel Dis,  Apr;12(4):251-7 
 
45. Higgs JE, Andrews J, Gurwitz D, Payne K, Newman W2008 Pharmacogenetics 
education in British medical schools Genomic Med. Dec;2(3-4):101-5 
 
46. Hindorf U, Lindqvist M, Peterson C, Söderkvist P, Ström M, Hjortswang H, 
Pousette A, Almer S. (2006) Pharmacogenetics during standardised initiation of 
thiopurine treatment in inflammatory bowel disease. Gut, Oct;55(10):1423-31 
 
47. Hindorf U, Lyrenäs E, Nilsson A, Schmiegelow K. (2004) Monitoring of long-term 
thiopurine therapy among adults with inflammatory bowel disease. Scand J 
Gastroenterol, Nov;39(11):1105-12 
 
48. Holme SA, Duley JA, Sanderson J, Routledge PA, Anstey AV. (2002) Erythrocyte 
thiopurine methyl transferase assessment prior to azathioprine use in the UK. 
QJM,  Jul;95(7):439-44 
 
49. Hopkins MM, Ibarreta D, Gaisser S, Enzing CM, Ryan J, Martin PA, Lewis G, 
Detmar S, van den Akker-van Marle ME, Hedgecoe AM, Nightingale P, Dreiling M, 
Hartig KJ, Vullings W, Forde T. (2006) Putting pharmacogenetics into practice. Nat 
Biotechnol. Apr;24(4):403-10 
 151 
50. Kaskas BA, Louis E, Hindorf U, Schaeffeler E, Deflandre J, Graepler F, 
Schmiegelow K, Gregor M, Zanger UM, Eichelbaum M, Schwab M. (2003) Safe 
treatment of thiopurine S-methyltransferase deficient Crohn's disease patients with 
azathioprine. Gut, Jan;52(1):140-2 
 
51. Keizer-Garritsen JJ, Brouwer C, Lambooy LH, Ter Riet P, Bökkerink JP, Trijbels 
FJ, De Abreu RA. (2003) Measurement of thiopurine S-methyltransferase activity 
in human blood samples based on high-performance liquid chromatography: 
reference values in erythrocytes from children. Ann Clin Biochem. Jan;40(Pt 
1):86-93 
 
52. Klemetsdal B, Wist E, Aarbakke J. (1993) Gender difference in red blood cell 
thiopurine methyltransferase activity. Scand J Clin Lab Invest, Nov;53(7):747-9 
 
53. Lennard L. (1987) Assay of 6-thioinosinic acid and 6-thioguanine nucleotides, 
active metabolites of 6-mercaptopurine, in human red blood cells. J Chromatogr. 
Dec 25;423:169-78 
 
54. Lennard L, Chew TS, Lilleyman JS (2001) Human thiopurine methyltransferase 
activity varies with red blood cell age. Br J Clin Pharmacol. Nov;52(5):539-46 
 
55. Lennard L, Davies HA, Lilleyman JS (1993) Is 6-thioguanine more appropriate 
than 6-mercaptopurine for children with acute lymphoblastic leukaemia? Br J 
Cancer. Jul;68(1):186-90.  
 
56. Lennard L, Lilleyman JS. (1989) Variable mercaptopurine metabolism and 
treatment outcome in childhood lymphoblastic leukemia. J Clin Oncol, 
Dec;7(12):1816-23 
 
57. Lennard L, Lilleyman JS. (1996) Individualising therapy with 6-mercaptopurine 
and 6-thioguanine related to the thiopurine methyl transferase genetic 
polymorphism. Ther Drug Monit,18: 328-334 
 
58. Lennard L, Maddocks J. (1983) Assay of 6-thioguanine nucleotide, a major 
metabolite of azathioprine, 6-mercaptopurine and 6-thioguanine, in human red 
blood cells. J Pharm Pharmacol, 35: 15-18 
 
59. Lennard L, Rees CA, Lilleyman JS, Maddocks JL. (2004) Childhood leukaemia: a 
relationship between intracellular 6-mercaptopurine metabolites and neutropenia. 
Br J Clin Pharmacol, Dec;58(7):S867-71 
 
60. Lindqvist M, Hindorf U, Almer S, Söderkvist P, Ström M, Hjortswang H, Peterson 
C. (2006) No induction of thiopurine methyltransferase during thiopurine treatment 
in inflammatory bowel disease. Nucleosides Nucleotides Nucleic Acids, 25(9-
11):1033-7 
 
61. Lowry PW, Franklin CL, Weaver AL, Pike MG, Mays DC, Tremaine WJ, Lipsky 
JJ, Sandborn WJ. (2001)  Measurement of thiopurine methyltransferase activity 
and azathioprine metabolites in patients with inflammatory bowel disease. 
Gut, Nov;49(5):665-70 
 
 152 
62. Lysaa RA, Giverhaug T, Wold HL, Aarbakke J. (1996) Inhibition of human 
thiopurine methyltransferase by furosemide, bendroflumethiazide and 
trichlormethiazide. Eur J Clin Pharmacol, 49(5):393-6 
 
63. Mardini HE, Arnold GL. (2003)  Utility of measuring 6-methylmercaptopurine and 
6-thioguanine nucleotide levels in managing inflammatory bowel disease patients 
treated with 6-mercaptopurine in a clinical practice setting. J Clin Gastroenterol, 
May-Jun;36(5):390-5 
 
64. Marinaki AM, Ansari A, Duley JA, Arenas M, Sumi S, Lewis CM, Shobowale-
Bakre el-M, Escuredo E, Fairbanks LD, Sanderson JD. 2004 Adverse drug 
reactions to azathioprine therapy are associated with polymorphism in the gene 
encoding inosine triphosphate pyrophosphatase (ITPase) Pharmacogenetics. 
Mar;14(3):181-7 
 
65. Marinaki AM, Duley JA, Arenas M, Ansari A, Sumi S, Lewis CM, Shobowale-
Bakre M, Fairbanks LD, Sanderson J2004 Mutation in the ITPA gene predicts 
intolerance to azathioprine Nucleosides Nucleotides Nucleic Acids. Oct;23(8-
9):1393-7 
 
66. Marsh S, Van Booven DJ (2009) The increasing complexity of mercaptopurine 
pharmacogenomics Clin Pharmacol Ther. Feb;85(2):139-41 
 
67. Morales A, Salguti S, Miao CL, Lewis JD. (2007) Relationship between 6-
mercaptopurine dose and 6-thioguanine nucleotide levels in patients with 
inflammatory bowel disease. Inflamm Bowel Dis. Apr;13(4):380-5 
 
68. Motulsky AG. 1957 Drug reactions enzymes, and biochemical genetics. J Am 
Med Assoc. Oct 19;165(7):835-7 
 
69. Nasedkina TV, Fedorova OE, Glotov AS, Chupova NV, Samochatova EV, 
Maiorova OA, Zemlyakova VV, Roudneva AE, Chudinov AV, Yurasov RA, 
Kozhekbaeva JM, Barsky VE, Krynetskiy EY, Krynetskaia NF, Cheng C, Ribeiro 
RC, Evans WE, Roumyantsev AG, Zasedatelev AS. (2006) Rapid genotyping of 
common deficient thiopurine S-methyltransferase alleles using the DNA-microchip 
technique. Eur J Hum Genet. Sep;14(9):991-8 
 
70. Oselin K, Anier K. (2007) Inhibition of human thiopurine S-methyltransferase by 
various nonsteroidal anti-inflammatory drugs in vitro: a mechanism for possible 
drug interactions. Drug Metab Dispos,  Sep;35(9):1452-4  
 
71. Payne K; Newman WG; Gurwitz D; Ibarreta D; Phillips KA (2009) TPMT Testing 
in Azathioprine: A 'Cost-effective Use of Healthcare Resources'? Personalized 
Medicine Mar 6; 103-113 
 
72. Pike MG, Franklin CL, Mays DC, Lipsky JJ, Lowry PW, Sandborn WJ. (2001) 
Improved methods for determining the concentration of 6-thioguanine nucleotides 
and 6-methylmercaptopurine nucleotides in blood. Chromatogr B Biomed Sci 
Appl, Jun 5;757(1):1-9 
 
 153 
73. Pirmohamed M, James S, Meakin S, Green C, Scott AK, Walley TJ, Farrar K, 
Park BK, Breckenridge AM. (2004) Adverse drug reactions as cause of admission 
to hospital: prospective analysis of 18 820 patients. BMJ,  329:15-19  
 
74. Priest VL, Begg EJ, Gardiner SJ, Frampton CM, Gearry RB, Barclay ML, Clark 
DW, Hansen P. 2006 Pharmacoeconomic analyses of azathioprine, methotrexate 
and prospective pharmacogenetic testing for the management of inflammatory 
bowel disease. Pharmacoeconomics.;24(8):767-81 
 
75. Richard VS, Al-Ismail D, Salamat A.(2007) Should we test TPMT enzyme levels 
before starting azathioprine? Hematology. Aug;12(4):359-60 
 
76. Roberts RL, Barclay ML, Gearry RB, & Kennedy MA.(2004) A multiplexed allele-
specific polymerase chain reaction assay for the detection of common thiopurine s-
methyltransferase (TPMT) mutations. Clinica Chimica Acta, 341: 49-53 
 
77. Sandborn WJ. (2004)  Pharmacogenomics and IBD: TPMT and 
thiopurines.Inflamm Bowel Dis,  Feb;10 Suppl 1:S35-7 
 
78. Sanderson J, Ansari A, Marinaki T, Dulay J. (2004) Thiopurine methyltransferase: 
should it be measured before commencing thiopurine drug therapy? Ann Clin 
Biochem, 41: 294-302 
 
79. Schaeffeler E, Fischer C, Brockmeier D, Wernet D, Moerike K, Eichelbaum M, 
Zanger UM, Schwab M. (2004) Comprehensive analysis of thiopurine S-
methyltransferase phenotype-genotype correlation in a large population of 
German-Caucasians and identification of novel TPMT variants. 
Pharmacogenetics, Jul;14(7):407-17 
 
80. Schaeffeler E, Zanger UM, Eichelbaum M, Asante-Poku S, Shin J, Schwab M 
(2008) Highly multiplexed genotyping of thiopurine S-methyltransferase variants 
using MALDI-TOF mass spectrometry: reliable genotyping in different ethnic 
groups. Clin Chem, Oct;54(10):1637-47 
 
81. Shimasaki N, Mori T, Torii C, Sato R, Shimada H, Tanigawara Y, Kosaki K, 
Takahashi T. (2008) Influence of MTHFR and RFC1 polymorphisms on toxicities 
during maintenance chemotherapy for childhood acute lymphoblastic leukemia or 
lymphoma. J Pediatr Hematol Oncol,  May;30(5):347-52 
 
82. Slanar O, Chalupná P, Novotný A, Bortlík M, Krska Z, Lukás M (2008) Fatal 
myelotoxicity after azathioprine treatment Nucleosides Nucleotides Nucleic 
Acids. Jun;27(6):661-5 
 
83. Szumlanski CL, Honchel R, Scott MC, Weinshilboum RM. (1992)  Human liver 
thiopurine methyltransferase pharmacogenetics: biochemical properties, liver-
erythrocyte correlation and presence of isozymes. Pharmacogenetics. 
Aug;2(4):148-59 
 
 
 
 154 
84. Szumlanski C, Otterness D, Her C, Lee D, Brandriff B, Kelsell D, Spurr N, 
Lennard L, Wieben E, Weinshilboum R. (1996) Thiopurine pharmacogenetics: 
Human gene cloning and characterization of a common polymorphism. DNA Cell 
Biol, 15; 1: 17-30 
 
85. Szumlanski CL, Weinshilboum RM. (1995) Sulphasalazine inhibition of thiopurine 
methyltransferase: possible mechanism for interaction with 6-mercaptopurine and 
azathioprine. Br J Clin Pharmacol, Apr;39(4):456-9 
 
86. Tai HL, Krynetski EY, Yates CR, Loennechen T, Fessing MY, Krynetskaia NF, 
Evans WE. (1996) Thiopurine S-methyltransferase deficiency: two nucleotide 
transitions define the most prevalent mutant allele associated with loss of catalytic 
activity in Caucasians. Am J Hum Genet,  Apr;58(4):694-702 
 
87. Tamm R, Oselin K, Kallassalu K, Magi R, Anier K, Remm M, Metspalu A. (2008) 
Thiopurine S-methyltransferase (TPMT) pharmacogenetics: three new mutations 
and haplotype analysis in the Estonian population. Clin Chem Lab Med,  
46(7):974-9 
 
88. Tan BB, Lear JT, Gawkrodger DJ, English JS. (1997) Azathioprine in 
dermatology: a survey of current practice in the U.K. Br J Dermatol. 
Mar;136(3):351-5 
 
89. Tani C, Mosca M, Colucci R, Gori G, d'Ascanio A, Ghisu N, Fornai M, Di Paolo A, 
Blandizzi C, Del Tacca M, Bombardieri S. (2009) Genetic polymorphisms of 
thiopurine S-methyltransferase in a cohort of patients with systemic autoimmune 
diseases. Clin Exp Rheumatol. Mar-Apr;27(2):321-4 
 
90. Teml A, Schaeffeler E, Herrlinger KR, Klotz U, Schwab M. (2007) Thiopurine 
treatment in inflammatory bowel disease: clinical pharmacology and implication of 
pharmacogenetically guided dosing. Clin Pharmacokinet,  46(3):187-208 
 
91. Thervet E, Anglicheau D, Toledano N, Houllier AM, Noel LH, Kreis H, Beaune P, 
Legendre C. (2001) Long-term results of TMPT activity monitoring in azathioprine-
treated renal allograft recipients. J Am Soc Nephrol,  Jan;12(1):170-6 
 
92. Thomas CW Jr, Lowry PW, Franklin CL, Weaver AL, Myhre GM, Mays DC, 
Tremaine WJ, Lipsky JJ, Sandborn WJ. (2003) Erythrocyte mean corpuscular 
volume as a surrogate marker for 6-thioguanine nucleotide concentration 
monitoring in patients with inflammatory bowel disease treated with azathioprine or 
6-mercaptopurine. Inflamm Bowel Dis. Jul;9(4):237-45 
 
93. Tiede I, Fritz G, Strand S, Poppe D, Dvorsky R, Strand D, Lehr HA, Wirtz S, 
Becker C, Atreya R, Mudter J, Hildner K, Bartsch B, Holtmann M, Blumberg R, 
Walczak H, Iven H, Galle PR, Ahmadian MR, Neurath MF. (2003) CD28-
dependent Rac1 activation is the molecular target of azathioprine in primary 
human CD4+ T lymphocytes. J Clin Invest, Apr;111(8):1133-45 
 
 
 
 
 155 
94. Von Ahsen N, Armstrong VW, Behrens C, von Tirpitz C, Stallmach A, Herfarth H, 
Stein J, Bias P, Adler G, Shipkova M, Oellerich M, Kruis W, Reinshagen M (2005) 
Association of inosine triphosphatase 94C>A and thiopurine S-methyltransferase 
deficiency with adverse events and study drop-outs under azathioprine therapy in 
a prospective crohn disease study Clin. Chem, Dec  51: 2282 - 2288 
 
95. van den Akker-van Marle ME, Gurwitz D, Detmar SB, Enzing CM, Hopkins MM, 
Gutierrez de Mesa E, Ibarreta D. 2006 Cost-effectiveness of pharmacogenomics in 
clinical practice: a case study of thiopurine methyltransferase genotyping in acute 
lymphoblastic leukemia in Europe. Pharmacogenomics. 2006 Jul;7(5):783-92 
 
96. Van Loon JA, Weinshilboum RM. (1982) Thiopurine methyltransferase 
biochemical genetics: human lymphocyte activity. Biochem Genet, Aug;20 (7-
8):637-58 
 
97. Wang L, Weinshilboum R. (2006) Thiopurine S-methyltransferase 
pharmacogenetics: insights, challenges and future directions. Oncogene, Mar 
13;25(11):1629-38 
 
98. Weinshilboum R. Methyltransferase pharmacogenetics. Pharmacol 
Ther.1989;43(1):77-90 
 
99. Weinshilboum RM, Raymond FA, Pazmino PA. (1978) Human erythrocyte 
thiopurine methyltransferase: radiochemical microassay and biochemical 
properties. Clin Chim Acta, May 2;85(3):323-33 
 
100. Weinshilboum RM, Sladek SL. (1980) Mercaptopurine pharmacogenetics: 
monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J 
Hum Genet, 32: 651-662 
 
101. Weinshilboum R, Wang L. (2004) Pharmacogenomics: bench to bedside. 
Nat Rev Drug Discov, Sep;3(9):739-48 
 
102. Weller S, Thürmann P, Rietbrock N, Gossmann J, Scheuermann EH. (1995) 
HPLC analysis of azathioprine metabolites in red blood cells, plasma and urine in 
renal transplant recipients. Int J Clin Pharmacol Ther, Dec;33(12):639-45 
 
103. Weyer N, Kröplin T, Fricke L, Iven H. (2001) Human thiopurine S-
methyltransferase activity in uremia and after renal transplantation. Eur J Clin 
Pharmacol,  May;57(2):129-36 
 
104. Whisnat JK, Pelkay J. (1982) Rheumatoid arthritis: treatment with azathioprine 
(IMURAN R). Clinical side effects and laboratory abnormalities. Ann Rheum Dis, 
41: 44-47 
 
105. Woodson LC, Ames MM, Selassie CD, Hansch C, Weinshilboum RM.  (1983) 
Thiopurine methyltransferase. Aromatic thiol substrates and inhibition by benzoic 
acid derivatives. Mol Pharmacol, Nov;24(3):471-8 
 
 
 156 
106. Woodson LC, Dunnette JH, Weinshilboum RM. (1982) Pharmacogenetics of 
human thiopurine methyltransferase: kidney-erythrocyte correlation and 
immunotitration studies. J Pharmacol Exp Ther, Jul;222(1):174-81 
 
107. Xin HW, Fischer C, Schwab M, Klotz U. (2005) Thiopurine S-methyltransferase 
as a target for drug interactions. Eur J Clin Pharmacol, Jul;61(5-6):395-8 
 
108. Yates CR, Krynetski EY, Loennechen T, Fessing MY, Tai HL, Pui CH, Relling 
MV, Evans WE. (1997) Molecular Diagnosis of thiopurine S-methyl transferase 
deficiency. Genetic basis for azathioprine and mercaptopurine intolerance. Ann 
Intern Med, 126: 608-614 
 
109. Yip JS, Woodward M, Abreu MT, Sparrow MP. (2008) How are Azathioprine and 
6-mercaptopurine dosed by gastroenterologists? Results of a survey of clinical 
practice. Inflamm Bowel Dis, Apr;14(4):514-8 
 
110. Zhou SF, Di YM, Chan E, Du YM, Chow VD, Xue CC, Lai X, Wang JC, Li CG, 
Tian M, Duan W. (2008) Clinical pharmacogenetics and potential application in 
personalized medicine. Curr Drug Metab, Oct;9(8):738-84 
 
 
 
 
 
 
 
 
 
 
 
